var title_f25_10_25760="Admin of a cephalosporin to a patient with a hx of PCN allergy";
var content_f25_10_25760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F61102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F61102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    Administration of a cephalosporin to a patient with a history of penicillin allergy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 562px; background-image: url(data:image/gif;base64,R0lGODlhKgIyAtUAAP///wAAAIiIiERERLu7uyIiIt3d3ZmZmWZmZhERETMzM8zMzO7u7lVVVXd3d6qqqgAzmYigz7vJ5CJOp0RptJ+fn9/f3z8/P8/Pz5mt1maFwhFBoDNcrd3k8czW61V3u+7x+O/v7w8PD19fX39/f3eSyb+/v6q73cDAwEBAQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAqAjICAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqagGtrq+wsbKztLW2t7i5uru8vberwMFvAcKHxMXIyWLHyoHMzdDRVM/Se9TV2NlG19p13N3g0d/hcOPk58HmfwEEquro8KfvSK4F7UUExwIDTflOAwIAsBMyEAvALQcF3nPib8u8eBBDPdx2AICABEYaPtHopGDBKwmzhIzCEcvEiCg3nSQSoOKCAAZcKWBQoFWBfQAI1GwJYICC/1YIAOwsMOQBxiEvGQBE4CrmT55D8v0ssECozQVKWyU44KqikHz5Dgi4ajUAVYuuxrbi2m5AqwEMBD71KmRoz7dxp6xMybfSXoIVERAVEvNBQ5xbARjtyS+fgZIMAiw4UMCAgAY9A3oMKGDwV8kAGmAeUsBBvryZ8QUIuCBBVQej6zp4uTAhu84MGCjQzNlzTn0Fcu+e1re4qL8Cry5wu/bwgJivDByM+fjabgUHEDQIeNBjO8pEDgdnChSAgwAJuAcMf4xrPQbkAyAAP8Q2AQRBLQYdSP+zEPxCCJCfFMgZZ6AiyEEFAAIKABDZAadZxE9i9QVEXYREXBRUAq6lFv/AAwR951tDCswXQFwlIgXTAA6oJkRrVQnBFYoI0FZfiwrhRpNmIrIXl443EXfgkJkkSBcBCZjVkm5m4aSTTalRx6RvNjow2EHkxdRjVDIZYMBTBSCQT3nuHcmMWvJ9aVNQaE621kDMwaUQAP05ONVdAcipF5F8WlJgHyVx8mefhPIx6B6BqlTooo4cymgSjj4q6TCTehFppZiicekR/uBEyUhGeJrGppmWuoxJCw3BTqf8gMqFqGy4miE/XHwEqam46kGqi7BGIusQvZqxa67EmlREZ0nOFForM0mFXlUDNaCVQqx6OBd7Yal1Fpr8BEkdTgANUNlTQR2Q5GpExEf/lxDSooeWWdBe6xOZrrDZWJKJndfKAsgGoGycDIDV0qr+PrtNsQjLQQ2QAgig7G5g9bQfAZ0ZoCoB1XbXG3usdQibjTh5CxO4CljcQFAGuMaiEgxmWNmLHmOG7kWM/WaxjCciFpC5kYEYYHA76ggxutTCOaCqCSftxsK0DoDfK2IeAyA7AF6cMY90jtjeKwXQF7KFI7e63k7N/TRAjAGe61vVdHI9p2PTwXTAU2FTR5BlNSHAgKdOVy2gRgT/dzRBShfOyrH8pCyWsv4tOHHFVhMDLtZ1NgSjilU10CqbYacW2uDsDliYeb5BDsDlF5MeJUylKdZ5ehYlgNpWOCnO/zDgGEsN+rCG937Ewq6M1m5LDU3d1rSBTz5n5WfWu6BNjTHbeUJqtiIdWfXZ5BueGKG5n01tgW2ZTZ0jid4BDJw7E5qjAYx78bv7Lv+ps+4RLBu2anG/FbzPLz/T9qNVOVKlPwFqoX/+6x0CF7XABCqtgYSCoAMRJkE+VXCCubrgkDSIwVJx0EAf7GClfEHCEprwhChMoQpdIcIWriKELoyhpGAowxpG0IY4zKFAdMjDGNKwh0CMxw+DSMRwDLGISMTGEZPIxGYssYkjXKEUp0jFKlrxiljMYhWhuDQuFuOJRQSjF3U1xjWIsYx3OCMQ1YhGOrCRh29sYxzimEM6yv+xi3cMgwUwQDgAYMACefzEHvv4x0ByIQQBuEAFAlCBCwQgBIbsBCIVyUhHQjKSWhgBLEaAyU5o8hWc7GQWMAALPopSE6R8hSlPeQVHtuICrNyEKxMZSywsshUVqGUmbslIXV5BBAEQgS8zAUxhDrMKJAgACY55iWQuk5lTsEAAAAlNSkiTmtWMggmyWYltcvOb4AynOGeoxXKa0xctPKc612kLZdixEO8UBzzi6cZ5ptOeyaCnIPTpTnwig5+AAOg//flFgk5QoH5AKB7PodB0GNShSkiUSnLXkXsuIX+ComgTGoq/IpjrLQvgiEQr1ARP7S8Jv7KCq7pD0ZP2sYP/1FjAU7Azp9QlwaXAohVOQ2XAAvK0aBK6aD+H0DMHNQBCK0lp/aig1C8EbqMWHYICcCSgmjphp0GlAlZrpVEmcNSMRIjMevyzgJt0qgA1YVzbmrOTiuhLMvUiWXmq9xH3EA9f63LWtshSMJ4cpE0szRi5ivBVdxRBAT1lh25klrufdIgw9apeuc7lPbnKh11pGQJ05GM+CqnqWk/iSV8r4qSdNIwfyWvVYFky1CEcgDl6y0dZ23FWA6RvXQlJzGI+lNMAtSp6BmhAg6zqOdjxjEuZa8DlYCOQjQHERkIIrOR+azPWijCm5DmbQB4wnKK15WieOhkAUrYcHGUVXMC9/4jFRuIp48qOJZzBiG4xMjOi6Ky3qa2ZY6w70CPoxjTowVG1hIJbsEWnM/LZm07FNl7WecVWcbsZTLj0M7uaZXlEAUidpBvUCPMXg+NoGXqGC1THLZVsxDMbvxa8OgNUjb2Jm7BAbhYim8FCS1mTkN18C1Tl7filBY2KdnUjALDAbsBdI8LKAOBZItBuuD6GiWhOB2Ecwe4iqCFRjR5bY/A89yMcjjKNd3jdw3oFAaidG62eyjaLDFe8RjiZw3gcYYZlaLhXfm/qrMTkdfHHvhMaK07y62Gk5ZMIwQ3eb06XgKhlNcmuZatN0scsBrRGPmIuq5JSVabO5rVL77rsn/9TA1geXa3BYy5sKqjx1pIpRDczYfPRLo0Aul4PXrQWM5OaRARae5qw4MuJXUbtJMoOuqUM/jGZ+7uHl4y5HzRUNSreSZN1dYSAmmrtHcZENCiMtAzSloc13qIXbJ8h3MJ6aALRXc9Do4PdpIC3wrRtxKiSQ970Awm6cEyAmS4gPuQmwgMuG5mFBGng+RkTUdpsHqigyR45Jk10jFVmM5ynIkbJS0yqgvAAlQfSUpUxc/xlMbZt9sJkwHcYHCUumGgpZfkRV14wypj3wjlCAxiAnuEX1gTk/GfRxUydQJ4FlYNCgun7eZ8DNNyc69lTREdSd53mINiZXMbpdjdI0Pz/nNuQmMk+w+jGk5zxBWFm7F7huWsTYLfOCGE4Q7f2FYz+CQmay24OoJXIyuoVqK9LO/ShOnlNDNlnj4HulhJJ1MZyHwNCGqNzbu8D0teOyNNK7dFt0V/rsTPfoNjwBLK3GFZ2kKQg6UcNMqne6ZK+ySfgeMwKjOjclnJ6MzUo7aLY1xMQdmx/3jxHHczvMX9y+w7mJQ+Ie61ED4biv11A+fm93yPtPKqjBT6zB/3KbT8FwbeCADGJeXBq7KPMU3k4GFoZ5udc9Qe4ncoEUL5DmP8F9rfeIgV4/W/ysrLpm3//1odlV6d9YIB4XcBy+cEUtOVvNjUE2rF2bzdhDygj/68HJQAXJP+xHa+wMxv4e3NHf16AgWbnICg3gXSSHh8HC2hzEyOXZABnYdtTgNynDQYoKOr2Qjc4PzV4OFp3byCYDTt4QDn4P0M4bUWoQEdoCkGYbRXHUO7ETlAYhUuICVJYherkQlOoS1k4QuPUKF0IVV+4CFs4KWPISmX4KGcoSmnIQGEohm2oBGuISXF4Q2+ICHPYJ3cYSHlIJHsYEVb4h4DYCuv2hn3IhDrYQxEAAYr4AUwgARAAABFAAUJAARFQBYV4bkmQiIwIABNQiVIAARIgBKAIEZcoCREwAQDQAZ3oBJFYdHiYiRuwARnAiZ4YBaOYEqUYCacoBB+gAf8dwAGKWAIAkAEboIgR4IgdoIgQoAGUSIxCEAEcAImKOAEecCsWlImduAEgsIofoIgcAAIA0I3GyInT6AEaoIzJKAEasIkUUAK/qIgaoESIiIoeIIsfwIj1KAHtOASOCImSCACUCAKyCACyWI/VWAKb+DuviASnKJAa0InQCI4cEAERsAEdAJC1yInCeIugiIweAAEd0IupuAHVKA25CAmJCI+cOIsAmQESAIwU4AH92IoY6Y8ngIoZoIwQgIr0sJBHsIspGQHnqIwaUJSTGAEgMJTLCAAcGYqUWALxOAE6yZLyxEO7OAT3CAAfGYq8qAEzGY01mYyraJBIMEhkVkj/fGGWx4CWQ3CVUkmR39iWEwAC2xgBOSmR8QgBJyCKoUiMGxCKIkmD80gE7wgBwkgB5diP9biMlCgEGqCNz0iURTBJi9RIj9QXlFlJl0kEV5mTlSiOEJABIACMOxkBhTkB8TiU6SgEE/CPhQmS1XCS3fBJrhBKfUGbrWCbU7CNVLlBX5hKrrBKfAGcrSCcUKCM/3iNXzhLsGQgzHmIX8hLuWQg0gmdX1hMRIKd1tmFzkQk3bmd43RNRCKe4DlO3kQk50mEdbiejyCb7HlH7mlGgTif9FkLv1Of+BmfCokp+jlH+7lqsZkp/VkO/2mEJimgCcMNpTigHzZDCVqg4nag//z5oAdjWBLKhRQEoWrwbcQ1KgE6oeHBgBlxDBzqhBXqWmCiHmHAoTRXBSVqaFWJoYTRaNE1fi7imyf6G+uxVVbAouaWdTFKhnfmZIZRMFQxFP5QPS3SGWmVG8xxFN3WgzD6OUagYUcxZ+2iVsLWCgIgWfiXLAFTMB0yFNACe3AhU60gM6CFV5khLmfVpGhBWB8qowvieEiVXA3hD1PWGhRTGbeFIQQxVlIKZEGicJlxW33mMCgiqLATOuPlGrdjNETQOrcBNLvBfoEaO0y2M7LjExZTW4g6FnJ6oUIKLLtXpD+Tp8QAaQMgFqvXcI1KqlMKZzn2VwPwAAsHNZqFdf8o5qrR5WiOAx/OQzX5ISCJRlMD4RgytiLrgWRyB2ROhKC7Kn5h+nZRExd6ihm04X9UZjFRymwfNnBUlWFgEySKegSxSqtBpTjwMyMAkCKVmhsi6HYDwWd5phTNOl11QVrUwKBT6qAhyixVwW0lMyVJ+hRLunrclh/fGmSjiqI2oaILomfDk1eUZWvss2iOUz1hMicAgyYVUQ+0xaYJ4axx2qAzWCjv8KJ8oaBpwKNQ0KIfKKtoyAQsi4saOgYw+wQyyz9zWqrF4rIWGqQAG7Q5G28/W7TEIrQASrOM4q9twLQGSrQ1m6E5GqFU+7QU+rBTCw1QW3tWy7VY67XSarT/V6uESVu1Ziu2aOu0bBi2KFsKX/u1h7e1cYu0bquyfLCzW3CzmHi2wvKj3pC2WvsEA7cEy1EvCmYFynMFN+u3QHq3RlAn03APPTsHc1u2TMAcSpA+o9FvBPgEjdujEwG54Ha0kxuDBGK5gttuWfu2DGEO7zcrG7d/obUudmUvdgUhbdWmN4FW/sIAmzUTdpGlqLGlgrgPY8EVghNqPSWDgHsEdaItWPGkDbcvDtgUo/U8a9ETqwUsAuu9c/W9lki4sAttLLNm1gMuuLchGHcUHpUzDLZ0i+Gp+GdbnlUYh/EwjBoQZ/UduoN8WVW30Zu6SBEzgMpb22C5G+OADfJz//v1IqCBZvolZSjDZULyunq7EbLrGd9yL9Rxclg3N00RZdGREH6XuM0hNbpaeIvmKczrOF7zvE6Fuh7lGTAIq72RYCzBujl2EVBSaBGnEy3WqzOrwXQYuw7YUykjJ84GdQVAK01GGi0ycJbRKlZWYDxGYC3zIBFyrkZwZfpqM19SI6ChOadbwDd8wGijIjTWZAr8Z6PDZ0L8EpmTbBY8f3mbxJvbFXVqBCqcYDBcEKFVOuRzxWvFu0G8owqbJDWBPndSsUTgHj8xwG6RAClCHlGcxmyLBBbWMPWysJQWvOliPaPGHGjVYhkSvhFma0dMtiCaDeq6fWosEea7wdLAHP+uBradjLdI7JNLa8O2vMfAnEHCfHS3zMfGXMvbNsaNs3zErJxrK7lnsFX5RWEHmMzFjCtSywYwO2DPrMe/LM3BzMw/A6bLErwCIxauEFK9Oy9p4jxCsBgqUnDg/BuOVRXqYi5M9y5nccw4GMvl3MuhAjQ3ca5DwxofMV8VjMhhJRmUYRmMdc8RY33/MROJsRXLFRsELQx0m28DTc1L1TdQ0xD9IcLSIT7Bch3ZsR09ZkA8B8QXtg+4ulZQAtBDC7Qh/a83lThPlmXHAF1LR1Lf8nVpsyEdcs2Ngx9zTBQxESSoY43RkAKau8wdvcppilkrDL77UsgtRmu9Vq+DodT/GgsgqDwYCPB08mzO7+mzxtC6TeUFfMuzOD3XdtjWIN25uny8RRDIemPX16YEcR0FPQvYXlXXNEwJHy3QSiAd8iqoPfe5u7wMcA3ZZGDYQsXWnbDYdOoE3VXQPFW7p3G7iPYUmGG8ehUv3asupBa+b7Ucg6WkvxEWBJPPLgOmFNwT5pXBIo3MeA29omvU6aK+09O+9Au/oSFACF1kZywzDXzRmWHHf6zAPaGtkrGnr5cP60Ew3+Uyjx3CWMfbPG2JqTLY1qAJ/RgGqggBGXkgJ8EgfO0yu4rISALeE7ev2RvKwIFhsbPI9EHECKY3tkEZXtGq76M7Ix0UAOEAoBN6/5qNUlhDUkVHWxoUbjrpibfIj4/IBDSpBDTZiiUgiemtBOk94oLZBGU83EXQxHHxxHq3yUNdBGjMdEBtrRjW1NF9xga0FQdhxXv6VCXWZrWTGDqBweINrfxT3pZduR21CKEJACcAAeB4BCaeiclp5UXwAe1N4htuokyQw7ndayP317TCFl9hF5pl2ulMPKB2ytrT2v6CFeqTFVw6XgirsUEOXor2dolN2HW9EwrwFCDCUmsuqMorZZU2vHHRLo3WFcQg287iGnSO3Hvi5LNYkXzpAaT5AYq5ikNQAsr4kfAYiYmYk/CYjKNOAaYemo9YmB+A6hDwjVK5k/1YmMJ4iv9SGZcO6wem2wTmTQWU54psXTExERAUzFKQw14Qt9y76n4vU2PZymi5812A6taKoIwcwJWgCI0a7gETwJVDoJdt+Y+nCO7DKOUfLomN2Y8fcOVCkIwnUOKPmJX5eIodIJC9CQz81Oubu+Rb4ADCfeTLtgSeMhDKQ6zRZei0AnA1MnLZcTTJuqoFjlTNex6xKvCFEJr1uJdMKQEhGesuCQEbIIxFcIrLCALpLgQZQJogmfLr/ogTQJUegJiKGPJC0I8xP4kZQJM5v+tW3dtbbPAMFq87slRgvCAN8iCms12L9uMaxTbOZu2J8OQnQJIdL5eOKAEbsOVCIIvc7o+sKYz/Ud4BX9+KLx+OyakB0QgCoemI4Mju+Ljt/9jzHm23430EBV95Q08ATJIAIjjAFWs+j8w93Mu8kK47C/vKiPDkkDgB6ZiSbf+I9RiPQiCQ3ggCi6kBHz6NIJn5Zl+Jtb7pWr+ToTmatN7qpHnrc5/vAe0G3/ZtSjW6Y8DvYHjVvv3bifcGr28OsT+/ZED7h/3gioL7ue/65gD7/k5nyd8FwJ/Ztl93xF/8WjA8mkEZT9O9ofXog5X9x9LO8FwuzqM81CsX3UtX7WC8HzUz1HCwZEJZaBoAHB38z+8JnK3TWKBeHhL/LXNkxAAEDQTAkFgkBABCANAELAIE52CgDBic/4cAQ1AdCI4LgKMBCCQFBUBD0YwKFAyAoutwAgTM+3I9LC4G7Jrg7goN7/QKEw8ZGwerHCMjuyQrLd0uMzU3OTs9P0FDRUdJzUoRhgC+zKTwEgICCgyurAAKYGG1sPiy1KaSZg0OFHANKL+0cNWiAA7UCg7cCBBwAxAIiAfEDvlucQ+wA7QNGgIUoi8XndQ1+SjxIJt4Gw9eA9CbBtTfSyPZ+wEGBIVCYEGDBzv985SGAYMCSZjNejBGDRI8TITcsZjnDpRWqoBdKWDnwZVjYIwgkuJsTRmPcOQUylgSixM+GQ3hxOPL0j+Fmt7xs+QgmoAETqjti4cQE1OnTxFBlf86NeBPTgyIxYLYSl8sNcmIEcl6Bew+XIBCGoN1y5gXNLiGMGO54NYtKeVydS0gxkEqm0wMjDWgd0GeXJl8WqJzp4GDJbNgIUhzK467ApRjFnpwdAydfZfNyek6gMGslWq+DIBmL0lPqq8FWoU9m7Yh2Z0c4qvdCUpNRwo+Mk1ciYyqIUbcQUpjgEECcEyWN9fdxECBicu1FIrunCFWAaaboVaAJdCm27vRMzqfnr3T9elgLW0vaQms1u2HS9p8AM7mWkEhgSa5JqAp5Ah0vMHljnegQWUQBMBjaRUlstmmkvfmQw/DDDkkZcMOQQQoP0kSSMCYBMpwpw14CHyORVv/dEvDwiyUarG7h8yIRjWQZPJLkg9DnArIIIl0rcgjERoxkgaqYOCeWo6whkEXp7wjwSebyG7BAHWMTw7DFECtNcLSQTLDIc1Mcx2B5lGzklWYeUpJNw1Ck85+7LyzyDwL4aVNTRxYa0aD/mzkJFZEEaqROfUUsVHa+Hy0w0j/kgfNBsRooAymCo0EzuAWkk+9QyiVlFRTXysV1fRU9aaAJYhJyVUxzDnskOL+Imavi2Kh1ZlrvPkuqyEmC81VJ5ycMYEHDo0zny5kGRaApJ4MDBa8rPHn1FXx5FYqVb2FtBQ/mRnAx5HMQIOnPUzcI4BMMU2puAA2taiJjP7YzsVC/+io7oAjWPz0jgHG64OIlJpAoA0mnVB0VNvC9TBi9yZuVFVyE0aAAWrjOs0QZwblJY1k1kI0GCeu5I/LQslA4IGHymg2uAlTNqrkAh+5cNuKPwGXZ4h/dvPiLWqZFgEt5FCg4/AKITizSudAIAyVmrDX4IZXJrqjBNRoYCO3EP3lXr8komiNeAj5ceegzWM7NrfTVBWrWHhBxdpYlmbJCciK+QuWgg3LNk4CWLvbJC7nXhcAi2gKeKuBWzN8sLXUuDvebB3xqZrNOe/c889BD1300Un/HG5HTz/SZ0JXN7P11GFPKHYiXw+oU7hrn113tXeftHfXfw+eYuHxI5524/+RRz352nL/5PZRnEWy+eVnn556bUl5vokFpJ1CHe1Did4Qh0PN2RPrrz8d/fTXZuoAO6DYJqk+axdfO1HLF2V99oPen/81swcd0MThEMnqDEfcFSsxgGkBERKTarh3LfVkJRo4CgZcEPErAngjGtSKxgbtAxdKEC4AzlGFtOphn6j8j4XYa6GcxiVA5pjQEOXBzvfKJbV3TWsADjwhFtK2KDQcxYKHs029ouEfpLTBagBaXBLqwQAqWGEwglDEC7EItCwmKYYvwhmylEagzbkrY3rboA8nRA5zTGcdUnhMEdtiGynwDRYnWsvJzNcFPF5hFcEIhzZWuMUs+o+FQ/P/om4Ix0YtQQ0V8TtbjlQhJu10TT7McABqiGWSFVFtcfgo2yWf2LAVUWIjCZBiWpygE1MIcpCsPIghq4SUavhlkZbKGK8UsMC/SZJXT0oAqJThxr9dIUo+Gtyx9KIGEp6hmCN8hQn7yEdBBdKVhaxmQQg5lQfgT2jXbGE2+QfOLYrTm3Erp/LOWad0so+c12vnC9+5zhDFM3n0bKNTJsSIfLJKnu7sp/7mYz+B7LOG92nEhAhalX8uz57Ga2jYEJJQyElCothcaD0v2rMY3gJFsLADyYaAo+ZMZB0UVAIH7wDSnWDGFtOs1ZMIFhlbJGGkq5hVLwN3gFUEblAAzSjx/x4qvKFJoQBVqCXSWKK3dQyxkwBQYiGQpi8r2eEMrlBFFR6TVF4SyAEeERtIvPq2nwp1rJwwJI/4MIxiNAcb02HGYzbnG7XWcUobw+Bb+ZgWtp4DJHaNjFJ5BBLAorOsugtq8M66im6QhBZw4AzVQEnDQqCLJlNCWtQQBcpoAlEBnEEG0ZQWVlUI4guiJWxhY3fY3yU2Ce5YCy2cZFA3rMWNx2rYa+MIo7sVIC605dHJYvus3WYSFgtIhk7fUtzTojZ1qu0dOAn3tCSByhDRBZFzmTu87PKOKgqwonuoy6/vnmm71Ssvd8+LmPQ2d72Laq9638s27Bo2vkaqL8/ma//e+7pwvxHLb2r7m7kAT+y/sCswYgfs3wEfeLUJDheDcedgLUrYVBB2m4XpS2FUYbh/Ggaghx/F4Z+J2MAglhSJK4Zi9Zk4xAu2RHP+5ptC0HG8oxAY+JomW3OyWE8qVrAmvMuIk2FjU1UJL0V1DDwe38nHD9ZEboRMiyds4W5DSGFV8VKZWhlBirA4yhc8yIQEDSHLmSEZOJ7JxusumckuvgQ1uEkEKbMCX0YozyAISIclSMFcS8jMjRNBuMLk2aATskgUVcdmOjXZWx9S5R3wCAWHVAMcFaKWNeo2hEBZBNBZ2tWlfbRZN8h4noruZoDXc4BNKaAMCJDPkMP46LH/wYSRfukNnCaSVlngWbr5EEQpe+07U++4v+uJoDmw4OoZVyNygiETtvaFivpkaxVJyU41qgDtlOaChJI93rCVXGwTM1rD5F6VufEL7nDvF90pVrf03Ozhdid43i2GTUXNR9Z37yneVMH3i0jx72/vO0j1tths/k2+DBO81KjuB16OYphdvVRHKMSgM0sYjUAVNw2vIOBoGLDne8DJpPBmeMPFTYrlbE9eZaiqUa5KRRpxoQqHNmUASLqThjykO3quKo9erriCnxzl7D4FLauxDGEOJi1zPdwejXELjb3DXA7CwzUSIbDBDp3owk75KFb+BIRJw2ybpawRge0E7lSh/wj8KcDOBTAPrQu96F0vnsNL0ZWI39W3m5W4Ebt9ABiHJnCbArncH7f1utudVaVz/OMhH3nJT750OpPTkT+hcCcznvP2FfDlAaL5Rnee9Px1L4gNXnp2Wl7eqnf9FdFL4dS/nqGsLzftaX8eyu+e9733/e8fj/vXz174xZev8ZFvauInn/ncWn7zoW/v6E+/39S3fnyff33tc3373S9v9r0ffn6Kn/xjBX/50S+k9K9fnudn//stCn/5s9L987d/+O6ff2vqn//+7P//kaf+AHAA24cADZC9DjABEVABGbDDGvAB3Q0CJXD0JvC+gO8CMTADNXADObADPdD3KnCVUP8P+0JQABeNBCvQBE+tvVQwvVqQ2NbrBb+PxWRwN2owu26Q394rB3/KAjCgKTDAAhLMB4FQCJmLCFcpCBUwBALgAiogACrgAgIgBBKMCZ0QCqWQCpnLCp8wCqeQAUdgc0ZAwsKwGsZwu8oQF85QATFgc37QwdqwGt4wu+IQF+ZQAaUQFi5Aw/KwCdOrD/fwAZ8QFipAwwYRCtPrEAsRAkUgAEQAxBrxEdcrEieQBAKABEDMEjFxvTRxAi0gAIxQwz4xFM9rFCvQBFgMFd9LFUOwFV3xFWFRej5wFmnxAj2kFnExFz3HPHSxF3sRqGYQev7pQ3hQYvQNB42x/dqmn27/sBi1C/+YcRmV8RiZq1Sc0afgaxoRbLuscRilcZ2akWcCJcmYJxnB8RszhBh6KhPUkSrCcSqgYJNEwUke6w7GkbyE8TXisTbucblM7yDyQBCI4QHokRHaMRJKosju4CC/BRjh0Rycoh/vDhtB4RU2pRzk8RD2cRMCEsh2qBAkshSIESo6cg5wLhIYkhNSEoao8Sk2MkvsIWaoLQpgZSHpBedK5AnGYgHGsSQISEPM8RPsYQGgACId4SUzoSRDISSD0vYQoiQHcnGO4mVKCCKJAS8Mih71AQrK4MqOQh0DRSG5qCWd4iX3MSChQBZKSACowaDGYjO+EkvGIAAcIAF+/xIo8zEUnklTPA4AuiwWJoIuqrINACE+mKOE9GHw6KUoYYEBClMcZOwqca4ciHInezI0mjL2AJJzJiInb4EorZImS+gOnOQs6IUefYMYwrIhyZIpXrIjfdIkjcLV2MImtyEnSSYONg5zxo8ihfIMQmhhcM4hTOkz97EATEkLNKYaMsMuShI5GUA5bRIWHoAyiQEfAqUu79I3nXIzBfIkSwQKjmIf1bEgkWU0p6zVcKEMxkLN1Kk1EcIsIbIj8yABjuYV5OMgc9IJrnMcr5M9ulEUXsEh9gIiB9QkS2I8zYEx/8Y85xIXmIUup6wa5PEgKTM3GWA3fYQ7NdMgoBI8j/+iREIuNBfAQf0SPbkSWV7BWuCS1F7JIaWCQd/lylIBMg4AMmRLP0MUg8axCNoFLzmUEw50yoSTIKFTRGsSOX3DPPMg23AuD1JBSQ/BQj/SJN/nDP4zM//RQyUUQaWyGTyORE3UPLmSMS1CHbUgI18UPn8qQPVSa/bxLxVgIkqiVgizK04TPefGLoczKxwTTxWSSqNEpnq0RFz0fNARPaD04Ng0o9z0HDXBnnaTNBh1G5ExLyE1GzO1wbhRS69pJKOxUS/qUdMJVLWRUy81SD81UcvpHVMVGk/V80oVRqvRU6vJVDf1uYJRVW+VVb3JVWsVU2c1Ur1RVGODAHAsAnn/1ZVwNUSS9UcwL7DyjViNNR9wgRxzrKBYYUACwokmElahQjSVtUwG5loPYUIESo7MCln14Fn9IVr3SfQ+z1I9ZQiWYB0Rg10BMs5s0FbLVYWQTFvFVV7zh2D9cV7zwV6r9KvSIVojAWPCB14NymALcOG25xZky1yqhj9cyqR26iw+ZUBiijfdQINQyoNOKoQiA+OgqXvC1V+nQGHxtWHdtRMoVqw01Tg21oPOjBnKDFZKaAGo5THrEVfwjBVcBWjHbic8bkSXgGMX1AxMCmVHlliwCqW602LXABeeRmO1YGrmRV3AyllCFjq8AKvmzAyQyKnqUWFCKY9qDopMaYoe/4M1fVMwMzYVuKNjD+Nji6tsA8ZlS5a3QOhJULZwA0cysCrNTkimuoVaY7YZ5sxt0ZUAaM3n+Gxp/MwQ/EPZGmAryCVzF+TtHCLuqsqRlO3l2rYNBsAl3oWUkqgeEVZXGYNr//UeSCYWEEVCBACwAPdQ8Ijs6Mgk7EEtfQNAoE7UXlZYsaVrrexdWi5ddmJsP+J3z1bm1mFtn2pamOg+nMjmpAhtD1WjINdaD8NmdLdyQS3TwmbTshLnAqEeaEVfi8bqzKfP9MCMlI6K0JeX7kGP4ipr9csJ8LZpbG1p5UJMRMt6fytt40SyPqkivHeU4tYVTknOxjf+fLN5b/cAcv93f3nXd0HXbBtYxiIirvo3eJFXyvIKgx83ZzWWOk5SswThDe6SfU+SgNPWa/5lP0VTDtgXaw5mXxyJYSxJLSdCs5KgsmrOPU+PXh0hhgfhrjzGb9+FgZWX7FI2fSlHCVijmRY340rYbsH1CTDWgAkYgasYDMh2hB3Hhe+pqWQ4iSVYlHIG2LJYWJ1SilWhi4/LZ7+Bfa0NgxbElDCLFRIniKdYguaBgcyg77oYT9HgaktGgAGsU/VYn3wkcXdXkngKi1EpjgsXNbp4mVBCSsIYmkIZZieMTm52eaG4sEj1nJrVTV6ZJWO5rGa5VX11Vas1VJeV/nq5V3/5Wxz2xFj/eZyGOSGiNV3niX4tucQCKjiIkhEcAG0adODKWEOOmVS6GZfJVSSb+Zi1R+A4IaEYeEsHGECpWQGAQxHEYXt2KMi4b5tt8JgPBaIALlH4tZWjmZkz55ujGFuP1V2B1RECb4uF5Vq0xEHugbdSI1pkynCoaxj4SojxgILvQNlGq8okV6a6IA+OTSFViqL7WByCTQTtmXkEunI9tJ9hL2epVlr4Rst0hVYoCDz8LApqmgtMpO3SijVohNsYN1d6hVcmzmOT64rd+BgEtyly+RDA12oYJkv0wKENr2DqbAGqOl21wHuVQznWJRiCYatnLg2kIIgOAWnYQBp6jhx3mRsY/xdxLaeh4+JXItqjTboJDEjtmGUAetaknNpxS+owUHY3GXNDnzicC4FyxXdvcO5eW0J608BoLNtZPsmdW4sJ7ixbQwnRLAVewNblxLa02nhbSZhu01alaTcSoG7Ovsiuw4ZmKA1n7MeiY0Q5NBpy+qKlvsHpckuNLjpLBMO2pyEV2PJhgrlq5LY57qOqJfeW6CUftNoPjKCrg6NfoAFg8jnoAuaxl8qqlsgMcu6Vm7V/S/gx70FkQFiZTIQWokC9EWRF+OCPZkR554y9P7iTBWtdQBmOPwxVIwHYqDoeHiMwliawVElTpqyd3/l+5FkM6NkmkDNTzoWxcqth1uXsyP/BdS2XdHGkYmVHEl7bN2L7qhOctr/BuO1RCF5GAGIGbPgbeB146dA7DayB5nLW9iK4hN3WSfYljBKYujclCn78Sa4ZR9pEle4s7Wwpaqbmnnh3gZsabIIXqgUcoee6cLKiDPTBLlO82YpBMImBmtexGoAom/kFEiTn73IrpxYEtwTTLk6aUkXcrCyBwJ/bwK8AwWe7NRbcw7ema75mtMiOJWjchKXgknpc7fhDTWd3jyM5LUjoFp4jxvjbqeKEJl/B0hkCClyETIYazcTYb5Ctl/LGk0G2yseYmlq7YtgqPld7sUFhPRLalC2nj8H8z6lDMMhcfBinsYwqF4Y80RH/AZK9YvDioJhk9Z/p4zZuWRRqVqGKWU8cANIDCGCdnbGbS6CX+c4tAXyKIOeeYtoPVppftdYNy9vLt9l5udqHdbmVud1pmVZRK659GYYJ+hLMuRLMfXyW4t+/PcIwWd5bqd37PWBDgQ8kimCF4k/sx5m3/cJ2daUN8j66QrGjenYT3lP2Pdz55OF1j91jOstlOZnrozUYYtwxCuEtTqauLAnKbGu1XSw8aqUwc2+6nOEhQrAp+QxUSuQViBVGmlrUImofWh+E6WkOOk2MIqXrWd35HdBJy6BEalkKt4O+ASRUI+alj9tbd8osBGk6+3IFYOX2icGP4MNnSDegm+cp/1sNSEnHoirgc4gV1JoZULcKptuy7RfLX10qYiWVSihp3oVBB4DcbaHIOGaR/2Zm3TGZn2XydbYXmMaEtpdyC6azv15W0dWDBcO+Qc3q9glnADuWWqRS5g4eghe4RV66CUC4o2HITypsCOfKWXt3sokx0QEv2PPwIdJaPqIkSEof3qIK6LPvgdTiz5XqKZ+vf+kchteO0rc17Lvz93iJRQLDU0ky7vJGDErt34BLGIPPgc5j5h5lMPz1L/sjKvski5jvq5fV/FlrnyJQiGFFysHS1REIFgEFAPAIDIqARqFoCDSLhYBBEHAArFglt+v9gsPhgLjsJZuVA0FRUGAYEv+PrkCRKCYOyufc0Vx3NSCkERYaFqIZJhYNBDiyWUFRNUItLDkGHDAoBCQUsO1xXmUlARTohTo2EJABBhAAHDQJJBEkPEZOVZUWsRYhDL5GZgIgOFY5Kli+Kh3Bdi0eSk9TVxdFWx9OLWxfPnhuCxEBiBcxJIAeNSg1BDwMB6xnz0PTXxOyOkZRDnYxBIAiMAUKAEoF/oAyaMkew2nYzDxsKHEiQ1pfIlLMOBGjxliYHGFpt2DYgnJG4rWh4oSgFCparIzreIjjTIq2GMjMSY/mRZ0+f3qJM+cM0KLUeFJsxEbIHZEARJUcAsAAp2cFeBUEmAXJViyN+hkFg5TQ2EP/CraETStWWlm1bue1feszLj2mOJ9mciokQFRMAxayGqrEmKN+WgCcIyb3nj26ix+noesYMuW1ld9OlosgymVFDDN3viw5NOmapY2CdpsA7Wkxqbm8bu12tOzaRG3rjI27sm4AvXfPZQsc9+/ht40jV9K7eHKKkj9Cjy59OvXq1q9jz659O/Pm3ZsDXQ6+9PfH5cfXPo++o/jhgU+rx7x+vmn6ttsDdeDoWaQ+Wm/pAwo7nBEWgGEfKRNWfLPZ12AZCzq402dGDXQgQfqxcQtOSilxzhYcWpHEYVbIUxSEaZ0YoVwpqnjUhEAdYUcCOFkxBQIYAqAhYgnckZIBU7Fk/4pLoxyGmoostoiiggT40ppFXjxZDX4+tSNAlVvVgcR/Adyl41OlqMOOO/CUaOKRSSY5FiVamQFIF64wSUaUEj05pyEWudkGVg696NMTCGKZz5Y4nROFEKg8wZkuL0ml4JloPtrmIKwsJGWcMtk5TaakZDNlTiS2RIAVbOg3aFagINAjI1qF2FVWYIUXKaQNRsMNm2r0k0cuy4iiByAkwekLnqLA6pssCAjkiB4F6pEsQJggYJEtnfhKLB1+FQQJttZ4KtMUQ+kXLZtTZIjJKUqs1kWBB2KRGCqxRojkrD9F044jdzEyyAF8JWCJA+uwipAQz2Tr26V41qKScvLkYf+EqsUQgY4SdSYh8QEzDpDwj0UMzOkaHW/qWWO77VspfLLOO1+9mOCblbL7mmtwLAjJwkWwciYByBMbXwPLn5hUAWABO09cCi1E+2aAzgrPrGe2NXPKbZ+1DRBTa/LSmzKtXdgqYL5KLNAvbLDU/DEzjLDxirA5s4F0z3i8ywcAfuQoYB1OSywAxm0zLYQlDbDt9xJ7Cjey1lnHezh9asI6TDBkI7SVIwvc7DHfPMsMgLN/6NPEtACFbaC0tzS8NOaEKcB2MckQXh9cigeXOOzoYT07bFPb7hzKuQ9XO+/d8o774sEn53vuwBP/uuzJA2e87cgzL+Xu0V8tV55iEfz/RT7Zh7U9WcJTL/3y4cumW6Zni3H9Rdx3oYDXYYRsj/siS4japdOv5zz5iNgTfxnqn4F9XEiAAKHUOoYQkH7KaxMm3gcGAFbOf9agmJHGtz/yEKJqhZmKKBzwM1ipbQidsISzaCGAJ0COg5iAhb0UgC/CNKGFDICZgT6IgFKcghWsOICzNEGJh7lsAAyAIf8MJynN8aVT99OIBGWiP4088YIPyqDGGrCOsImKcCGExQAGITG0obBpgOtZHXAyP+XAooxPEdC+GPCkG0qBh2xq2DdY0bI2vGETaSugZeoHNnK9KVcH2JVvelUwYO1xbQWxFmyO1cPVKUtzA3Hc6Ki1/8gNSiSKupPiydJgunMVZJBavB8w3LaGMNYMlK8okIHGBsnCHEAULikFHE0hx5V8xAD6+eIvDPM4BXYqECyzmb745S+AQUJg6ItgzjQGG4bp4RtcQEDE7Ga0irHhYgzIGBIx58etcRKDnrycFckhDKv1rEnAqJsa0uarGF7xnHd8mxqlgIUjVGEcbtBcHpqUo3eBjWluYAADPpG57xmxCPbiks0wcQAaEoQZZRMA1NBmMEWazpU/O4be9OE2iiFtEpfLJP7CaZ4MXo4qICHHLUBIykkByISSU0ATbFWVS0QSjQp1aC6oEDoEGGAKdrhlLwZSAEEVixJCPGhkcNe1QP+CTWw6nWjHLBpCywEJc2dr2Er60ARe3o1TedtbVklqQZNSRpNagx5UJwYtmU1UcnxhZsHclrnNuewg/HzETytZupE2RK1mRatoCDvYBRq2qWdNrHwY+81gOhYiJY2smSgrtYRa9jjgzKxaBOtPajRxMWy1rGADy1kGReYYQfkIZ6qhSC8AkA4HlIabYnvZx2ZDguj7gvoaMVs/AbKIDiotYcuy2z0wbR6fha0DZWsP2+JWfG1qrnNdw8eCNWNGkbluNhzw2z5u9rQV3K4K92NXLrghGaKYwyOdhbNXPpSn+rDEMLCiw0wQ0qj0baBDf5UMXkWyVEl0DfiqodvrXi//tEyVSAOoS+DFijc3iGDhOF6x0aEBzQ0GeAIb4EjHO0jstb8gAiDCdkyQ2VcrJp5bmQrggKpi12yWgGPAfCOYKWI2DK4wZAktYtCdqXQ/OHUhTm/1s0HOV0iVKBAqETKAoVnrYo/gwrTyQENv4ni4EXYUWWChSgKct2j0HMBGqaASRXaUIICA6CmiMKcmsXmI0KpojCkaBYHAdRY2mmc9cvzAtCWTnU77MRXGaDA1uk/D2HXaiv/FBRfLrMmL/JEgptKvAbAGXdkkq+vsQ1y0GpeF8QRzctFbCmZYhKt40BYp5EY3TLO0UoIzdC/QsOIitPEpCIAxrLM16yRItLWq/wYvZKeb548mgdBBRcUqPwKMfiQ4CXFeV6SDjd2BKIsAnPgLcjcm0sJpecuVhcgxbDUFUsfM1GOWpD48IkKPdc7dSN4g6lLs1sIEuQCDIAnMDuDfISwDcokZAp9v52fe7rFpYM3Zvgs96npmIY8GFfOtPWLGYAyFGE/GbqW90PFVZ4HTwByeuOE1DSFgGdQFZm6e9woQaSXDp0JlxkI1wQlPeK1O0Mr3IAiDjCFErryTSLISquwrB49hsiXfiDQEhXROjpayn47u0jMy9TStPLNXL3bVndj1LCN2y1u/7dehWPakH5yzY5fu2TfZ9j5T3S3LlYaCvQ7ht8OFO3rfO//f++73v2Mi67BRbRcgWqxpiNhmT6/7/xLydM16Gu/UW3tOQv0FOiuXI9B1Gj02D/bIS555lLc7eYP8CsyjdyAKWC+7ieFeTjGLhvMuwH4dkeId5jfJwxiGv7UF8ELmVDlKD/1ag2f5BlSYAIb/WRWGxuFiVCyaIGZD4qlZsEY3AMVUVrHYHK0EF/Pa8YKjcaANHm7iGz/9XbZlz1AvZpkdDTpEQ7PQCsZmqL0ZDdOec2tra+eitpz5hRf6PY/6kVc5DYz7cR6qRd8AsVr8eVVBYEHF/dr2cYxUWZyu8dqHCEAFWpsAgh4BHo8BPki5TcG5GV51MWDrNQHMcAK8QUH/CyqL40BS6lhgSuCbKOibXC1Av/1bgnyg8N2dCM7L6LFHNaDc/hhhpxHh4Syh1TVdA13QEwpXEyoOFTLd0mGhYlnhFZKg2A1fFw5hEVbdFkqWGDrhF0aYGX4eGkIKG6ad1oWhG5Lc8QDeHeJhHuohHKIdHc4KH6YMII6HIPrhGRYisYkgIR5iHy4i3DWhIjYi5EWib4ghJE6iEF4iY1ihJWYiJ87h2XniIVoABjAGBljAIo5iKZ5i6KUiJQKAKWYieIRAAFxABQRABVxAAITAIs5iLd5iLu5i6PWiLeKiLsYieIwAdIxAJCbjRywj+jUjJjzjMSYHBkAHKTaiNX4E/zYSnzZiAjdSI3LkoiNcwCWOIy0S4TmWYzg2hy06QgVcojveIhHKIzyyY3OIQACIQCzm4z42YT/eI3iQQACQQCwOZEE24UEGZHNYQACs4iU25EOKYEQuZHOYADVeZBdmZEVyZEd65EeCZEg2zx6SZEmaJEkO3kmq5EqyZB5KSUvCJHaQFh0uQih+oiSOIdTRJAh2Itu1iE1W3k5i4jFmBlBqomMZ5W7UJDsW5R/OpBsuZTg25Rs+JRpGJTVOJZokpdlBJU9eYlbi0kp9iuosmhnMXU9I3WJsHuNJhOdBBHc5YhSdpSsBhVu6FkfMpSvyCRfMnwKUiUzYpRfkpVcWl/8XyJkqLMBgzsNafhdbwKVVPaZOLRjYYUQsBUhZSoRiHldufVdgIh5eYgRYlpU5wYG1uIFQMcACiMI6EJIIEYOAjcQAyN4aQJQBPNL3eVQH4WRhvokC/IgBNABAZQRjqoVn0uVmPthRbh8osOVnPkhkMoRxHsJg5qVous0rVFocjMTQnMMgxQT2+UaguYOY+R+u/JPD3CACJhBhqhwXJKEFGtQ5PMBtikknSA7tAZ/GRdlb+ZUewKYb3AKRKRUD3Ne+xMnNmUyRJdIr4FeS2UsCMNkqlQKsWQFaKic7HB5t9sjdyBCVTVKQ7VsBBCiBipDY6JfMDKhqqkJ+NgvpHN3/kw0LJqmBtcSnHHDBQrmTvjFL65EBiPIoI3Ya0ghBQX2EKMURcA5BfMWMtaUXArgRWQLCJgxCmfFMk4CSbDoiY0XDvqxKJgiLnp2nNE3M0FzgMYVnyBWEM+Eal6Tapv2DYAxUQQlAnLoPK4DCFhVE45DpzSxF9zUYmb6NwQCZSlSoZkWEQeUDQnTnPyGa1/BSdvZLnH6CDuXpo2GBMORRolkNq0xfLGCMb3qMmjJCPPVgC7aW3vyIK/yl9YUYGUBq2FBfaPpkXw7Cx0UNKEVcxQUg3OAJB+oRughnreEEAh7XVkKhezJNDpHBOWjbAVDpYIAFm8kMKyjN5VgmR5GZ/8K4xJ49SRetUxYgSyJcVTHAyrdWjrvpw7cGKjOsgQMcXlyCwcfFFS08QBOwEli4Dbbh14SGay8dZiutki8hqQLoATNQq7ZWq9NkVDtdgyYQEMFOE7QlXMh51JmRgb7uy49U56x+BCiY3i7EEe/J1S/JwsC5kEX44Jx+BJMYFRdsAhQEWabpJVJ6weotRD+hwWZo17CN6cboKjO82uVAGj61acjhi64kQRwMksQJgD+Nq7pGHEEZ1LhWnKJdQ8bBgkBIVaHC6xccwRbs09IYFMQ5IIaqm9KqEwLkmgI8jqTaTRMA7VdBAqfhCWBZFD5lgR3QAdNWWwTmjavCyt8C6f/I5aQUYcO/Zl+TPB8Lvokj3AENmgsXXU5PgazRmawbYYI8DKjTvpTL3tzULhEN/hAkhdGXuJWFzmzh6SAbuEmq3EXNUVlMfewwrEPa8hyK2h7mRlLk7tVfKazdugyb/MP7vCwUTKxByOC7fawLyqqLUGVa2s9ENGdRMKshpi5QTO9bdsRNgEFBBavbgRvWQa+JQGchZO9POAA6gVftnK91dcRZXITtxc5eamVVViJ7NqJocguCPd4Rju/9DmUs6q+lpE//KgJ0Giv4duFVioFmLtHXDfBR8C9qRVYClw/+Fh1NjGvZRXB5rYMMsQIn4KdrLotDHdJ/bZPjXlIrxSz/KVgBCp0mwQ2uYVlw9QQwGDiwYopXB9Nao1LKEiBTxE0TiXVgEt2QHakBqaqnqBwVGXEnz2KwTnblDTvBaobwCCnZCF+Kj8YwkeHofZIQchJPB+PqvTbJPjFp/dHmnTXBLrHuncoCKshmlAgDDn3vhdKwUOLx4GQwF8EKpF3Vq2pYd6Kqr/kpEpVv8TnvF/QwkdVaEbDtsY1n0FYgx3wbPhFrFqHRk+DqbranVRImrqbtvz6OL2AsJx+AuVIUa4VTBwfZBzuUoICqtSHvCQMcUgVv2+gmHWsy+yFiHteG0haCDpNX58ks6kYEraXt2pYy4KqbLbmtrlIq+XRwGRAz/20ZcPhqqSJI4XSiwTVP0zEzrMFGRArLcEpwjxhLQ/VSJhi8su3qYDMLHcjaUvGO7VtNc/hUcwN3h3RW4TYjQjQxlCGA82oVHDRkbUQojdSCAsykcyKLgbtar+94L0DTr/hWsCLogd7sFMHR0JSuplH5Qgt3ccvEUhGIqSVvkwAwS4kmqBLMzzc4AzTwmIuawuXcFy2oMHq2s4LIr0Vr803qMzcPQRoR2RlZnDJ/s6teEQEN8rCxtDnwhSxUwTrACSJXKpQQgQ6VrnIEmsXMiLLZKRK1zBNMNFP6pFBPnkaHzRzc67VSgSgvtS/PsR2jF1i4D8EiQIMVDDn3khdQE/9OsNJuBVtIBRVOJ4Ibr8RZS2VaF+4UarTDjIQjm8I9FRovILEvZDIqc8FJtwGE5ojYuAJ75SysUMXhdfXb1MxYbVPD2WatqERKM2IND6Jjnx/NBjQeIekM6gMVvPLLHlWP7rJdI9dddAzdFAxhcCm5djYrr8RDN43RIZEIvXatYZJE9zRWvmRMcvd02O9p3EhzsHNyXu9XimRhBTMU40avZTdRnjdv6HF5TyJt4x19kwYDC/B7p1V8L2H6HrQBMVFjEkJQ3Vgb6ndnNUdB26YSeFdd9i9+p8EwgOohdGs2O0ECpNwjU1AGl4GUKcaqVBc9cC8XHnhjockCNMB6/rT/T9glhJvBPj2FOIvB+Yb3i1/TITjARqsKYYQ4PUAsiZc4giNChSQDkCSDnO7IjUVCgpBECdWSsu4Qh5d0FxBA1bxPpmgQC5vmGhSaCrdmr8heexPCPiH5I+1oCUHLD1pClhdLAQwFUi+BAxxsYZT0l6Km1/ZI+nItHt35gEraGjyZh4OC91lvkCsJInSY86EPH9QMnY3fX6APLz25HL3PlxrAoirBvrwrlivxlEZqE1steNZYi0cxlLxVmD4Mq1oT2jx6mnYTbGyMo3VRjiTme0XcpePsrWM6X7r5rS93zxJypp4QLYMqe+OagMu3oSPO+j3JK1COQzHrj+MaG1eU/9tM+ty9VidrjpX3uEUZyynTUrSyMi0/eKnvLcQYeYYJDbKhDdTg2cJew8Z8g3dK02uhcrYLZ9iggr4uAip/K0v/eUBs20L4G0Ip+6Ez+6kRgPX9w0brLbL+DaQTDFh5Tq5Tua1rO8ekOMFgORtgcuMYDaD+bAoZ+2zTXRREsqq5mtxOzDjIGB/DuykIBo8ETe3KiT7ZMb6n3kv/OuedgtsaS0EEndmymMEf/HiRV7MzyS1MgR4Mr6n/XpPLrlBZvAVytjs/Qy411JTNLi+MLuSmUL+JeYRHwWHjVS1/Tge2lJrXVXLVOB83PBKxlOjkPMYDFMZmejRw9oDOVNApBP8k37EnHz3pZaZ2AYc/H5YRxkGGg8eIF/rgz69EwO9wIL5pUfFp+Ld9EPg/Q76ETfEeR6J9t53od4aLz3fnj9tnqnNRtC8Oj0VQ3coiJ3v+or7JTQOcj5O3N96Yf5c6Y/tYNDhi8aFxCkgcQPRdxl3tZyE1rGchSGdgHpg3EwJfC7/WuIHRCJlPFPQMK78Cl8GSLwARKYchxV5/+d4Ig7lDweYXAKhHlzaTFY0VcKmg+wI3eI3RXRnX0UV6DQEQKAKBBwAxDBwMAQKAEGAApAZhwCFtDBOAbCCxbB4KAMFAEDBIAWZAoHpQqx0JRDrOjDvdgcKCPOxrE0MgKBgSoBr/QiArMFRgMOTLm6TMC6jEzNTc5Oz0/AQNFR0lLbX0XAjwQxhoa7oTINtSQ1BYi71dSPBzaGiLFRhjayvCDGaAFDi4NFrEiwtuelq7knpaKHhVS4g9SGAYNmWWGvcMNliKZY2rbXZXa/DVJTiXqgcAAxBj1JZiCwA2Jo4hO5b66fETTxcvXwF8AeAGb5GBXecYJDgwzVSbjR09fgQZUuTITOU07XMy5pkaPE8MCEgA6JY/ZUgk4dk3LFgABFEmlfGHYJkUBM4OAtXjRMiABU8SVFOzxA6acKXKmeSEFA9QmDIJfEEzEM6aA0VpLZqCcwzSOP/CCIwzp47BPBqDLUOi/7KJVDWRhhxAWiAjVlGESR5GnFjx4k+GKaVK2GoluSYOCiwpYpkazYV33m6OgxEiLnutKA5Gp8BZMTVINWIhxCRiaGDfqpK6GkprkzKYAWheo+AhPHlM7t0TtGZtqzxu9cHNE4w55brMVHdm+Wo2F7SlpQh+4tMqY/LlzZ8X6ZjSGTd+JrcB1GQAoDF4D7Bhz9PVc32HYrphQBfx/hjiofkSUM2IIQpy7ZL5+GjqEl26cyIm0W4bJTdQdiOjlQcbkeKB9xKxwh8t1jiRPQWWm8Q5lCrBJT8KnxhCgTRk3K/CQ0hEI7ADGBACusLQI7JII488BaT3DnOANCRD0vAwtv+e9OQ1KidR70ott+SyJCgP6jLMO8Y8jCLWxKTEyi6zRLNNN89j8005GyNzTjsVi/NOPfcckk8/OYnyT0FxG7RQQzXJ06MpJ1HzUGsuWTRJcjqabzokl9wIQxiHSCxRRz+V09ONIo2jUUo0fTTMaUhlqU5SHvjmE41MZTRRTNWg1bvmnMSEgVuVBDXYQkU1hdVUhU3KWI5aLdZSTnKtBFq6MJH2VF4rSWUxYpHl9klPIwlkjyQU/Cs4RRhxhIF1qJkGL/0GsAXWBcwA50RcL/HmkKhU0YMB9sIVYz5poFBjgSoaiuQIN/BB4pFVnZV02U9IdGCJcu0pIKZHLAYQ3Gn/SFwkmHTBNbjASsSFo4BYpAL3jkGAcgCJedWxsa0hBoDkXMS27bZnIrct4AqAGGHHlgGKW8AijKSSysplohAuAfkECK9W0JpbpAEEOuuljYfMMqs1W1hS57J80nrgYS+Z/SQeAOZZ9Jhk9k2bmWm0xqeiyy4azJ6xMRkaJgBUZtiARh3yjgg1zFi3tQKQUYBqnkGZ3GfLGUtUXSSM4q8rSYZJwsdbHFik3SrCWqIaNmLeLikClvIDV7AMcPemV77iK6osFIBjK+aYmBeJvpUNtBPB/AHMWaQG2PrBJGa9xK/QmQOPGQN2HwvLgQ0gvGmsnuHKkJ4GSOCLPMIWIDZt/y9nf01PngYgQbV804wNEV+iHo5CdkkqaADuj18WplawsBwLNnloRCuwQx1/CAdGeukQZdrhq+FBzFXEclsq6KE802Bkgs8j2N0o5KOqOU4WA8JD/UKGhhJmR1dSwMgASHcZaDwuGdXqSOXat0MoeYJEBeBcTuiDIn2JLn7MWRUgqOILmMyMRvq5FxEDEYdlvAJHKxHRUYS3n918hQ8gjCDgXNUJioWxNUjwhRcN8aMgfex0+PsOG/mQHzg0gFd5GdgeDAAkSbiwQxepETjKFjsTBQBnONyIDnm4yEQiBlVquAiYrqQskhRPURYcyUUGdDlFMtKTfSLJI6XggL9xyf9McBrjJT+5vlW2Ek+u3JIlYemmTs7Slqm8JXpkmUv38dKXGfplkXbZKUku7lqOcg4wg7nMTtSSmXRiW3l+NZNN/EqURkomKJ+5TSxxkzzD3FkxacKtbIbCmd7c4TnRKcZodsJdIWsEgDjmsD2E6w35CA8bSPaEIsiPAPkamjHr5QV2GOgKXXhEGc4wAObIMC4y24kbqlAEhY2rnJRb5zptslGOdtSjHwVpSEU6UpKW1KQn5Sgu3QkFpWUPM9fgQkMC4g6zVMV/sGrA7wjg0BZJbpN6MEAqXvKI+AkgGoXLHTlYc450GMFS7bgoNDM6VaruLBQHeKOPgvcXu0BwH7j/Cwu9KoqWI/iECa8zJCFnwjpemYF05FIEW9xKIUbwxF86jaDnhBGLaSKqqn8F7EeIddMe5e+DfYtfEAUCLwPVBGqLeEABGMpA7rSFNEKlYvl4Q9QX7k+toUkedXqjuPrxVZzVDGxqVWtO3SgRjoPLSEzW+MSaqSVEzzDDD2OzAEgY5UNqNcMT6Tq46XRhenFQgLMACSAOAeVDe82RNlc7XepGjCTVoqSRIhnL6nbXu+pMU5ZOGSZScgm83kXvKs+b3kmx171VXS974/te+nZrvui9b331+6n8dre/+wWwoP5L3QEH2MB3KvBqE3xgBrcJpQ+GcIQlPGEKQ7jBF8ZwL4Y1vGEOd9jDHwZxiEU8YhKX2MQnRnGKVbxiFrfYxS+GcYxlPGMa19jGN8bxDoMAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Figure 1 in Ann Allergy Asthma Immunol 1999; 83: Suppl. Copyright &copy;1999 American College of Allergy, Asthma and Immunology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_10_25760=[""].join("\n");
var outline_f25_10_25760=null;
var title_f25_10_25761="Components of Roux-en-Y gastric bypass procedure";
var content_f25_10_25761=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F52350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F52350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Components of Roux-en-Y gastric bypass procedure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 537px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the components of a Roux-en-Ygastric (RYGB)&nbsp;bypass procedure. RYGB involves the creation of a small gastric pouch and an anastomosis to a Roux limb of jejunum that bypasses 75 to 150 cm of small bowel, thereby restricting food and limiting absorption",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_10_25761=[""].join("\n");
var outline_f25_10_25761=null;
var title_f25_10_25762="Vitamin B complex: Drug information";
var content_f25_10_25762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vitamin B complex: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/42/42659?source=see_link\">",
"    see \"Vitamin B complex: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F234522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F234515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Dietary supplement:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      General dosing guidelines:",
"     </i>",
"     One tablet or capsule once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Product-specific labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eldertonic&reg;: 15 mL 3 times daily, before meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nephrocaps&reg;: One capsule daily; take after treatment if on dialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rena-Vite, Rena-Vite RX: One tablet daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F234505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Content varies depending on product used. For more detailed information on ingredients in these and other multivitamins, please refer to",
"     <b>",
"      Multivitamin Product",
"     </b>",
"     comparison table.",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F234497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9626984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with food to decrease stomach upset.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F234506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary supplement",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F234527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nephrocaps&reg; may be confused with Nephro-Calci&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F234509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F234500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iron toxicity: For products containing iron: Severe iron toxicity may occur in overdose, particularly when ingested by children; iron is a leading cause of fatal poisoning in children; store out of children's reach and in child-resistant containers. Adult preparations may contain amounts of iron which should not be used in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pernicious anemia: For products containing folic acid: Doses of folic acid &gt;0.1 mg/day may obscure pernicious anemia with continuing irreversible nerve damage progression.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F234513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Iron absorption is inhibited by eggs and milk.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14189050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Water soluble vitamins cross the placenta (IOM, 1998). Refer to individual vitamins for additional information and specific requirements during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14189051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual vitamins for additional information and specific requirements in nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F234511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food to decrease stomach upset.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nephro-Vite Rx Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $46.43",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine), \"Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B",
"      <sub>",
"       6",
"      </sub>",
"      , Folate, Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      , Pantothenic Acid, Biotin, and Choline,\" Washington, DC: The National Academies Press,  1998.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10312 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-FF4A722CD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_10_25762=[""].join("\n");
var outline_f25_10_25762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234522\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234515\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062227\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234505\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234497\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9626984\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234506\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234527\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234509\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234500\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300222\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223649\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234513\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14189050\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14189051\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234511\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324101\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10312\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10312|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/42/42659?source=related_link\">",
"      Vitamin B complex: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_10_25763="Manganese: Patient drug information";
var content_f25_10_25763=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Manganese: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/31/38387?source=see_link\">",
"     see \"Manganese: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F807895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mangimin [OTC];",
"     </li>",
"     <li>",
"      Mn-50&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to manganese or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703831",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad liver disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12073 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_10_25763=[""].join("\n");
var outline_f25_10_25763=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F807895\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014865\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014864\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014869\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014870\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014872\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014867\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014868\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014873\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014874\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/31/38387?source=related_link\">",
"      Manganese: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_10_25764="Osteo in patella";
var content_f25_10_25764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Osteomyelitis of the patella",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 437px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Axial T1 weighted image demonstrates signal changes and cortical interruption overlying the anterior and lateral patella (white arrow). Incidental note is made of an enchondroma (asterisk). B) Axial STIR image demonstrates high signal edema in the marrow of the anterior and lateral patella with overlying soft tissue loss representing osteomyelitis. A small knee joint effusion is also present. C and D) Pre and post contrast axial images demonstrate enhancement in the distribution of edema in the patella and overlying soft tissues (white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Perry Horwich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_10_25764=[""].join("\n");
var outline_f25_10_25764=null;
var title_f25_10_25765="Hyoscyamine, atropine, scopolamine, and phenobarbital: Pediatric drug information";
var content_f25_10_25765=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hyoscyamine, atropine, scopolamine, and phenobarbital: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?38/39/39541?source=see_link\">",
"    see \"Hyoscyamine, atropine, scopolamine, and phenobarbital: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/38/18021?source=see_link\">",
"    see \"Hyoscyamine, atropine, scopolamine, and phenobarbital: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Donnatal Extentabs&reg;;",
"     </li>",
"     <li>",
"      Donnatal&reg;;",
"     </li>",
"     <li>",
"      Hyonatol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticholinergic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antispasmodic Agent, Gastrointestinal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/39/39541?source=see_link\">",
"      see \"Hyoscyamine, atropine, scopolamine, and phenobarbital: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Donnatal&reg;: 0.1 mL/kg/dose every 4 hours; maximum dose: 5 mL",
"     <b>",
"      or",
"     </b>",
"     see table for alternative.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Donnatal&reg; Dosage",
"     </caption>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"120\">",
"     </col>",
"     <col align=\"center\" width=\"120\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Weight",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (kg)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mL)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Every 4 Hours",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Every 6 Hours",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         4.5",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.5",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.75",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1.5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         14",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1.5",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         23",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3.8",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         34",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3.8",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         &ge;45",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         7.5",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Donnatal&reg;: 1-2 tablets or capsules 3-4 times/day",
"     <b>",
"      or",
"     </b>",
"     5-10 mL 3-4 times/day or 1 extended release tablet every 12 hours (may increase to every 8 hours if needed)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F181264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir: Hyoscyamine sulfate 0.1037 mg, atropine sulfate 0.0194 mg, scopolamine hydrobromide 0.0065 mg, and phenobarbital 16.2 mg per 5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Donnatal&reg;: Hyoscyamine sulfate 0.1037 mg, atropine sulfate 0.0194 mg, scopolamine hydrobromide 0.0065 mg, and phenobarbital 16.2 mg per 5 mL (120 mL, 480 mL) [contains ethanol &lt;23.8%; citrus flavor] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Donnatal&reg;: Hyoscyamine sulfate 0.1037 mg, atropine sulfate 0.0194 mg, scopolamine hydrobromide 0.0065 mg, and phenobarbital 16.2 mg per 5 mL (120 mL, 480 mL) [contains ethanol &lt;23.8%; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: Hyoscyamine sulfate 0.1037 mg, atropine sulfate 0.0194 mg, scopolamine hydrobromide 0.0065 mg, and phenobarbital 16.2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Donnatal&reg;: Hyoscyamine sulfate 0.1037 mg, atropine sulfate 0.0194 mg, scopolamine hydrobromide 0.0065 mg, and phenobarbital 16.2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hyonatol: Hyoscyamine sulfate 0.1037 mg, atropine sulfate 0.0194 mg, scopolamine hydrobromide 0.0065 mg, and phenobarbital 16.2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Donnatal Extentabs&reg;: Hyoscyamine sulfate 0.3111 mg, atropine sulfate 0.0582 mg, scopolamine hydrobromide 0.0195 mg, and phenobarbital 48.6 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F181251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Elixir, tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer 30-60 minutes before meals; do not crush or chew extended release tablets",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct in treatment of peptic ulcer disease, irritable bowel, spastic colitis, spastic bladder, and renal colic",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F181300\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Donnatal&reg; may be confused with Donnagel, Donnatal Extentabs&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F181298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, excitement, headache, insomnia, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Lactation suppressed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Bloating, constipation, nausea, taste loss, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, urinary hesitancy, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, cycloplegia, mydriasis, ocular tension increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction (may be severe), anaphylaxis, sweating decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hyoscyamine, atropine, scopolamine, phenobarbital, or any component of the formulation; narrow-angle glaucoma; tachycardia; GI and GU obstruction; myasthenia gravis; paralytic ileus; intestinal atony; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; hiatal hernia associated with reflux esophagitis; acute intermittent porphyria",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic or renal impairment, hyperthyroidism, CAD, CHF, cardiac arrhythmias, tachycardia, hypertension, autonomic neuropathy. Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance and psychological and physical dependence may occur with prolonged use; due to the phenobarbital component, should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal. Use of anticholinergics in gastric ulcer treatment may cause a delay in gastric emptying due to antral statis.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Heat prostration can occur in the presence of high environmental temperature; use caution in hot weather and/or exercise. If diarrhea occurs, may be a sign of incomplete intestinal obstruction; treatment should be discontinued if this occurs. Low doses may cause a paradoxical decrease in heart rate due to atropine. Elixir contains ethanol (up to 23.8%).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F181289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F181260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F181261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F181271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies with this combination have not been done; refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anticholinergic agents (hyoscyamine, atropine, and scopolamine) inhibit the muscarinic actions of acetylcholine at the postganglionic parasympathetic neuroeffector sites including smooth muscle, secretory glands, and CNS sites; specific anticholinergic responses are dose-related",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Well absorbed from the GI tract",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1059366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/38/18021?source=see_link\">",
"      see \"Hyoscyamine, atropine, scopolamine, and phenobarbital: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintain good oral hygiene habits because lack of saliva may increase chance of cavities; may cause dry mouth; notify physician if skin rash, flushing or eye pain occurs, or if difficulty in urinating, constipation, or sensitivity to light becomes severe or persists; observe caution while driving or performing other tasks requiring alertness, as may cause drowsiness, dizziness, or blurred vision",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13370 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-110.170.48.130-053DC9DE2B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_10_25765=[""].join("\n");
var outline_f25_10_25765=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181276\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059367\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059362\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181264\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181251\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059370\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059369\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181300\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181298\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059373\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059361\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059360\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181289\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181260\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181261\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181271\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059359\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059372\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059366\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13370\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13370|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/39/39541?source=related_link\">",
"      Hyoscyamine, atropine, scopolamine, and phenobarbital: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/38/18021?source=related_link\">",
"      Hyoscyamine, atropine, scopolamine, and phenobarbital: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_10_25766="Gastric varix";
var content_f25_10_25766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F87068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F87068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Gastric varix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 401px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGRAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigApRSU5Rn60AT2VtNd3UdvbxvJPKQsaKMliegr3zwf4Qg8O2a9JbyRQZpccg919sVn/DLwemk2MOoXoQ6jdIHAJyYYj0x6E/mK79omKPmQcdc9x/jXDiKt/diexgsJyrnmcb4sgLWJlGdyHGRVKx/eRKpbGFzk1va7b/8Su6VWP3a5GCXbD8zjgBRmsIya6nZVhHdI1bJvPuCgBwOxHFb1kigkMyjjH0rIseWQRkltvJIxWpbxOTjA/Cicn3CjC+rNNFZNu1d6n+ICopkKMQBknnpSWb3CRMC4VPQ1Hf3LJGsiMHAHzeoNZcz7nX7Iz9YuY9M0u6v5WwIVwq+rGuR8DgnS5b2dstO7Nz9e1T/ABCu9/hmytI/mnnmLnPUir/hOOI6La2zqqPEMMGNdML8t7nn11aVkbCofLU8EGqluhuLl7g/KqZTHTNWZ1AVgpKlQdvvRpsBa3Xgs/U5FTK9txRWpaRsYIBMeeDjrVqSICAysygHoO4qKGNkKKrDy15wetW0dNwYr8nQg9Ky95dTsS00I/DZ+0+JdMSaWKCJXLM0vG4DoB7k12mqS/2drt20oEolx5aqOUB7HtXmur2aSysd52Z3AA46cjn611eh6tHe+DRYyOTfQyhizfM5GepNdlCpZWZ5ONpO91sbVrrUFpCIrgruRy8Qx0z1zTZpjcWMheZVgkIwSehqO0u/stjepLaeYblAqyFRx+dNhsxFGIi6mNuADzg11o8xis8T6daPFO7GFisoXJLHsBVRYLLW/DutWurQKxiQuqkYfJB2kfjWrBY20kbRxvtaNcqc9TUWmXSy37STovynYxx1ApiPmr57e5bRb9WWVDviLAAkHnFIw8szRSgsG+VSoBxX0B8S/Cmia94d1i7t7IR6laxB0uEHIAr54LPb3q2Ny2ZYwpilHRx1zSYPQzFbEvkPkEE9qcGCscnuAKdfL5V15spwXJGR602P5ZCWUEYJzSsK49trpuzggkYxULkGEumeDyanjVThieGHQVFNEpgdUJHOTzT2GtRLpV/dYyQzAFh0xWk+sW2l6/G1sWms449hB4ySOtZSJJJEyF8g4I/+tUeohobQQyIqnIb3/OkVsep+AZZ/EltJaaNayXd5BulkVeuwnjr78VYti4SVLiJ4p4m2Op6hvSobTRrjwr4L0Hx/4IuHiJQW+oxSsSGcnH3T1XIPSq4vr7ULwsSrz3J37gvGfWsKumzO3DNy6GqH2uVLD5/mz6VMbhQu1pFAA5JrLFvJFGWmLHHDKo5z60senSzsFQuzkZK+lc133PRcSlLqkkszCKCXywcK4HDVc0p545HMsEhjPOD2rQjt3jhRGMZAHYdDUkNvO7FMnBqeZ9xKmn0K0em75DIGBBOcZ5FaP2YQWs6L/GMH6VbSNGOQpCgBeO5pLvfI/lRoVYgc+1HM+5sqcbaIoICBxkFMBVPpUshUAlTlvUVIQ7XALoTtXbxTLNQqSLwHLYy3TFDbfUVlHfUcGSQjBG49d3FNuV3nyZCFEY3A54HvUF60UBzvDt3C1RlE96rfZm8onjc3f2pLz1E+V6JWN/w9ol9r9hql1p6BlsSV2lxmZguSq+9cjaXf2yLzHVokJKmNjypBwQa09Gm1nRY7q30jUnt7e4BklDEn5yMEj3xVCxDwQyWsVvJKUG9wsZYg9d2ccfSq5/5TJxafvCS24ecOJQYccAHn8qDbbmGQFGCc1p2sSXEHnJGF3qCB1z6/SoXjlRXDLjHA+lLmkJxXVGBdQA4YvHhSTjPtXL65BG0IhLKZT8yH+ldJqLfZlMildxOMH+LPasGKxeC5dtSiO8DcvPSt6d97mFVRaskcfKrK5DjBHWmEYrr9W0+K7snkgh/fLgqV7+oNciww3TFdcZcx5tSDgxtFKetJVGYUUUUAFFFFABRRRQAUUUUAFFFFABRRTj14FACDrXqXwq8Gx3Zj1nUYxJECTbxdQSP4mHpXA6HprX90oZT5KnLEdx6V75obmztLa2tYhHGqAAAda5sRU5Y2R6GBw3PLmlsdBbRLucluTzt7VbktXdVLMAh649KLaLLDCDIXn61anJEQXgMR0rhtdXPb62MHV1jaOZEG9dmM1xosYmfZLGS6cqQODXcXHyxupUb2GOKpHT3QwyBRt6YFJPUvk7lGzg82DcQE7YFa0EIjUbOWPQ1PbIHALQhV7j1NTBljkO1B6CpncqMewxbYKNzc55qtf2aC3kaLhTyQfWr7KzhFxxjpSNwCCu5ehBqCtTyrxFBJceM9LgjXdDFApOORkk5/kK2Na0yeLdfWMRMkYG6LpkD2ofSrrW/inbaVp7i3U26uxdeFABNdHcWl3ofiSXTLy5iupNoaN9pUOp9q6op8qOCVnNx6nJWWrNJbzExsGA4U9Qa27Bprq2jaceWzLwtMudLK3s3kxKEd9wHp9KkghljuNx3MvC/Q0pSTKhTZdhijiYMudzDqBmlMUkshVHUY569aurHsjHA2gYA/pUQdIoC0S733AEn+VQ2bRTKV9bTNZvLtAXsAat+CbqO1mnFzb7WdAQ/NQ3Uzz2jBVwAfmA/lUem6lJo+p295NFHLBECBERnINXSkrmVenzQZ6V9qtbjSgzYD5HAIPFLH9iZj5WZeAMAZC/XHSodJ1OzRxfNEn2WZPkVEBKMa24YRcb5bBRbmTqXTGa9KLTPn3GzfNoZeoWsAEMat5bScZzVKa0nsIgsqRtiQglT1Wi8N3f6gdMmjVPsjbnf+8D6VsXUcFpZK7jzZFO0Rg8fWqZG+xzd5qcthKUhg8+zunMZP4dDXnfxN8DQ64ljN4atkjuoYj5ypkksD0xXp+jx2873IlDtChLhW6BvasCK6k06a6v7DzmIYk4oFKDPm5h5kLW1yrJeQMVeNxggik0f7FLqsSalNJDZMNs0i8lM9wK9M+MPh/TLe4j1Vnliv7oeYIozjrXlKrukZBH935hjkgj1oIsTKI0lmWJ3eJXIRmGCyA8NjtmmGVcSBc4IqeRmiCiWIxsy5AA6iqymMPykgOOjHjFKwK6ZGjtEAjNuQjI/2TUl7C0kaM0isoA2tn7x9KaLsWsF4i2yulwgRXfkxkc5H8q6HXfCMOjeDtA8Qwarb3kl85MltF1twMEbuevakVY6zWr+88U6H4Zt7uNraDS7XyfKiY4lHGCR6jArU0u1FttJDFlHBAxgVlaBqNveWSMJEW42hWibIYD1Ga24pkhjZmlAZOPm53VzVU2enQSUNCw0M7QckElsgeo9aWByl008cv7zGGAH4VS/tpAWjiXc+QuccGok/tBmeVYAATwMcD3rnO1O5oW8Ehk6Zyctuq6jN5jmPZtUdSawlsdWuCT5sOCe2dwq9/Y8oQAzSlv4tp4JqDSMS+l5CqEyugbPY1XvNUtLY+bJcKVPfdyPapYvD8HlgzszA9geKItG02WWOKZIWjJO4E5pXL21KYvpLyIC2X5wRgnuKJLK8nkG5lRQcnHWuhElqmnxW1tCgMbnfIRyw/wAKq6bp9/4j1z7DpYFvEIzJNcyKSqgdhg5zTWuiIk+X3pbGZBp8EMzuWJfOMt603Uf9GgkkITA5zn9asvp97omrahp+qkTPFteORFIWVT/Fg81j+I557hLOxtoDLPdyiMIOr8gYHpTad7EuScHOIaxa6no76U2sW6CC/AkUI2S65yV+uMcV0v8AwlMGjeJdWk8LabGmmXtoiMAhCo4GM4PWpPiMz3njW1sgStpptrEqxvzscjkj3I2j8KyHlEUDwbSGY8Ae9U/d0Rlb2iUpFBUFpZoI2wMFmIPQ5rAvdSu7mWb7FE0yAYDDsa09VhvEiEMcZUZyx74qppMSw+cbZpURCCwfoTVJX1ZMn0RzEWnahcvLcX4aDyHDLGw+8a6O0aC8M2SSzqQVPJB+tX3jmuZ5/tDBwVymax5LZ441ktIwJjzzwM1bkY8rM4JcGVo1ZQqdh3/Gua13TGaR7iABiBulVRjHvXVRw3LLKQqK3V/r7VQeOeNiyfO+OV/vL6VUJ2dyakFKNmcIetJWlqtkYJPMVCkb87f7vtWdXWndXPNlFxdhKKKKZIUUUUAFFFFABRRRQAUUUtACV1Hgvwpe+J9TMVqm21tx5t1cNwkMY6kn1PYdap+E/D994o1y20rSog9zN3bhVUdWb2Fe++LrG1+HXwqm0bTpWe5vZcSSkfNJIy4dh7fLxWdSXLobUKfPNI818J2kZnuGsot0HmuEBPO0dCa9N0WR9yo8QRsbt2RwK5X4facsWmiQ/exx+NdbaRM0JZSAUbYTXnzdz36ceV6HS27KQ27PrkVXkO6Yvg7ugz2qGG63qyg/MBSmWQKpA+tZN6WOpR1uRQEtM5mAxn73rU6sysylcoOh9Kg+0h32k4Hb3pUuV2S5+XaPzoWxctzQiEcVuzlgwx0qC3gudRvobXToA0rAuQxA4FMUCWMuDyfu/Wmzz3thLay6S/l3UriFnADHaeowaqO9jGcnCMmibzsXLxMFWRDtIU5GaWfdjbHtUnrkVs+Lba0sbjRYYoyjvJJuZUwznavJrH1IMiOU+6kfOetOcOWVjLD13WjzHmVj9q1LxZqOoWNw8E8OIUljYr09xXb2q6p4s1PTg0QV7C2bzJXb5psHrnqe351w3gJpIYLqd2yjzN/Ou7e6eKTTby1XcYJA+wHG7B6cVopNKxnUhzS5o/EQR3Mv2hYbu2e3uCpYLICDjpkcc0O4tCR5ZYyHc2ei10ETjxrrcn2t5dONrbhYVR8s4yfvZAyKyZbS602/ksdShGeTFIPuyD2rGpHrFmmHquWk1qUoJXk3OwIGcLU8W05TYDF1z71JcQ4mG1cADFCJ+5IkToayTZ3WVioQE7bVJwee1UbqPdGyucLk7T7VfmUiTEhypOB7U26QieGOZQY2GAapMzlsU9JvrjSVaWFTcRggtEx4+orqvEGv6jrFvpkvh+OZDE3mTxI+CVGM1x0sUsUhiEagMSM/3q1vDF9caPqzZKxRNEQDu712Uqnc8rFUFPU7dLgXniQTtHLbR3SqAGOTmpNURReyq7EkN9/sKoJfNdQJMziVx/EO1Je3EEQSSWXeSOVX5gPqa7EeTKPK9R+ptHa6U7WTh25JY8FvauSkuLmzgaIR+YlyvQ9q17wRCBr9ZiseMBB0NRWt7Ys33hI5HGTwKpCbuijqlrZ+IZrVbuDD20PLMc4wK8B1EyNe3ksERSB5mVdwwSOn5V7Vr9+h0ue000XEOsRShk+T5WXvz+VcZ8QIo7jwnYXM4ji1FZSzdsr0NFzO2lzz2eWYxA/ex+7+lXfE+i/2Zfwww3iz288KyKwPIOORWSlzFIyxl2VHGCW6AVFPdKHKgl9h+Rif88UybkxbCAE5UJ901qaLby6bc6VrE8D3NnDdo7W+chlXDEc8c4qvoGlanr94qadayOi/PK4X5QB1ya9A0tIzdRQDy/scHzGNTkZ9QaznLlNaUHJmp4o1C18beIv7SsNIn06L7P5Kq5ALPnIbj0FMi0eO1t41upGaUjcSX61sy3dugJtMbUHWoELXrpLIGKp2f+GuOcz2KVNJWsFppybFCxKZF7VpQ2y+QzPKQh+XGec+lEFjO0krQbBBGoZizc5pVglCCV/mUqQDXOdsEmOt4mW1UoCyIecdTVu0P7iRGGMdfWqyGWMYxhSop6yKkO0nBJ5qbmqgrWIpEVtRsLYzGOC4nWNmHoSM1sa34N8P+HtB1yeG7e41O3ZWXzLg7oiSu1dvfILH8KwrsQ3Uey7QHsD/ACrPg0Kyhka4TcZJCN+WJz6ZqqUuW6ZjVoyk04uyNKFUSMFcNIVO0etLpXifW/DtvPDp9lb3LSESbJBghvY55quWAO1cNtPBHXin72nmablQF70otw1TKqQVSPLLYq3Oo6nr2pXF/rCpHMUEeIlwFUdKNKv7DS/EmnXurW0s8MAJVY/7/ZvoKsysRuxwMct61nlyzKob7xx07U7ty5iVSUIckdi1qN8dU8RalqtujiCeTIVzlsAcc+lUre+3306XEeFUDaakmaS3uPMhD8qBVTVXlMqNHHuB6/Wrvd3MZwaVkaF5pxkR71pty5wUB+6Kz2+faqIFUcg4+8O+ajt7ySO1liKkB2wRUyFI2ViCSQFxVNmcYaaks0KeWrrL8x6j0FULna0LRocjrnGKv3KwwkPCCN3BqhJ5hZoIIA0hGFYnGGPSnF3M5Kxl2qMboZcLHzuyOMUl5bo6kREICPlPqPanxxOFMdw0Lbgd+w5wwpdJ0a/128u7bSZoEksrV7ljI20FF6gHuasyclsc/ei3a0EH3G3Zfeuc1xeo2ptbgp1U/Mp9RXfpbXt1pNvqM+mzw2s52Q3MqHZIw6qp6djzWBf2i/6T5qbm4C+o9xWtOTjuZ1KSnG6OToqzeQPbzFHUg9Rn0qvXUee1Z2YlFFFAgooooAKKKUU0AlWrK2nvLmC2tYnlnnYRxxoMs7E4AFVwpIyBxX0p+zx4DutLtJvEes2kaXFzEI7COVf3iIT80n+zuHA74yfSpb5dRpXN34SeAh4M0dpb5Y5NcvAGkcAH7OnXYp6nPfFcb8eb6S58Q6ZpqYWOOMTsP9o9K92ufmnT+FwpyK+bdauV8ReOdRunJeOObyYyOmF6VwTk3Js9XBQ1uzr/AA1B/wAU5AXUKwJJHrVvT3ka4KiP5X5q0sf2LQl+XblTgelRWBh+yWYLHzCpO715rGR6tNNyNID7MT8u5W9aZfTPIEVBjPHFPZovl3EtgZpLqaA6bNcAEbFOazW5s3rqY17dvEBGUXcDww61W08S3eoMlxuEZG4he2Kgs2WYpOzEwHBBatjTJWfP2a1lxKcB9hwfpVqPYiVRJ6s0rSTzEOBhOnPWrWpObazgms8efHKrKT39qjhEiAL5e0IPmyMYq5GqTalpsT9JZhn0ohrOxlXkrO/Y2fFsMs17odwI9zZkG0HjcVWsC7Ri96soPyKwPscV2PiEwCSwLj98kxkQA9QBzXKapOJzf7V2s4ZiB9K1rpRkmzhwM5NNW0PK/CIZLC7ijUY81vvfWug0vVFs5zFcKd45CnpXNeD2aK2u2yX3SlcCumuEt5UkiZiZyvB9vrSWp2PSRrtbreR/aInKSA7kZT90+tXWhbxBoEuvavfFL+zzFBGhwuF4yR6mub8Baj5Zu7SdiwifGc8/Suq07+07rwvrEdgtsLRXJPmHLEd8VlFO7QqjTipx3uZVpcXd9fw2WnwNPcBd8u3Hy8d6hs71pri4jzko5DZ610/wmh+zaPqt/cSKfOm81ufmjVF6HvjjNZGr3ml63r0t7pK7oWjBknAIErd8DHAH9aqVNKCkTQxE5VXTexSuGPVQOO3Y+9VXmDxs3UdMHpmrUyfKI1GMA96pNtW0EbrxnqPWsUehoP8AtLC2j3p0PDVUkLyqrSrkdmx+n0q7c/urGGGGMsWbLZ64qKbm3SPLBF4GBWiZzziinHc3thA8i5MTnG0GjRtYNtc3El5NE1uygeU/OBTLu0kkZgkjGJWyK4/xJHNJcJOSW2HDoOMj3rqpzbPOrYdSdzstY8Sw3k5trNo/JjIAxwD7UafcoLlozCBGRyw9alk0TRD8LLPWrVVXU0mCSSKzFnYuflI6YC45rPL/AGWMsjgsVGM9q25raHJ7FNaF/VNZjLJNCqhlBj4HzMaxhpNhfzWkmveebeSQIyh8HBPX6VJpkC3urJpVhtfVJY2lXzX2rwMnmprOZbi1cXzLFuBDyKNwQjuB3q1IwlRZah8OfCGbxLa6DZWepXuozv5caxXDEM/oTuGKhg8X/CTw3JJDZ+Grm4niYo3nW6y4IOD8zP7VR0LTtKtLqz1qzY/2jbyPsmxjeccNjsaz4PBehy5mcS+eSWJc/eJq+Yy9i2dxefEmHVLaytfC+mx6bZXB+Yywom/j7oCdq5jS9Ejk1OaQsY4kXnPRmzVd7OS2n0+3tThYGLDjoK37eUxo6v8AN5ncfWuStJno4OjZ6kTWEcLM64JBBC9mNaAlDFB5abvTHSllKZAHQDIqCNmAIJAb1rlaueorIddyBrgpC7+XtG4KcZNG5fKjXc4CjGCaYQFcK3Mh6EUycsU25xnjI7UgTsWIL1EdwwJAGMUqiJlJD/OeQOxrPITZ5as7kdTjrVyCJY1RicEjjPelaxtGVxp3NZecFBcNhl9B6023mxA3mIAx6YoikDTSww/KwGTnoaW3WaW5SOUL8/y5FNK5Mp2K9jG0s8rb9oXoB3NW42aOSRJflb+6Tx+VLk21wYlClFPLDnJFWri5hm+byx5iDJptCTKN3KHEMakYPZelRoIxLL5q44wMd6sAK7I+zaMnFQ2rOkkzKu5C20ZHT1NTsNMhnkYgOASo4AFV5JVtVYuy/Kc/Nyea0J7YMB5jYXPUVa0dfD66tdt4iijew+y4R5M/eHsKE9bE1HZbXOUGs28180IH7pz8h28H1INSAtDeeafuM20bhxgV0N34hh/4U/oOlzaTKks4KW7McqgWQnzAevIOMVn+Uv2e3EvzMVwFHQe9aONjmpyc07qxQe5adXJ8sBDlVI+9zT4r6O3tmtoYne6mm8wSseFX+7UE6SLKpU4TPYVDLOouEVzlD3pxepFSFivcPHHrphMSCFlbewGO1R6XdX3hrWJr/RiCbmBrd0lGVKuMHirkBHlvGluAzPxPu5x9Ko3ls6y4i2qQectnNaXOWyJb/V7uTwzp+iXSp9mtLhp4mQfMGZWBX6fMTWBfyQNcLsLsNu0eufrWldttiZlXkja2TnFaviLU/DyCG30CwYebbxiZ5CciRepHHGavdAnbQ8+1iy+0LtbIuUH3j1Yehrl5EMblWBBHY16AwAjBkLDd1yMkVzmvWXmSGWBOgyfcetbUp9Gc+IpacyOeopxBptbnEFFFFAC04ISM8YpACTXcfC3wVL4u1kC4EsekWx3XU6DoOy59T09s0nLlV2NRcnZHZfAH4cNrNwPEWs2scmkwOUt45DkTTA4PHdR3r6ckLADaRjHA9hWVoNvDYWlvbWtulraWyCOKKNeEX0+vvWkTiQk/dxxzWLnzK5TXK7HMeKdQ/sjQtb1KRsyLbv5ZP8LY4FeC+AIGRPPnQtLM3mkkV6N+0Lem28KWtvExX7ZcYb3AGa5zwNHanw3aSRrIJg5ViWyMVyM9vDR/dp9zfvm89ECNnAPAqaxtQ2l2byA8Ic/nUU0jWmjNOArAbgMDmtafS4NK0zRZobp5Uu4y5DnjkA5Htzipaujq5uRpE0cMYhUgDp0NUtQTNhcDAUMpOB9K0JFY5BXCEDBFUNZl+zweUBlpBsA+tZWsaR956mNo11GfDUkUtqkvmJhCe3P/ANauvk8bWKaVCmn27R3cO1vKKFY0PfDd65OxnWCL7KY2URfI525AP4VJYpJLr1la2ln9qiLZcDH3euea0jJrRdTGrTg/el0NuK+N28s8igGUlmx61YVmeSIxoQ0eHQkY5qbXIrWPWkissbAg3Kv8LdxTkmPm7JgFCLxSkuV2BOMoKUeozW7+e6uraVlIKIy4HI5FVIt0cNzI4BO1ic+mKvIdwb5gR1yKpSOii43uCTG2AfcUr3d2EElHlSPK/h7dM8V1EqfeldufSujt4RbyybyCrH7hNcz8PIjJcXgiOR5rKOepzXVapqFtawyOUDSp8uAM4OcAVsovdE1JcsrlbwhEs3iHWQFVYlkGMDvXdXAgl0RNPtN1u7MWndP4xXM+CrYrDc3MibHnbcRXSICqMMZz3FYuTTL5FKCuZ6afPai5bTbuS3iuF2SRpg5GMEHNJpsAtovKVAqqADx1GP8AHNaUSbYWbn8KqSMfLZsgKfzrN9PI1pxUbtdTJu54l3KMeZn17VBD5DEneCfQetNv4oDcwjcfmb5jV3y7cpthi2HpuxWiV0KVTlHeXJNMu0hVUd6WaFWgyr52t81WY9PuRax3Wc27sUBz3FNZRFGyhc8jn1pOJMZ8zM66SUgKkRwetYGoWkZ81CvLAjJHeum1FpJGxANpAz1rMvIUNk6u+Lgc4px02FONzmfCc6SWV1o7M/mxybmReQfQ1cnjcT7CO3SslZHsPE0cpTYsq7GKjBY1uWTyy6iNwDIpySea3uzkkuV6Gbf20V1qVpcx3QtrmFSu5WwcHg05USytpXjbfg7Tk/hxWzpNr4dudJ1ibXctq0cubdd5G4Z6ACi8FnM0n2aIJE+CI3IO0Y9+9UpW1CMeZs1tWt9B8N3PhW5s7lru4lkVp7curptI5yB05IrRstOjvPHz6fqFo9pBdRtJHGi/dGMjANcE9nE0peLarAYV/wCv4V1raxB4e1+y8zV5dWjnhUTtbkrMgHVVYnjoB9K0jUuc86LgtDnNaSW1125slbd9kkaLf7+lWYJAH8t+HA+Y+lU5DFcavqtxGZWgmkLqkrZdc9s96GmjtyjYbD5Qkgk5FZVPeOilLlSuayLiYF3Dr25qZpEL/IR+NV4TFcRZVgMdwaQLG0fyDmPoc9axszqjJMsw7pZjhctnAAqHUGa0dLdVDzyttVFGST6Crul3/kRzM8arPgBCRxzRaa7BoXijTbrXvKSyAYm5KfdYjGfwojG7SIqzcU3Ew4ri5tb+Wx1C2ms7tOWjlXawFXJXJz1LD7ueldF8Tb+11XWtBTT5IbiEo0rTIBkq33eeorl/Mje5ZJPmVS2ADzntSnHllYujUc4Xe5cMSW13GsRVmZdz4NSX58oPKvG0fL+PeoLa3by1aUFpSCOKdcMm4LLkALgr1NStBtXH828DeXjzCO/OaS2lUxvnAc9TinxsjgMq5+XqelMiUMrMij3FO5cewsB8xTls5Ykk02YOke0OSmfujvTvMiVMYG8DB9qCyExiM5A61LG9BruEjaOMhw/OT2qpKRJvBAOBj1qxOEWJsjaWPBFQKoQSCPJz+lKxMpPoRXLyNYwQXdxK8FuNsEBwQo9RSxgkIi8NjIycU9tk6kD5mTg+1VdRnSERl2KOxVFI7ZOKvVkbK4662iUjORjofWsDWmCy2yry5IIFdJr2k/8ACPeJX0+SQzxtEsqPjaPmGelY11ApdJtuTGep61UdzKfvRuipcgvh4tyOvJ7AUjmN9pbcr4ypIxj3qxPESrb8EOcj6VTuoXaB1U9FGCev0rTdnM46D0SylulW8aWGMKWLKOCRVFLiCe4edUkxjbhhz9ar3E0iW6/aUMiAcCiF8xgkhTtCbveruZWY7UkMG0iQsx6KvJrNupBIsYUAuQBgc4rXMUU6ort+/VSM9DmsO5VoTLGVBlLYLg9KI6lS2sYGsWXlM0sY+QnkehrJ7V1sgEsYD/Ng8j1rnL+2MErY4U9BXXGVzgrQ1uipRS0VZgbXhHRLnxFr9ppVptWS5cIXYfKg7sfQV9eeH9Cs9J02007TkSKCDhQoxluhY9ySfXtiuA+Hnhi18NW8IVQ126/v5upZv7o/2RXqWkR7mDtng8AmuGpV53yrY9P6s6EOd7mxbQeRFg5Zu9LNKNjcfMeMdKfGW7qKg1FSyrggDPWtWuWNkcCblK7PJfj9PFDpelWMlus9zdlthLf6vbjn8c4qj4GtWTw8wWMfIMkelHxuCv4r0CNjuKWshHoPmHNXdFilsLVPKmYxzrztOa5ep9BQVqaNGKCOXTiJBlDuyD0qa0gRLazL7zF92MtkquSeB6Dio7jc9hsjcLgnNWLzVLk+HdP0u2gjLCRQsgyW+96fjStfQqpNovXMeV+QnaD6d6xtWt2kwxkKzA7h7Yrop/Dl7ZWlzdPdrJJGC5jCnGKwrZjcSRm5OZOrADpkdKiceQuhNTTaK+gaxc6daalbz27zi/BKzghefXpzRp19d6HILqCNHl2bXic/6xfqelV7uZ4ZniYALGfkU9AKbeMXj815UIC9Pwqr6GqhHV9y7YXE87fapSDNMSzH3z/kfhWsxQj95nLLiue8PyGXTcFxvRu1dAgYYbaCfepk+pnKKgrRIpFEO0ZYIwxis97qJJA8q4tx8rpnh19a1LjzLhlJAXZ196w9dgSHSr5w37wRnB9KjU0pNON2cVZx2+leKb+DRrtrjTI8Sq5XGGNdFFqum2Xw9ubZdtxq+oXDK+R90bjgg/h+tcP4alaITqvHmkHnvit3TLINdQIcuituz7+tdnNyw0PNdN1KnK9jtNHDNbr5nyyBQCKux3DQp1DKxxmqttlH+bvV1PLKBUUZXJNce56XJZWGuXB+QkK3HPSqsv8AqypOX9KsysWiZQSR7Co5hEsQI5YDj2pAjAvH/eBXUBs/LVi6mYeWsTkKOXUdqryw5uEMuck7vpUckgE25M5/izWi2MpnRQyyXGmx2sUpjRHLqPRj3NQXfmoH3ncTgD2xWRb6miPIJt43D5StazXsckKIcFXAUjuDTJTSKTArHuEgZ1GCc8GqtwyLkPghx171qCGIIsSqNncVmvbxiZzKPlXhfemkEpI4PxaxUx3BY7I3yrD1rS8P3f8ApNyFcOrBSAeM5qt4pgEulXyhlRIlLKWODn2qppJR4bXy9pk8tc5PXArWKucs3rc2mW1ubuRg+0qcHjkGtzw7pH/CR391DDcC2lihLxg/8tCOAtU7bwS1x4R/4SGLUlx5hLQc+uMfXmq6262et21xbOJPssqyAg8Pgg4/TFEopPUdOo3FqJCrTgvaXNvJbXsa4kjkTacfQ0adHAk4uJcII+pxXQeLro6vrqarPDHbuYhGEjOSepyT361kX0NjDZ2s8rt5hfEqZwNtTza6Gii+Rc25ra41pfSSyacqLblV5Awd2ORUdveWytp7XmmR3KW8UkboX27i3Rs+1MgNsjFYCv2dlBGepPrUbT27xSo/DMNq46U9nclwTVkc/b2EkEjeQxjSQllTOQB2FWYhcI8q/aGCY546Vbjt2RdgbBOPfFWYxHFnau5T97PegFGxSP2hYy7EMqgYwc81qxvptzDAl8PPmPWKToKrOIQqIQVQ8kY/SkvbKKYxqgVZV53AdqixSuaMsEcFx54YZkOcbuFA6KB2GKw4UjWWUyn5w5YEc5qR0aOba8m/A4HpRCkZc4O8dyO1Jqy0NE9TQgk3NtLMNw44ptkpkuZTIcoFwp65NIlsrzLI8rbR90DtVx54VCx2wUAHPPc1CT6lMhZhFHt3bnBA9KWQum7y1+Zj0HpVhIFIBJDMeSab5jEyAjaQODVWLRTJTY5xgt941GNu0EviPHJFSyko21h949BQYl2FQMox4z6+lBlOTKwYzsEXKofSnMsYhKqzAg46dfxpsyFJE8ogSd17UwsheQFyeKCkhGG2ecLxkgDHfjrRcwCS3MTgFyMg+nvQG3SbU9PzqQsTKgADbhtBHWpaGQzq9zL9oubh5ZY0C5fngVWcsYHIA2kBsYqRoiruwfI7gelWGEZgyjZXbiqjoKWxmqWns2ZsDacD6VUYpbKFmcMC3A9c1etlwkkbjhxwP60RWWkHw/qn9oSTf2oJE+ybDxjvVp9Tna6GRe2z7yFbdvGVA6YqC2VbiR02gMvJyOoq/cQRiFi0mxRyct0qqxCjzLcE88t6inzMjlRFLDFGNyK+4HHTmse4jiM0wdCCGzxzWxO0qhZIyUDnI3VmXdwnn/uTlMfNJjvVQZlNGQGiindGVyjDpjnHrUctvBKCNpC46kdKsXzhF81CA5BBYmo13SQLnLFupHQVutDnmr6HL3MJhkZT0zwfUUVuTWbXnmJGheQD5VFFbKVzjlCz0PpzTgClqCM/Nj8K7SwjLMP4R6VxtpGVe12uAFbJFdlpTls72BwOgrzaVkrntZimzW6DFVbxVdcPnFThlAJY4GKqXkyeSrD5snFdsmnE8anFnjvxstxJ4k0Bo32n7PIuT/vCrOmQ3EtxZadYqJLiROBnAFRfGxFXVPD8meAkq5/EGl0e7a3a0uk+WeM5VgMkCuO9nqfQU7qimbMKj7PLHcjZNFIUIP61LMrW0lu0DAvEfMwahuQGkkVpvNO7zHfGNxar0ex5fM5PybentQ5LoaRV1ZokuNY1TWpjEypb2WM/IMM59znpRY2HlM0gIO3JJzzVrw1Y/wBri4mjkeGCN/JVlGd7Y569qzI91vp9wZpCZQXVm6ZGT/hUyu9ZGUJQUuSloc80nnai7rmXaSxyemKntL2PUGaN4wNwO32pdHjWK2diQfNHXFRLa/ZyDFtQE5OTyKUU0tTsckkVNIn8nULuMAnBzj6V2llOs8atEQVI6muDumW11CKVZFIkYq2D612NuClqPJKjgDilIzkuZaF27ZXZULbeOeOKwtViSWyv03A4iPPvWvbZZGV+GHGTWZrcSwaPflMszDmgUFbQ8h060eaYxxkg7eDmu+0S1aKKNc7scHHWuW8MW9zPfT3UVpM9tbjY0iKWUH3r0HRYsxMyg7up46VUm+UinyqoW4EaR1ZjkD07VbSPZHI+cBqfHFwWPyr/ADolQIi99x6Vmaynd6EVtIqRPgjPv3qORdq4CZLHjnrVmVY44QrAHnNVbneYA/Jx0AFALVmVqEbxPKr8MCOnamQ2xkldiOHGwHsPWp5BLKB5kXB6k9au2kJlbyRwn3ifeqiwnGyuc9d2BLGONdwHy7qzb2zltjujkYnOTyeK7fy9gdCoKEEFvWsZbTZ5q7TIW/SqMnG5i2urPaqyyvvJHDZ4rRW8W8tVG3D4zw3NZeoaTHKyqBsk7JWD5k2lapKZtxRQNuOlaWOepdF8NZz62BrcLy6WVIkjQ4Y/jVTRLXSIr+YXs72FsqMYAzF92D8o9uKdNK01yJdjmMjIIHFZeoaeDceZuYpIoyOwrSJg02b7IlyjRWNxPFbHD+SJDjd61ct7ZrfCqpA2naMdz1rN0chQrRdUGNo71UttX1G5u5Cw2BXKgEdBRJXVx01yuyOxTT0v9OuryW7EV1Zxbo4SOZfYe9Zt1brPEkcwVtygbx6nmktRczxy/N8wGetOnIkt2DMoOBkZxWcVZnRJsqWkN1G7RptkSPjcO1TCWFpPKUF2B59jT7HSJLCWC6kmFx/aEm0QRHc2V7EdgfWrN2I11OdoIRAAcshH3e3eqloZU27hbwmS5Jl+RR0xzVmOFDlt4+lQqG3bkYZPekaKVgMEcDJrK7OgddoJIRk45yCPSpYYA6KQ/A6sOtIiRFcMTnGFFWUi8pRtxnuPaiTHyszJSr3BjLYBP3xSQwJAk6ghd3QjvU1nBGZZyWJCg8nsaVIMxtvBC445oGlqMtR5KBHOZD2x0qcwIluSTh8/LUAJaVCOT0Ge1SpIZHZZUyq4pM0sTwTGKMbky/8ACwOR+NPMiOmR948E1Hcyxq7JCmEIwQKiVWJVEA29aSAeZEjkKyqSTwrdqZK5RdoXdn0o86MOyspxngntTiVaTd5mARgcUzF7lNo9iq3JlDbsU1o8yblIbIyQO1Wm2GQbWySMVWkjMfB+Xtx6UFRIxxIrdMjnAq7pd/HYXjSm3M7BSARwASPSoV+Ro1XkleKawwWyME9QKTGytPuG+VTwx556DNMjCRhwuSpORz1p0zLtGCEGeQe9RROs0sjquNnAA6ULciTZXe9R5WcggKNvFRNFmRm25HVfU1YFn+7BAUI/zHbzxVe6kDusUMmGY4z6AVrY5m3c3vBUOiXHiB7bxKN9pcW5jiZ2IEcmR6e2awNC8Matrl3rNn4fEUqae/LzShdysxCYzyelMyUmETpu29Gro/hpE0Ws68o1T+zPtNh+7l3J94Zx97jPbHWtIJPcmd1G6OKybvTUZueOmc7TVDULVWtIWH3hjjIxx61NogNrpB3ZcqxHPUjNQXMMSoscYDvId20n7tKMSZEE0Ru9OMT+XweiDk1QjBV3jjYeUpCt7VoARrcukB2soBIXoD9aotH+8lf5GcMCcHrzV3MmimI3jkuGt5DuU/L65oqUh4rxj8hWQZA7fj7UVqjGSVz6Vt0cTBlTMe/BPpXY6cAsoZuAR0rjjM8Li2Q8s2TXQ6dMQ4WcnHQc1wUnqz0sXFyimdAm0sxJz7VSnVWnYRjJI5HYVMi56fdPelnVUjDKw3EV13ujx4vldjx741x7rjw/G/BCynI+oqtoVwqLEuwPLjHzdMVsfFi2Nw2mzpyIJCH9gRXO6a4LiVlJCenFcr3PoKK/do6xmClyV2rgD8f8Ksyh30+ZYOGIwD6Vl+bJNtIIzjoe9a+lNtsiSSWzzmpZp0Oph1OCz8ILcxMqvFB5YxwTJ0HFcLq9zJa6LHa3AJmmA3MepJ5J/WthbSCVl8xm2ZzsB4z9K5fWro6n4iEURBSH5cVpVlzWsc1CiqTbRf0y1K2iBVARD17UmrQBnMhbOByAeDUmuCW10aSOIkM428eprBgElroqLdSFpACMnqTUs6YO9zIvrRprxJmGLcsAyk8Z7Gu70uLMYCuTgDjtXHXqhdLg/ebWc7ip9q6LS5ri3aPcgeN1HzA4xUMFsbjMQPmOPYVz/iNjLYairXUVuqRhgHOAx9BW4yp5e4uTu5HNcz4k8n7BPBMDul+4/wDcPrQXH4STwhBc2Hwj1VJpUjurq/3FUOGKYXj6da1NIi8vT4hvIZv4u+KwtG8NQy+F5tQ+3yfavtOz7OzZG0Y5xmt6zybVTk/KuK2qtHLQhrKRpz+ZsjRiCvYio5GbO4DOzovrQu9gqDgDqaljjbzT8wyTisLGl+XUqoHeN2lGSTkA9qrzO5jJQ7V6AVr3EEkSlAuW6kmqM0ZcMhAHHYVNjSFRPUyUeXBG4E9a2LU/uEVR8xGSazZLULexHB6Y4rR00yOp3rtwSBTRpWd9QitwYisrEHqMdfxquYm3OYzgdwK0EAWfMgwSKGGzAjUfMfSqML2OcuoJJZI2KYYdK5/WLKRi0c0ajnGQOtd3qFvPlXWLb8vdhWVd2rzKSSCFOHPvVxlYmUec8+t5fLvGtZDsSP8A1fGAx9aS+jHkqqMSSfwrb1/R2eBnUsjLnaxHSue+07tPkjeJvtEHyuR/PFaxdzmnDlGaZ5kF3C+7Ayc4Paq/jK6k0jVleGRTA6hztGM//Xp4iZUt5JpdmfmyP8K7XSde0vR/D+orremDU1v1CR7MDcCeFyen1rSKT0ZzTm0ro5Oys/Fp0mXxA2myx6KsRlM+6NQYx32ls/pW5b28Fz4WnvZboLdB08qAMQXB68YrU8X/ABV0288Nat4VtdDvba4ltvsSESqyR/dwAR1FczoBCWkC3DZKcFz0JFE6fLqisPVlNWmXdNuLjw7r+m6wsH2hkfy44XOd+/gY57GtnXINTfX7mTWrP7HPOu/YT8hH1qLw/Yf2x4htIo7xLd4W822LLlHkH3VI9zmtbxlPq914laHWEhLWsXyeUeCD3qFqi9pqxhSIAqur8einrV23XfAsu47W4YdxUK24KM2dhH3fQmpBgLtQ/OeorA6+YahVJODlRz9KJJdsysuTuWlWJgCdgz35FRL54kA8sbY0I6UFcxcwuBs6t96nuoYkPyvUEfyplhBcXayfcACEkGmJKERUXcTggnGRQESs0eLjcmdvcVK2DKjIcKx5HrUSbyqqXyDx0xinx2zQnZPJ8y88dqLXLRPKQYwRgOTg0hga2Hnq4OeAV61UnMjLtB3DcORVlUKq5DDCqflpqNiJMdIsklqTHsV93Oe9U7k+WqhxgZ6+lSCRkdhIwY7flHpVKTzLhHj3YIIPzUMgmZmiuFCACPHU0/AwBlSGPU1VuYp5RF8w3K2CKtyw7XWIqoZcd6lmoM2JHDsGVSAAB0FNm3jc0ZAXH5VYVMFwuMkDPGaa7wMXjbJwME44pCexQuolmjVnUg+3f3oggE1xAsUip5rCNu20Huak1WVIrq1gWUOir8xUVWuAVDeQu+M8+h/CqjuYyKfi2WbSmuLWzjacRAndCMgr3J/nWj4osPC1ifD7+GtTW6urtGF1GLrztnyA7sfw/NkUvw3/ALZu9a1y/wDD8sDXNnaMPs90gYSk87Mn7uQG56Zq94x8UeEPFXhnS9V0yGKDxHaypGLYApJFGSRIDgbSOBjnvXXBKxw1JSc0kYczvHu3lSqrgAdRVIWaXE4afoo4DenWl83zkMk+AEbcQP5GprLk7id0YHTuaymzd6aEDW0cSSKm1Q3QCue1QNbXcMrKPKcbcd81v36QyRBoS+3PPPSsXWk8y7gzzH2XvmiDEySa3KyM4jQB1B47j3rDiV1lkZ8JuOCPWujlgZ4ihm8slc7hzgDtXNXMiLMWkYkg4RMH8zWhzvYW8j8112hVKDHFFS3aMvlSA4Mg+YelFaozZ77rjEy2ckX3zLg/Sug06ZpYmiSMBkGQaxNSRo2s92DmXOK1beYwyRTRqNq8NivPi7Nnt1o81JI6uxJaL5jyAKbqE3ltGVTcTwRWcJMS70LbOxqzLKzMmCCCucmt+fQ8Z0rSuc94rt/tUbqVA3IQeelec6YWtpWEn+rThq9QvmMiSO+3aDjGK4AiKO9m8wfu25rBq2p7OH1hYntLpJbkqp+QDitazylq7oxxvrDiijS5wq7U6qy981sW7W6L5a7xG3v0NCL5bGlMUt7SaaSQjcuRXN+FoV8ya8f5ssce9T69JcC0wCGTHH0p/h5f+JWFwEJNWiZq8S/ql7E9k0u0MQfu/wB2uYuZ3vHR5u3OG/pV3WZCrquAkJ4OOuarXltvtkkLESqOg6GkxpWRU1mNjZNc7VXZ8ox710HhuVprFRvJxFjB6VjxIZbd4LnlmGcHrkVP4PuXhmlQrmMHB9qUtiVudItvgqTjn06Vznjn5LePHyO3FdPLcr8qgD2A7Vw3j55zdQMhBROue1SaxUpDdAtWjuVQncjfOwJ712VsFxlQqgcECuO0J7m2YTXsXll1zESOq+orrtHJEbSkfePANEiY7GtBGPJUR/xHnNI9u4kOD9w5pyksAW+Un0qSNZprlba3O+Rx1J4AoMe7GGaWRsZ5PFQyr5HLff6VYlWaK6mR4tjx8Z7fWmtkRM5bdKSMZ5oFF32MuQM0pG7HNX5Q0UcKq3zP1oKLLIpOA4bntTmVTLukY8NhR2+lRE1lK7sEuTjJyfWp0CiEEj7ozVIRTyuY4SM5yCOwq9GCsRQkHPoaszm7FOeczq+8FU+lVLZUbf5vXNa7FDA4YKMccmsiVRvPl8AdaL2NKfvFfUVYQ/ZxhoCd2PeuJ1i1ns5FvbXo2QU9a9AjVJ3j3OoU9DjrWBqdhNFPOs6NtDZjBHT3qou4qsTh4dPS+uwl2z2wCM5HTPFO0idL3R7i2bnYp2Y68dK0760eG8Lk+er4G7rj2rEntp9G1ETxD/RZPlI74PetlucMoFHTYlmtEmwQwfY27qTXS2NlHql/bWcs/wBmtGcJLNuA2j2z3NYVjHcy6n5UG0WpOdxHaupuIYxbLGuCink+vua0MYuz5TovGUPh6wt7XR/DjL9utZcvOFDDaRn5nHU/SshvtE5D3krM7IEyxyT+NM022jitmKIoQnqB0qVnaZRj5tp6is5SOynT5USCMqAm3KKCS3pSbfKIPbGc0kksoVgCAMg49RTZ/wB8AmdoJ28elYlxj3FKos4G84xn86mBiZCAx4qurvvAhUOFOB3p6xyOSHwidSfSg1JYNrRFAxXbkZFQI+xGyzAJ3PemlpIomYOCp68U+Eia1JkYHPQY6CgAswr7kU42c59agkZnnPmZJ6scdqjyYJEwwC56etXN2XAZSS3I56U0AeTvCIg/dk5B+lQFTvbD/LmpHLBWAVg4Iwc9KikDBXCLwxyW71Ri9xjRKk5lJ56YqNSrynzFzuGAB1qx5qCBZbgfLG2S3cmmNJb3KSPD8hUfeXqKCWQxqyy7YnwO5NW4I/NVAeeT8/rWVbSTSRIwwwB2t7mtXafIBjch+wFSzVDwqoTnIZT1qIhJoJMBgMnk+tSvLI9uM4DEZLVWlnEOnFyu5l/iPQUctxvYzLaGSXUHuCm5MdKs3dybe6s0gQMSwJRuhHfiorXz3jljjmVJ+i89CauW8H72Fz+8nCcntn2pqPK7mKF8Z39vL4isbnwIBpcr2j21+Y49gk3HofXjvXK/2WttHPaiIBzGCrD1zz/KtuJEFxLJGpBV8sfei5cx7pHbdI3APoDWt7mapchnyWxg0eS4VkdVlSMgtyTmrGn2t1EnmEbdy52+oqvqlq32K2bcyK82NuOvvVyBrnyx57OwXgYPT2+lTIqMSG8tg0SSxfuxnlPWuevzLLcoqfMN/WukvFdkdn+VTwAOxrAjSQ33y5VAM/T0NECZg0ksFmxCs21up7fWsm+VjdyM0Ksc5yK2XhuI0YDczbs8nIJrMu4ZmdJgjEE4J6AVrzHO46FcpNsyqlU9CKKtW8Vxc2skhVtsT469BRWqMpHvupRF76yJPCtyKtBdjcn5SSKbrKFLh26BQNv1pflltSxz8ozmvOXVHs3vCJNFLKZkgGShPWtJGWGRhISR0BrDguRHNE7hgg7VpCeOVyc/KRxV9DCtTs/IiupmMm0MdmemK5TV7ZJdRaMxtgrxiumuCY42dgDyOnNZ0Q+1Xvm5Kg8Dmk0dFFJK5kxW/wBnuVPJQDkGpgTI6rGuDnNWtQDM+1Tj6VSLvFcKRk7RyMVJ0dBmsok1pIr5YqhKAHGTUvh+Fn0aCR8KwHOPSs3xLceXYvMh2vIuADxWvYSpa+HrdWwxKcjvnFNGE10M3xKr2k0bK2UbB6Zz6VUjuZH094HiVZQc89TVjWJTdaDG5DebE2R26VinUkuVEjH/AEhhgZ4yatBJaF63CfPKU3S5wBu7d6Z4Wcw6hdg8h34FLpkYjX9+D50pGfRRT7VBBrsyIflKZX3NKRkt0da8sSlSRzjNcx4kDXSyeQu5iwwMZzW+g3RhpD1G0euagk22F/azqgLKwYqeQamzOnntHQr6rLe3umWj3ihZLdBGoCYzitKzLyWMe5iHPOAKdrkkt7ZzTKETe+QOmBRYqfscWMBzxnPUUpGcPhszZnkluNrzD5toU7RgYppSS3kS4tGKzpyDjNV4pJfmDSfLjp61JazFg3BC9MUJmMk7WWwmoy3NwrTwyh7qV1UjAAJrTuvDc8GnyyfbHa5QbimB5ePSsd1YIHt8CSNw44yTjtWjqniyWWweG3sJ/tkg3OVGVVe5zWkFCz5tzOqqqa9nsZ7LtRUHBGMgHOKj8OfYtZ8RXdi7krDBvIVud2cZ/CktVF3JDFvAM5C7hwSK7XTtB07Tb1rm0t0iudvku6jlx6/XNKjR9pK/Qzx2JVGPL9o8/vr5tFu9ThlSQG3O2Nip+YZ4x61r2WkatNZJfIIY0aIyCMt8xGM88cV2l3b2tzGWuoYpIyBlpUB2jr1rnPEusMwjsdLljJkGJJYyCEX0GK1lQjDmbZzUcVVqKMYq/dmPEzyWq3DD94w5HbNVZwTbLK/DH0rQttsBbncqjpVC7Zric7htQc4Fctranr0r3GWMYbyyzthD09aztekup7t5TgxgYUitMIUjLo+4DsOtVLtPNiUdiefWqi7D5byuc5eRSvC4UfMBuFUJ7cyWrLcEPlPlHety7h8qJiGJbvtPaqMmlXt5plxf2ymSGA4bb1Ue4rWDuYVYWWpyuk3H2e/+x3J2xH7pA5NdKVWFjH5eARwc5rm76Ez+XOgDTQNvUDvjtWtpeordmNZeHwcjvmtXtY4XFxdzSIk8sMBtz0IPWrNtngkj5h3FVwNiRb3xntTpZSgUKucDG49DWVjeEmPk3iYumFAPUc5rTh1SxOhXFpPZg3czZWcN90Vkb08sBw3IySD39qS4SFQYVf5dmQBQbb7l+0tZNM05NRlVXilZkjXuT61Xlmc2AJLESOc8fpSiaWext7ds+XATgH3pJrpB8oViMYIHIHvUl2M+6823RGQdeMH0NCSlE/cjHHINTzQ3kmm/2hNaTrprtiOfbwxyRx+IpiCONd245xkBjRa2rFzLoNMyvtUJyRyT2p8DBl5znP3s9KhwGJmbj/dPFTxYMoCbVQjP1p3E5X0GO/m3awxgFedzVI5aNWRQA3QU5SLcySRqNzdBT2zIEcKcng8d6YmVI/NaKZplBUHp6+9ZspUZgt1Cl2BZs9av307W9qZGJ25wFxzVLTIjdGaV9o5yo7ikCVzVsoXFoPLUdc/jU+wqgVcM3cjv9Kt6Pp0uoX8NqJ4rUbN7PIeCKpy77eeaJHVkidhuH9KllqBXIkmnhighkmuXOAkYJyv0qpq08ckF/ZQSCK4VCCCOQR1GD71ch8QHw5eW2qW8aTXpIWGOUkA545x2rm4ZYJNXnnuwkV1dzvPLz8u5mJwD6DNbRWhlKtZ2ex0WvR+HD4R8My6XIBq0O1ZwuQzcEtu7HBxTYZk8kTbgChwD9aybeFftskMkJKK2AwHGDzmrkzRCJoEPyrkiperCMeVFZTPC11LIgkjyCFzjcPSo9VvllmVbSz8pGIwA2dtOn86OEGQMdw3IDTJVDQb5sglg3B60gbRJrtxNeXMYkAUrGF3DouB1p1jHJLaPh8Ko6mq+sv5d1GYwcOgwPWrQEix7CNoYAnFIRBqMckaqS7E7cke4rEti738oWNfM24Jzxited5DGSSTg4x3xWLu8m7lmkLKpzyPSnAzmTXkW+ABwVOeoOKztaQz20flthVIUjOMH3rW1bRtattB0vX55Yv7L1CYwqiltysCQM545wazbxUHnRSH5m+79a1SOZu6dipKk9uggndlkTG5F6NRSFppSzSMcg4GfpRWyMpJn0j4lVoLUlhluM1S027iutPVSfL3HHPU1ueL1UaJM6qd6INvfPSuRt7mOW1RQvzoN3AxjiuCWknc9bCv2lIku5BFciBm3Ec81ZjuVUZ4wPbpXIarfytqMLWbHOfmz7VcTxB5oCTxMqk7SwHemdDavZ7G+HmvJ9qZMfqta8FksKDcRtA6+9UNGjgitXlWQ49KvyS+bbbVyVA3ZppmU5O9o7FO5Vg6qEBJ71j6yTErOBxjGRXQ20quRvGeMZrL1YAxthcqDwPSoLpybdjzfUrmXUJIYw5Ko2PY4rqPNmk02JoXDNCPnGO1ZMqoonCwYWMlsnjNW9HvjHAGLKkbHGG6U0J817mmrRXOl7Rg8HcR2rmdM0+K61FEjIPlvlWPQ10etwf2YxhYx7JU37o3yBWVoz4s2lIB3E8gYwPWr2QpSL2o20sQjj27pJSMBTnipLmxudkNxFEQYDubPX/8AVU2igNPK7KSmOMn+VdLKiXo8lJNu5NpzwMelTuT6mTaXSFYgxUSDJ2tx+NGlq2oXtzLcIfIUbVPv7VVt9PtH11IdWvfscSI2XQ/ePYZrR8MW0kOlSW0snmStMWjlPDbc8fpV20uZxm72J2UPZ3KucY+6MVTsHddNUqNzqx4FaVzC1vJKu8uPbnNY8M/+lywRZAPJrKR009VdGjLOxVCBsbvmpyZBF8gJzjOOOKiiIliO4EEdiKsROS2I+mADU7Cltsa2ox2ELxm3Yncq7uai8M3Wn2l/fx3lzEjuQoEpxlecj+VRTRoLJOB8p5amWeh6RrcT22qQEXbv5kbnKnA67T+Vb0rt6I4ayj7NqT+4oPFaLLObCXMcbHymBztrYuPEU7afZ/Zo2N1FIpdjjDAZz+JyKp6lov8AYk0C27tJYTEqd/VG9PpimlBHGUUFT19amXNTdkVH2VaK0GapeXmqXfmS7ooFXaIkYqG926g022htrYymFcEjnAp9smEZyxIPGDSK3lFlDZbHT2qLt7nQqcIq0UJFKiQS5xk1VSNixZ2IBAHNSxnIZXAO70p924t4wirub1pMuL5dinI8tsofOVzwMdar3LtHIHZSFYVauTIUVoxknsaoyTSplWwzd1POKEbLYzDJ5chWMbt3XPamWV5qFjYajBbEG2vMhuM4HtVhIC82WXr1xV+K3SJVQcxj7wqoysZzXM7M5cWvlx8RYHQH2rI1CJYd11bwOWgHz4GBg12NzEhIKDgHI4qmr/vbmG6maOznQ7kC5JI6VtGSuc1SnoUbC8ju4IWbHAw2OdtW1EbkqDuUdK5eMPpd4jK7fZ5s5z69q6lNgEcgByR8w9KuyOaN0NK7FyRx2FXYpLd4kaGJkdRhu+aqSyCQfOrGMHAwO1JfSyW8JWItvIyCO1ZWN6cm9y9p+h6vq6XM2mLFLbQthssqnI6jFUgXTTzIsQaRgVK55B6VeuI73w66PpGqSMmp2qvcJgHaen4Gq9hDcQQxvO3Ei59aBWblZvQm1jxLFd+GdK0W0tnQx7TcSvjDbf7vPHNYOnWza54lttGsZ1+0S53NtJEY9a2vDV94eg1q/wD+EkIS2WDbGdpK5PX8fatn4R6boz+ALSW8WFbu9vJoo7g/61CXITH90hRmtIR9pqzCU4Utlqc3q3hrVPDdxG+sbGgmfy4ZFYEP7kD7v41DNHtY4BUIoIAre1PxdoA8O6h4bs2ur67trgRLcSqW81geZN3r2461lG8iWJg4OXO0cc5pTgk9DShOU1eSKDlwwkYHA61JdXL5iMLHbkcCpLnesoDj9yR8x9KoTrJBA8sbkYOcH0qLG17lPUImubyJCSwySwBrUtkHkDy1EYJwM96z9KjknmkkBLO3UnitCS6gRliZlURn+8MA9hmpbLirJssStL5ih93ynbkVDM4RnUN1PHf86sTOzRbhyS2RjvVLUJTC5Z0+6MkUJMpysNsDpk/9qnUkle6hVYrTBwAfXFaNxr3hqD4L32m3k1uNYjB8qFsNM8u/g5AzjFY9rL51hcskaKZ237j95PpVe2gj0+80/UNQhF9b20oke3b/AJaexrZaPU4pxcxbDV1aGHyU3svDZHU46c1DZ3KBLhryF1uXJ2ID0qe3gWe8ub2OERQyyGRIwfuAn7o9qk+wbr43DOdzEYzUNm6vLcZG7XcTNdBhIi4Vc54qwIEWzmypYIMgdyandREXmVAqZ+asu+vWispp0B2M4VB6k9aQ+VDIZDf30SnA8obwD2PpVu4DeaX2ttHHB6UzRrXyojLLxM7fpVgSNtnijBMhyfmHX6VAJX2Mu8dkiZ1HL8GqNuDeEJLt2NkBu1W9QeSG1EsyMGU4IA4FQaZcxR2Ylk7kkcdPwrWCMqiGXB1N7S2024u5pdOtHMkcROVDeuPbJqjqoZpEJUZZtowuCPeteZ98Yz8rt8was673NNGJJctjBzVXZzKPLsUJ4iwRsnYvAx1P1oojmH2TypCRJvIAx15oraOxMz6s1aNZ9LdGwMKDjueK8yvWa1tZ5VGEPyle4PrXrN5DE6bpB91cfpXlfjCMwGUID5bjkCuOtFp3OvLKilBxMTQ4muJ0aVSw5w1btxbxpBIvlgFeQT61W8NTPb2KuIg2ByPSta7ie5tc5A3LkVHQ72tdSppV2scIW4UgP/dPWugiYE7DnBXAxXM3Ng1pYozZYISWIPT0q7aTzi0gmjkV13Y3EU0RJdjWWTOVCFQDjJFQXMYMTBgWFWgzBU8w5zyTUF/KImYKQRtyB60MUbqRj/2TFPayySSor4ICHqa5y3VJGa3aPaIzwD3967eVS0EZQAHGSK4i8Dx6rLcEbVHFC3NFqh96oCToVZl2dTTtDKPBAjKVjPBrMXUzNLLEwY7vlB+tdBpSbQkAUHYPmNaPYyaNexhEUgdVBQnAA9K1ZYRt4HzH+6OBUNirxplOUA4OOat+dtA28g9/Soj3E9jkfGdkt3cWFsVG6SQZA6jHU10dhA4QvGc+X8oH8qpTavFpfjbRjKhnyH3YAOARWzaO3kXkkUZzLLlc/wAPNVZWIlJxkhjzojFpuDjtWJbKDeSXJzgnAwKs6rKjlo8nzwM7cVatIEisELMCxOcelZPU6F7kRks7byF4UjHIqWCQgsMdB+BoKIwEjnI9B3qdgrFCnyoelKxMpKxLbXqwWsiSrvLHOD/KjV9Re9u9P8oeS1qfMUoe/p9KiuUV2CkYxyCKhQ4uPU9zT1tYxVOnfmsaseoTy25t7lhIgYtuYZIzzVOSX7wUfL0BNJnALdzUE853qmBg80N3YoQSloQtvZdu7HPbvUrsqbAQSxGC47VH5gNyF4+UdBUE12kKu07BQx4GDzRzHUo6FlHWHEyAuOm0daqmadrpyV2qRxTIb8XO0J0/vY6H0odlaTy3fa1JsFESd5Vik3ndgdRVFzIIY5fLbe3U1NczeU8YmYLGQeB1Y0ljctcW01xHZzS2kPHmqjYx+VFm9hyqwitWWrOOM7HYguw+7TJBJBPIhUlTzkUunala3EkaqDGx+7uXG786ttKsrKLj5JCcgAfoapRZi5p7Mz5UcRYCYwcgHvVCVk83z3jVmUEbT0rWuHkS8XcocNxhfSqs6wmJm2ODu5HpVxVhN9zjtbgkn0yZY1zMrB1PpU2j3zXWmRFiWl+64Xt9a2NQQCYbUPpj1Fcto5fT9X1G32MgkG9cnNbHLUXY6MLtRGZjleCvY1KtpeXmnXWoRRZ0+3JRmyOMVUuJVZVOdueCT6Veu9VmTw//AGVYqUtXbdOeu/NS9FcSv0ILeVZbFnRAGZQuSOg65FPnnDRRkFuMBgD2FMtJRKPs6IRtGPrVi3OzZG6gHntzUnS7Ii03xBp9n4c1vSpdLaa7uAxhkaMMAG6c9sVb8H+JNG8O6a2ma5ayFVeRlk2KygsuOM98Fhn3rOk8oXD/ALs5Hv1HpVHUZLeKEF492cKgPqeB19zTU3HYylRjPcfqfhrTvBXh2xv9P1EX0N7IWVBjOCOAOc5HANSwQai2j22sTWZS2ncxxyN6/So5PAXivQ7iy164ht7zTtPAuZYBcDMaL8xAU9SRnNXdV8QXHii5UQx/Z9I8zzIocj5TjHb3Bqpd2TTa1jF6FJpzcW86nLMhGWHQn0rNur1rtltzCynP8qvSYt7Z2iHmIh+YE4qlpE019ezTJEBGpwOaSNH5FhZHW2le2XOxeRXUeDfD+g3nw8fWvELNE8jSHzZJdoTDEKMdyfSsVrWd7q30yzUC4vZAinsg7k1H4q8P3+kvH4dv9Q+2aXDi9gjRdoDMSCCO+DyKlRVnJk1U5rkW5U0+9kOjQAL82TyOSRRdu7zSwyxnjH3uMDHBrb8D+DW8Wzyzz3b2mn2zeUrxAMWkB6YyOg5qhd3N1qPiG4M5jmWFjb70UKGCHGSPp71pFWVzOVS8uVdCFVFvbIoTcWGOnA96V4/PuUhKgxxAM2O9Sz3cMVwyuwSJjsUe9LFJ9nuCAu5WH3vSo5rmyi0iKecNOREmI19Rg1Dp8Ou6ubt9D09r63tGw7oVHOMkckfpU0l1F/pCjltpw/8AOtbwpeSeHPgrPr/hpIpNQnlYXfmDdhmbywwHbbuBqqS5pO5Fao6cVYwLO7FzaecAzxFiGU4+XHUGqtwY7q/hjUMbeP59oxjNMst1hoxinYOGQnIOcknOfxp2ixBQHkH3hjA7Cob1NEm1dmvp2nzajqdla2xw1zKqZPJRe5qXxZK8XiyfTkFqwsY1RZbcY8z6k9xVeyu7rT9ThutNkVJ4TuDHpVSScSvc3pG+5mfe5/mRSuhJNSv0MTWrmZoxzyG+ZCetKlnexafY3c9nItpckhJNvGB1pt+yXG+ZOAoxxU5tfEVx4A0/WVnik0Kzu3txFldyFiOT6jJFawOetMJgr2zopLFeUwOT7VmSiOZVMuI5mXkdlNaheTzEl27I41wxzVGaSI3pkdeSMlcdKCWZM223hALo8rEggdUoqMyQJLPMxLNK3BxnGKK0jJWMpo+tLq4Zg6KPkI6jt0rjPFdoZoJkYYKrkH2rt1jSBiZX42hjjoa5nxSA5uZCSEKfKKwrK5rgZJTsjg/DwZrGWHL4BIJFdJpo/druJZEXABrldCuHtLiVXBCOcfMa6tYGha32SgoV3NWL2PTk2mVL6K5muSFYeXIw3L60skkdiscfBRWOUFbG6GZ/9GI8xeSe1ZUunpNeebI+0Zz8vrTuK9xIfEVrcwrtAjf7oV+pq+J7eVVlkYeZjp61hXtjFcnEAUXERJHGCc02y2QNHBfb1mIJVs0XGtDU1e6CtHhwiFf/ANVZN5py3MUiysyuVJGPXHFX5EilUG5VtqcY9amdhCRICJSfu8dKFuXdJWPO7K9jiuI7SZStyvOSOvNddoySX93HaWIQXVw20M+cD8gawfFKxf21aX5hUNvEfyjjHpXQ6estpPb31jIEu4fmQdufWto73Zz1Fo7bnTwaNqOhlDf3FvPFISv7oklcfWodWvbay02W8ldVhjHzZ9aqJcahqjCTUr2V4gT+5XhUJ9B6Vxfxjud1ho+i2srB7m4zKB3UDGP1o0lKyMYOVOHv6ss+FL7+3dTvL8r+7jwIj3r0WynjjgkZuA3Y1xfh6yisLCG0tFyoA37hzWpc337wxAjYnQ45zUy0NIL2q1LdkpuLi4nK5XG0GrpgIVWAyOmBTNIzFpbSMyqC3QDmtbTpoBeb5h+6VMgHoTWKV2VUlZmYwVpFVeAvapY3QKTwTnpVwx2tzZTXiyiKckkRDjj+tZUyNG0bIu0MuTj19KuUeUVOSmPuGXBZzzULTIjKwwQPeqt5LyVYZzVRo2yhDsAvWoZ0KKsaz3SMq7cDnoajnuYooRLIyYRsHJxn2qtC/mzRsoGOg96u6ZY2kupxPqoItADuG7au7sT7U4Xb0JbjFXKMbS6pexW2jbJLiUnJzkIvqa1NI0m20DU2TxTPaXX2tf8ARfkLINud+dwwOCKebuG3137Z4ft4UgihMLkIdkpz2NZesao+t3cS6lYxL9kyyIFLcnHLE8fw1tyxh5nHOdXEOy0iWrpLSeaeXTgEthIPLA7Cs+aFmUklN+etXLRRJGTEoAHYdjTxDjczDOT09Kyavqjsp2hHkTuZGlJE3jPSLTUYlmimJTa4yrHbkZFetoqQW4hijVIgNoiXgAfSvJNQtZRfWFzbymCZJxtm/udvyxXqNhd2d1POLe7guLqPHnrC5Krx29BXXhbWaZ5OZqV00QatoGn6nayRvaRJIy4WRIxuXHQiuLurebSrv7LebJDtBWROjjpkV1PiTxZpuhajbWF6LiSe5x5Soo59uorjtSudU1DxPcrqkCWzRHCwZBKJ2yQTk08QlbQjBSlzWZIiGSTG3a3UNVS5gfyiquCc+ver00yCIuzMQOAazAgaF3aXCE8DvmsLHpsr6hHLEVjnA3MA24dhXGaq7WuuWd07BhKGj21192XngZGJdwMBj6VzOv6fp7eGTqVxeKmp212qx24PLIRgmrRhM0rJLG41axtb68EFtcOEeXKgKT0G48D8a2PEGnWWha3HZabcNeW7QCViZVkIbcw27l46D9ai+H3/AAja6Tqd/rLWss4i2RQzkHqD91COTWDonlwW7NAioZG8wBhjjNOdlGxlTblO/Q24ZVEZKxlGDEn+lR/aWZH8xdrBsBvao4t2+RrhsrnoPSo7u5W2gkmJViD8qnmsjoabZDLIYpWLZcHvVe4RbiKTLshIyCB0Paprmee2aMalZSW00sXmoGxtceoqhb6pYXMpjEu4uPlOMZPfFDTRSnFaMkHi7xpLZNY3d5BPYvEYS5hQMUPGMgZzjv1p9uqQWYRScRruBojaNUkAU4UYNZ99Mm3YjFd6ZPPWqbkzOPKtkQXd40sawgNskYAmtiziTTwQcFQvUnHNZOlqs13boq/u4zls966lIxNcBJLSSdATJKEHPl9zWbZtHuR3MOo6fa6PrtnJETPKyxkHOwjHJ/Wqt7Jd391dalqc5kvLgqudoG1R2AHArQ1W4trm6xpInj0lSGjt5G+4xHJA98VQS3n1rV7XTrOSOO4uPlEjD5VH0qknJ2RKtbmYsWsatpWj3+n6ZceTFcOQQFBPIwTkjPSq+k2v9naVHGTuI5Az3q1qek3Wi6lNYag6TSxEEzR8D5unFMdgsojcZHBA9K0d46MUYwvzIZdw290iK3+tB3YBqKSUrII0O4r94mpEthHeSyDcMjjnpUkAVZJ4xjzCBk+tZIsjCJ9k37eW556GqtvLew6XNpccywabcy+bLCFBBP16j6Cpb+OVkEKq3A4x2qteNDboIkMkr4BHPQ002noKUVJale4mS4mjt40wi/KfoOlavypbtGqkNj5SKrWNmGZZJWVWblsDGB71qeH7A+KtcuNPtJ/sltZwNNLdSJuUEdF9s8/lSs2wc1GN2WfETWB0rRo7e3RLoljcSDqVA4zXN3k6wwTYCgkDn+lW4mjNsxMomCSGPzM5DAHGaydcuFDRW23c8h3LjpxStrYG0kZ1ouyJi3MTAk1Y83UDpyaKL0rojTfafJCgDf6k9T9KnSKNJT5gbyyuMDoCakjiQM8LE+UOhreKscL13GTh4k5CmIL1J+8KoxajZu4aMhio2hlOc/Wl16VhYSwRgtPjCjPJFb8HhBfGckLeEbaTS20mw8i9a6UHzroDPlhc/eweW9acY82qCclFanHuyRwHG1kLFm3HoKKl8D2elXeuxxeKJp7fTSkguT5m0IQcEZHbiimomcp32Pq1YYRYqZmLAIMH8qwfFUiyWoWNRtGB+dXdPkmnkSIjCryRVXXTBNI6KSGIxWM3zRuXQjyVbHmBEcGotHdELHyNxrpLNUkiljLlyY/3bD0rnfEdqDdxh8nccZ+laWnbbO3DAsNo2sKysezIs+GUa0guPPmEhL4IbsKv26JM20TBRv7+lVY7i0V0jm+T7V9xie9Tww7jsICDOzIosS9EUNSspoZpZrSQEryPwqKPbf2sd7KQZCMEDtg4rRu2SK5ki+7JgZH94etQWVrFHYz/AGV1IVTx79aa0JkQNOm/yL0lYmwEaq63JgeSAyq65wuPSrGr26Xdpa+ao81YwwI7Vmtp6zRoEl+dCGJ7HHena7uQrlTxcgheyiDDmVSa27RDLcRRwkM27n8q5nU5PtOpIZ/nZJAQDW/4edf7Vjeadoo9xywP3eOKtEyfQ22EsU6rtySRkDjFeW+Kbxb34qafC5ytuvH1IJr1CG5c3biRjLjduc/xeleHXNyIvindyXS5PnkDPb0rWmt2cmIlZJHrVllbn92x5G5gT1qWGRLnVliKkKvJNQ2o2SCUMduMnirPhq4WbxBdpOMkp+7IFRONzShOx0wQNatt+UehpMu8SwbRjqT7UI6xyyQtzjmr1i8P2VZC2ZeR+FQaTlZXGzyrdPbvNbjbGojBU1BfHMzCN1VQQdpFK5ljidSfl6iqFzhbpHGCxAHWiT6BSi9wkWGWGRgA0i9KpCKORwoiPt8x59avBfnYFMJ1pweGQNIFwYxuH4VnY36WImVLeQDYEI7CrMgjlj2t0IrPtZ/tUhZ22knir8cZSJwF8zJqlYl+Y62i5W3tE3SHJ/Cr+g3OmaJBNczzk3d23zxlSclRwtQ2X+jxRtayt9qZtsgz0T0qC7s1l1CO4K7myfm/u1rCKRy1I875ZbGTZyuyzyAbXuGMgX0yc1Msc7IhZuev1p94rLNth6K2c1YWINKmG+bvWbWp2RajFRWxRuIBdWTxzcNngVU02yutMvlu9Ll8mVuDuJYMPcd617pAFGOqtk0xLckGZXyC3QUJuLuiJxjNalW1htZvHcWseJHXciHyiykKr8AEAH60tpcLqfiPXL7JKSyhICe6quM47c1fjSK51rTklVDbhv3gk+6T71DNDb2+sXssIXylkwPL+6B6CtOa8bM5FT5J6Fe68xIgsiqqY54qi8KMECt7jFad0UuAJR9zP3ap3cIjkWTaFix0qUdFzKvCUWQKdrdveuS1yxgnQDDCQHJJNddcOsshZB8y9KyE02/1We5tbKDzblUMgAA5X1rSKuZ1NNWYultbw7Y5ASSchvTFbMscTOkkZ46VyV8l5Y/ZfttvcW5dsBnXaD9PWuu0zTZNX1Sy05Zo40nbaXz93im1YyhOK2EvJVtsQzFh5g4YDOfoKpzIL5Cked6cjcNpz24NdFd6TF4f+IGkW+q6haS28cyfJI3zZZTtyp6dao+KZI5PihrsdqFEUccW/b08zaM/0qHCyuWqt5KNjN8Z67qHiKOzhkiSzNjbGJCuGLtjk+wrofilqmgpofhyw0mOCS9V4yvkoQY49uDuPckkGuZiieS9ea4B2c06KC1jlaSNUy/fvT53azFOmrqSZLqASGArt/1gwWHrXOKrG7O4jYBtU+9WNWuRIFh3szp/CKtaZZLDEksm5i3RT2NRcuJp20EEVzFHbMHTbkketasF/dWEjy2TRiR4jE5cZAU1lRxxxzxucxg53lT1q/hLlIxGCF3Y5qDqSVjOeIJGTBK24j5setZGGjmMgkljuIxmN0YqfzFdK8UELrCQSG5OKy9agjVDLb/dTrRGTi7oicU1YktVnlge6nuJZZnwSZCWJx7mnM3mXCk/KcbsH+VNsbpnCMp9ivpU8KBZgAN5JO0+mattvczirKxJGPMtvMXkEkGqt45jvYDCMRuBvY9a2ESO3gcPnew6DrWdcXVs9m4Malj8o9c1KRdhl/cxvDNJGTgY2nNZ+mWAMkss2S7crzT9MjhmP73PyfdHoa27eJGUHJXn71FylC+pDLaKzn5ioC9O2cd6lfVnsvA97oOnWQgurx8XN4W+9F3A75zjn3p1zcEoYkycHrjrVW6YGFVkbk8cUrtMVSMXHlZlw28en6YIZyPJRcKDkEH0rDEyyTLk4kJ+UHnbitLWsNABLJuCtnb6mn2fhyGL4c6h4u1a58i4EwWzgR8bgHwwx3PzZ4rSEW9TCpNRRHNL5USD70hOWA7VKiNJA3mYRm5x7Vz1t4p0+5uk3GRJcAZwOTXRecpjzO4+cZqnFrcyi1LYyL5Htrg6hZkefEQYyw3DcOnFdhb/ABuFhobpF4fY+ILhGa4uo3VYnnxgSFAM1y48i7iHlMVWN8kj7prL1SKJJQls0i46AdCaIT5dEialJTWpmCBBaIt22bh9xI7EsdxP5mipSiyfLcs/m/wn+lFUmZtW0R9RaFbzW15I8zF8k7RmppbVZLySR1AwMEelaEU0TW6OmN+wE1QurhWv9qHKuuWArHlXKhRlKVRu2x514qhEV+Hdj5cbdPelhQvtO4MJUwc/zroPHGmQ29lBPA7HzuW4zWHbRoqx7GYYGAWFZtnsUasakbooQ232qJ4LsES2sm6Mj09q6CzkALRMQSDvxVO5OyVHZOSdrY70pikhiNyrg5k2j6Ur2LlZok1eNXvUkUgMFwfpWbZYtZJFMm7ceVz0rWwLmYtNwwArKuYQl7JJ1TI49aadxW0IIbW4tL6WdpGaFjlVJ7HsKkmaCe5Ywh4GC/MM5FF1DK8oaGceV2BNUJLeaKXcj4QnBzVoybuUrmFl1CNpCHWQ7hjvWkkQksS0TKJA/KkZIqncQpFNGC5YxfMD6+1X7WfexNuoXzOTntTuZtalyG4EEkZdx5gxlRx3rxrxRGdX8a6xcaeOYW34z1I44/KvZI7UGNpWIaQ5GM968r8PWgh8aanHcEnJLD3Bat6drHLiItpHZeDNZt9U0tCZD50Y2yKTyD71ehuzp3iKFlYKj8YrzvXJLnwj4hW40/K21388kWPlatuLxFba5YuYn8meP5gp4Ofam4JmNKdtz2OdgI96kFXX7w7n0otZA1sFUfN7dq4jwf4ha7sPJ1BsTqxAJrqI7hAhAcAgZ69ax5TtU01Y0JcpGcTBiR0znFUmnUuuSGwvX3rEu7p3YBshcY69ajCFVTC8+ualps1hKyOpjZnj3P1qEs8IdjgEfwjuKzVudsSoeD9aqXF4/wDaLKHATy8nnrSsHMbk2BArIEYnkY61PZSgAB379PSspL1QsY2EgCnrcrIrJyqk53elCRT1RqwkW0jTklsmrtxchrZWt1HJwQKyZf30axxk+Uoz05qJJZ4iE8k+XnqRWlzGS5mXJGE0ZUnaR2FQltpkIDdlHPWmTLMCxB2g1BGJRkvITuY8VNir2LVxKfLwOWPp2pql0ACHAH61VuT5W3Ck5OOtNdleP5iw+lJoE9SRcyGSK5JXPzbqbE9ulq5SVsZ5yec1XSJkuEeQ5Q9j3qaaCHdJ8m0EcAVLT2LbREpMeGDMc849Ks3Tma33MMDbwPWolLBN5wyAdKqTzholZMgEYFaRWhlJ6mfcSfOsgykf3fxFZ93qt5o80d5ospS7xtJPO5avTDYhEpzntWNqISTYighx39a0WhnN33KXjPxFe+JrjRVv7eGF7PKfuhjfkrkn8q3WtWHl+TM0cyNuR0PIrlpohLqVsMjdGd3H8VdezhIGZSC7DcB6Ck3cwjFFzRpbG10TXNT1aSC91yO6ikhS6+Z3CYGFz+NcyZJpdYvtTlXF9qc4k8gcYB4x+grQtZEnlImTJ78frVWZ0GpRiGXMiHfGT6infmVmXGm4X8x97BcWsskF+pik/uEHI9qoXF+lssrTxenlitC71O7vdWurjUWDM5POOB0xWMbBr268yd/3St8o9aiSSLjdkGjQSXl697Mu1N3A9a6cRmCSHPzIxz9at6ZBZpHJuHl7YztA7mopBI9tK0jY8tQVB9az3OiGm5U1BF8liFbcxG1fXmo7S72lv3mzZyBnqar3l7DFCi53TE4UZzVG20uS9V5TMUcNyvpTUQdQ3TNw0gPXgCmF/MjC4CsB93b1qhoA8uWaC4JMiHnJ7Vu2WEuyyhSNp61D0LTujn5WWynYS/LE3zZHTNaEbmWNGjPzdtvUj1qzfxwXKmJzgtySccVzkOoz294bSHDMpyG9Kpsyb10Ne91UJsWXIPQhep/Gs2XTZ794vs5eGHduJJ9a07Gy86Eyzgb2OSTV1wkEqhSMgdjUuRpFMbaWsUA8kMMgct6+5qWNJEjkjVsqvO6nbCCzAfN256VUuZMRv8xEwHXsaL3NErEpcvprOD84PWsyQuYwxPKn/OanbzGsUiDgbzkn1qjdSERrI7EFMAgAHNVGNzGr5FAIJ7uC0siJrq4mEaRlgNzHtk1D4t8P6pYxzaNrbt5tuPPhgSUPGu7pjHf1rpPhV4NXxJ4mfVdQE66bpriSEhQBNNnOzkcjvxTfGs73fxA8QzT3hvlhKQCRUC4Cj7gA4IH97rXTH3Vc4faKU+W1yXUfF+iX/wAKNM0FNOB1kwLBtjiRfs7If9Zu6/N7etc8thqOrXlppOiwCS/liKKhcKFCjJYk1ZW1WYR3HlohRdpCjpTLS7u9N1aDUNOmWC9hP7t+DnPtU+0UwVJ09iDxD4dh8Ja/aWMV/wDaZJbZXuFDZ8mXuh7fjWd5P2iVZmkCKT949Knu4bm7lv7u8l3X13IWmmzjOT6VVmiZ5FgztjiXBI7miwO/crzysjNB8r5bIcDkD1FFS2ttAXERcF8/u8tjH19qKEiJs+mtLhMtu0at8yrjmpJLLZIzDIcptJPak0zMdnJKv+tAJA/Gr2fNBEwyTg8dqxjsiJycZtI5K8tpBF5E0jSAZ25PQVz6Wz/ahDHIR83JboK7LV0C3hKqdnauXvEC3RKtjJyfas5aHq0ZJx0JZ9PmjjkZmidV6Eis/wApmk3Fjgjbt7fWrkDCNhFO7sk2SvzZp1xbN5ICHDDtUNmyK0Mmxgs/zZzyPanahArgOG2qnUU9YJGRy8Y46AHkU6MmTtjb8rKe9EZFW0MSdQkix7iybflI96q2sk8Uc32oh9p+Sr2qxOY9sfAVjjiqcUxCYdd2VOc1rfsZNEZjBd3XBZRkjPWrml2vmpkNsdux4qC2gIUY4dhkkmrscyiZRs+bGAc00T1sRvDNZo0xYsUbOPUVwf7tPH/mKw/fw5APQHNeq4SKJROvyNE2TnOTXiOsTtD4shdPuwk7sema0gY1rF/4jSzNqlgihJCQfvDjt/jWRo/huaZm1B5fJKsQixjH51seOpIrmfQ54RlC5DMD644/SuysY4TDGiJ8rjIHpW55zi7nLaLq1rFqEmmag6wSSAOsp459M13Nt5JQJNKOOUYHrXkfim0iPjOGCQGOMop65Pf/AArVmtdRsiJrWdpLYjCqc1LgjWnU7nosssTzSBpAJV42j+dN+3xwMUeZSCAB9a4q21i2l0aGG0t7q88ROCZY41Y7QDTLBdSvYB+5KurFWVuNpBwR9alx0NFW6I7aO9QuW8zdwR8tZWo3ItWBLFjnknsKyo7W+hBZgdit8wBztqE22oXczQsSqE859Kz5TT2rsdRpt60jqBIMnovtXS2FuSXaQ7uM7TxivOF0y6ska4gkZihHBra0nxNH57W8xInAwQe/40Ndi/aux26XqgSGNSGRaL7VJHs42SNiWzux1zWRbanAsW1sBnGBz71YN06pg7UjByD7UtS4tMvW2oFogZwTx3FNeaKQ5zhQe1V1nSaM5UDngUoijO/YPlz0oZckug+VVyAGLHORzUJypOelVproRSHHLgY47Cozc5iQKw3E5NCZnJW1NLzsrzj5RVI6pkKHHBz2qBZnlVwoBIPc1CGXe+5Mk9sdKtpsmMk9zURmFs0kTYB7n0qu6B8ZYDHJ5qOElYXDN8h4A9KpXcq72RSRxnk0E85LeEJH8xAzyCT1rmNQuf3Xmt8qgkZNWtR1FEA38lF6GueleTVBHBEcrv3OPQVRlLVml4aMN4YWk+WDzVEknQ4zzg12Xi7T7PSdZt4tMuGuIGg81i7BsN6cVz9rarbaesEOBGuBjHXmpZ5RA5eaZcsuc7c4NTLQUL38ht3J5VncNI4V1BKlKu6xoWn2XhPQNQsr9TqkyiSeNpNxKk8EVR/4+w6NgoMk54OKpzDYzQ/wldo9UHYD2pqyWprJczIZWlvbiVh8sQbHH8VaNvADAiJkknj2plnlkVAAu3G6pwQqjYxXrzWbV9jeKUSSFPIfErliOintWPrWpv5aQq2HdiMCqOsa4puTaWrGSUcFx2p2lae4/eTAySAZ3H1oSaIlO7L2jaZHFA11dkmaTlSx4T1rUtZF80ICvlu3Uf1qEM0fkq670IxtPam3SyRlEgh+TcC2D0quYjcramq2k8UyMQHYgn1FaVvcJceXllVET7wPU1VvYFn3CX/VkfIc8A1m6dPM80trGoKpwDjpUSVzWDsal273RKRrhR/EBzU1jpMcUWAAzH5i56mrFnb+VC0k53NV5Mbvk+6QOKlmyiiHcojGxVHGGz0FRTxx71fK4VcD3p0gAhnIHWTAz0FROBDbjcwLDIHqv1pFrQWaUSXTFCAQBxVG9ZSxIP3wKW5k+VnH8XB+tU0TzHRN4JUfnTSM5zsMR5TLscEQoeCOtTXdijW10YXyzLhT3wfb1p2n+Hdd8S6jeW2kPAi2kYd/NYLknOOT9KytI1S5DRC9s5YN+UDSqQHIz909+h6VootK5zOqubU2bLxP4q0rwraaDpjR2WyVma9Vj5xQ5JXaQVGc9axtHtBYoYVYHzGLOc5JOc1rlfMmlaQliF4Bqs0KeZtPy4BwRTcm1ZiVKKd0TK9nPrNlYTuYLSaZFmlBwFHrmk8ZWWm2mt6haaPcZsoGQK5fcxPfB71q+FJfD6+E/EOj+KZoYX80XNoZGKMX2HBDD35x0rjdIt5nsAtxtWRjnk5J+tWklG5hz+/qJcMBAE3HdyT/AEqogFvaGSTLs3ITupq7fSW6xOznBAI465FZyXuYVm+x3MsUq7kdYWwQO+cU/QlytoyG6L3EabVjjZlOMdRRTpZo/sCHeBMTu2gdQeRg0UImZ9R2SsmxXyu7nPrWjdhQAVIHFY9rNPLLJHJgFcYxV+QN9mX0NYR2ZFVe8mVbrbKg6Z6Aetcjq0Rh1OaJ1K5XcpP8Vdc9qYHWTdn61meJ7OS8sBcw4M0B3N7rUSjc7KE0nozAVV22bopzg4I7Gr+0yEHdh8cjFZumSs8Hmf8ALM5KD0NaQBbJBxu7jrWLVjvb1Kqu4uTlQEkAwfTFIEUyytF1PX2pzkpCu8EsGOKrvvWdVVWCOuc0jVbENyuX2y4CsvXPesSWJ2d4QePYc10E0STwqCTkHrWfcQiJWKZ3DnPr7VcWyJJGZaysjspBCqfl3CtOaAEwyFApY5IHNZ6x+ZGJecbufarom82JF3ZKH8SK2Rg9ybVblRaO8KsCEOFavH/CW2/8Q6jNdruUqx57c160+Vix5bSsUY7TXmXhdY7XxjqEBHyMD8p9zW1M56yuHiCL7M6FMGESBgCfu12nhyaO4t0ZGy0Y5Nc34qQgiIx7I5m6sOwpPDt5Jp9wkE+NjfxDoR2qrnMZfjZBF44sJD9x4V5P1Nbel3Do09tMA6g4AY9sdah+IGlyXVlFf27qzQH+HsM5qO0uFv8ATo723JEpX8iBg1ZnKNmdD4O16bwf4pn1KCxFwk8HlMocqeuQQcGoNF10S6rdPqCSRxXd40zAHdsDNkjP41rSWmkJpOkSae0hvZIf9JDNkB/QVz5skdpAUdQjlnBPp6UXKhFbnrfiDSNFGmm902QNl1Cxq2VPYnHrXGa1pYsr8tDvKtzwOKl0m7jNqNxJDqdo7A1PJJPMgWRstjA+lYzl2No02lqxiwRywJuGDt249TXI3+mGO5aYRNkNtO3vXUwxkN5ZLFt2evSo9SB8lV2kOjbifX60J9RuDtocvp8MgvG8pnfaCdjDpV+O9nGnmecEPHKI/Kz8xz6DvVyy0nU9WvJYtARXukTzHBIHFVDp+q2t6YNdtTBeR/MVBzlcdQfer5b6oz55Qlysvw6kjfOCQR1qQanI5w4ZVY9QK5u/gmglU2YIh7juKt2LvdZJl2IeAW7n6VnynRGr3NzzY4wxyGJ9e9V5bhtzPEo444rNjCLIRNOCVOOadGvkpva5QiR8Fe4pqISqEttcOshcgnnvwK1YrlcsC2TnJNcteSiYssbOAGxmqIN/sk2uyknjPcVZz3bd0da920qP84QA9M9awb/UFDH5t8mcAelZU094qtGHBYDvUumadLeurzYQD7zDoRUsNit5z3U7Dac/dwRwPxrdsLWKCKFosCXdgn1FU7op9sS0skJj6ue9aRmaGMbkUBOnrRcqOpdurjyXYMU2vyMdqz5WVpJJJGBUjAz0rI1G9meVBHgseQOtPayuzEgmOMjcQO31p2uNuysjVeaOFVlU7yffvVaAvcnzJTiUtgewrJfzBewwxP8AKOv4d6340MYQqArHqfWomjSm7FzbJAyNEFLMMsM1g63qE6wGNN2SeqitOeUgl5HCnHbsKwbcT3+pgEhbdG5z/EKIF1KiLWi6YsOydlD7hnnk5res2mSPfgAFsbcVAJGjcpGuIx0Veo96lkuG8obWXIOQe1EjOKvqTNul3SgAEcBarNdSxXAjwrmQdDxTJPMZ4irM0pOB6YpjQC5vGIk2NGerenekaWJZwkMcssmCifNj0rL8P3Sz3VzKqkKGAwB973qxq88CI0MLtK8oCgD+f0pNM05raQgnY6jJJNTIqO50VnKYwzScqexp1zI+5W2Arg5waquREvkynJIyCveqd/POAI7clR0O6pWp0XsizGW8kO7MoLbtlQT3OZy4BKtnIxVaa4bKRszZjX86izNMxcqSTwCPSqUbmbmLM+18MrHJwPStCxiMW4Oo3j9BVaGAySJAQQ2dwye9TyNLb3J8w7mZe1VayMr8z1MPUb6+ttSvW0nUZLX7TCYJ1TGXX0Hv79q6XUvEltrPwr0vSbiTzvEOn3MQjxEcKq9SrgY5HWmfDw2mqan4j8M3dtCLnUbNntbh1+dXUdA3UevHvWH4dSZLKNLyJUv7SZ4JRjHzKcHP5VS5mjnmo+0saNxJlyEyZiMZ9feq5RyzOZDwOnpVq7Rw48sYkznPbFWtO0m48QapBpul4S4mUku/Q469KmzNnLlM660e5trOyvJESS31EMyupO4BeD/OsrVUa2vYjFKY9i5YdsGrkj38XmWt5PLKNPkeCNCeFGeSPxFc9qcc9/JBb3EyQxyyrG8rE4Rcjk/TrWq7HNJ31Kl7qOn3ks0PnqNw4z0J6Gu/8N/FKbQfCEPh5tHW8iggeASGbavOevBrT+IkvgHQvAbeF9Jht9S1CSIm2mtFSaZZRj55JRyATn5a8uyYtLhaNQJio3hjwT3z71o4ez0uYQmqmrQy2hMVnF5se5iB8vZee1Fa2qaB4j0nTbTVdXsWhsbsERcjIx7Z96KEkW5I+kGDrcmSNcgrir9uzm3XcBjPcVWjlDLtTC5GeafbXLtA4fnYeOOtcKdrBUTlEdqalRGWHykgZrMkO2Z/nPlONuPUVs3E8dzYZJG5e3oaxLxVLIvPJ49qpvsVh9FqjAEIsNQkgx+7blSegBp0pkikDqMxEZB96m8XRvbJZXWxmCN5bcdQe9EK+f5ZDAqBgCsJ7nqQldK5TWWRmAm2lucAd6Zf3P2VEIjyOn0q1PBkpImAyHGcU54llQmTG0j61EWb8yM0OeiqeeR9KddxMZIgB8hGWNSOz7mEaArt25p4BZUiJG4D+LvVoTdzn2Bi8yJziJieg5qqd6MWiU+hzWrqtuI4gz5V8Z9qoF2lg4dd+OorSLMpouWUzlxMT8w4ZT/dNeY6uFsfHzTA4SUZUj1613VzLKII5VDHacNt71xWvru1JZvLyW4XPrXRBnLM6i9sxrNrG5cLIMlVrm3iubaOWCeDOw/KQDmr2jak6QthCJI15B6ZrUTUrrYjG1MpkHzfKeKdzKMLmbomu29qostSjPlv0dj29xVK08jT/EN1p0DB7aU+ZCwPHIziptdhF+6sLXyZsdcdV71zOpbrSez1AFjCr7JDVIicWek6FbNdXTwxL5jbt2BxiqU8im5mTLeYM5GMc5q/ok+ySGe1kMLSLuLDkAYrOv0H9oO8bH3b+9RLczWwzwvdM7TxTHChsID356V1c8EjQblBRscc1wlpujvhGgIXdn6V3ttIzW2GbcVPGaymjpptMbZ74lDyAllHzUyw0PVPEsV5e2UsUNtbttYSHk4GaY1ywLiTADcE+lNsZJIDKLe4kSJhhlXo1NKy1NJeRTstT1LSb6DUtFEZkX5XR1BVl9/WtW61+/v9Zm1C7hiVGiWIIBwBTLe2aCzErIpUsRgdqgVNzs7/AHCcAUe0srImdJSdx97At2vm24Ck9QOlc/eWHmXAmSYW9yg4UjhvwroI5RAoiZSuWwuKt6HFo8viB38RBnhSDKkLnBz1q07mE4SitDzWZbgBjKxAzuDDnJpn2WeV4z9oJZTuIrrbg2Zu7qLZts1c+S+O1UptMLx7oimCeMHrTBarUyAksDsCQ5znr/SrpmbKDeMn8hUM2nyWznIUs3G4VWl87dsjUFF65pD2LPkJLMZJnPl5IGOtTX2pW9taC3jJJI4IFZQ+2SS7BtVGODV3S9M8iVXnPmkAgA9qCWTaJELdpru4DbcYTI7VS1rUGmk8i2BBZsbsdqsa/e/ZrTyBu39Anc1F4ftWwZ7hQXYZ57UAP06yW0kQsxaU8nvWvdM8xfYRx8rZ7ioo2CtcMfLOMYx1FZkmpPBKoaJgpGSQp4NO6K5WynLbMuuJEkpVkXc3Hb0rqFt2JwWHljox7VhaJGbi+ubuZy29tqgc5ArfmnxECFby89xioZaMbVJYwHLNtCjBX1qSyVpGLGPZuUFMdqqXSLJPK74+bk5rXsJmVWDhdgUbSKcSZkczmKYgITlfmJP8qhQ7AURdkW3fknNWphH8zbizMOnrVZsXKlQUGwYZBUy3Kg9CaxeRokkY4fkAGm6hcxWoDs+WK7QvXJqsl0LWS4kLbgg+Vap6fFJcXYvLpfk/gT3pFov6HaCKKS7uj+9bAQHtWmgWOaSUuDtOD70ycI6guMYOOKrTTr5cpjHJYAe9KxrsXZLyLy1cKDIowBVO5naRVcplxztU0y1tXkHmTNgk4qS4RWlitokaNmwMjpjuTRYOa5W1EzNaRzpGBJIwUL7VowwCNQxfepXhR2amtGkSC4uJP3cQ2qM9amLKVhb7sLcg92ovYQls7IwkePLDPNGSY3O3c20/gage5DYVsjLce/NVZr2ZL2eLyiqMM7vpQ3oVFItWDXlhrmn6zp6xpe2ZLYddwcFSuMfjVeEzm6vJLjH22eV7l8dCxOW4qQ3biISD/WKvCg81d8VeE9Y8P6RB4invbKezaSKMwRhvMPmZwScY6+9OEnYisoJ6kUJWWSNpAdzfNgntUf8AZOr6hBqmo6Lci0XThlnV9j4PULjk0hkCuszFQnlcE9Kzku1uDcRxyMoZRkAkbh7j2qoS7mM4lKS3ktbFZZJzPLM+9iSdx9aZcWpvLYsBgSNgqTU0qqrw/NmNeAaqtIqTSSSyFEB+QZ61ZnYXw9q9x4D1ubUtOjhmllhMbeegkAJ+tY90+qDW2j1K2a1uZ/8AStjjbkNzx7Ve07R7vxdrmn6Hp9zBbz3ZLmSfO1QB14BJ/Cr3xGvdW1b4j3NvqiW5n0SBbBzbk7G2DG4ZweTk1aTauzm5kpcpR8Q+INY8Ram11rN6/lx4CW65Ea8AcLnHaiqc8jrbhuCWPH+zRVLY0kkfUmkO0kKhlG4A8nrT9OuFvYnjB8u5iJyD3qgrTWdxEU+6e5qaCIG9W7gOCMiQeue9eUm0tDocFrc07SwRpvMifhuXB6ZqK8KNPsaLawPpU0Exiddgyp/ipLyDz7pn3Hn5gfWui946bnKvdlrsM8tGkhiuE3wSA/eGRXK6lZjTr5lszutx0z1FdS08gjEbgMF5HtVG9t4548qdslZuKZ0UJOMveMOCQNG/fJ69Ki2rAdivln55qX7Lvdh5jBgeBio723iFzGWlYMMZrG1menddB4VQoUj5mBOagELSRlFLF+qsPWmrL5t1NDFIXTOFqxvYxAxsN2cY6YqmO1jGkWZkeK6XcAcZ9KyLu0WOQiBjxzjsfaulullDNwuCO1Y93E+V2HBP3uO1VERkuJhGwDqqsM4HrXLeIFkjso5nId45c9OgrrZ2jNvKmSVDcHvmsi5t0uIJ9uNwGOT1rdM56iMvTrebaJLdhKJMbzXTWEl1CeVGVHNchpt5PorLbsuUZ+ff6V1D38jwGVSFB4xWkTIuX9yLpAJYtvPTHWuT8WaW76ZPEiMsTN5gGMgGt1tXhnhMUxEE0Z4JFa0MytYlpSsqOQhU9896aYnDmOJ8BXhubD7LOyl4DtAA5I9K39UZYoxhTwTgVxM2PDPjN0h3CNm4Hbaa7q+DzOkKoG3jcufQ1fU5pae6ZL74ZY3iUMGG4+v0ro9Ju/Pjj/dsjA85rBitn8oFWJkDZx6YNXdIv5f7YME7n95yAVxiokXSfK7GnqUaq0hDBs9f9mm2N4sVuxIJGMZFSajFLGHYqrO3BrMs5TGrK6gDOMVm9TsUlY6CxmxDtnbcrnOB0FWbi3WMiQyKYxyBjiqlg26VUUAxEZII6GrNyRJGySsETIAUelJRsNzKsk5M4ZEDqPmBxjFZ8ztLIbhUKSY2so7j0rUu5Yo4mCphAMArzVKCdnjcsB5uePcVaIk7oqy/v4/Lkh4PBxwa5zUHu7BnMJPkjsTnFdNMrMc5I/vViatCDBKI1ZgRyc1cTnkZ6axEzKMtK+ASCc1Wn1aVVPkWz/e5OOBVLTvKjuZFU7No5OOvtVlL5tTkMNuQkYO1gR6VozBysFvrUjsQ9qWKtwcVZ/tOdQfs9u7knJ9q1bS3tbeH93gqvOcdalfyI1I2fM4PNA1MxrS0lluftd5y3XDckVobgVYQq+F6ntQhMUaBMMWHeohqFxEmREHcfLgDgD3qGEXdkcTxATESDO4Ft2c1W1C8EdpcttPzDaBVlnMjo6xLkg5FZF7O1zOLUZBXktjioNTb8GK0OkgPBl3cybifWrtymQP3rZAORnjOetU7O6CWogQYx/EO4qJb5meQ7c44AHegoWGJLid0eUEDhR61cs5YgLhF+8BtAb2qvFEcoYhhyu7mhJVlc5hzIOp6VRPNcS4nlN0EEbbcY445qS1nitJmBBeU9QeaqapcNBeKSOCvygGmQKbiZdikSOcE1NrlrYdGxunYsgwW5UjrmtZMQgpjaVHTuPxqG3g8qEsSC5PH1p104jVS4Jc/zrNqzNYloTKyJCwABycnqKp2wWW4ZuPJTkH1NV7mUFMYxKFBI9jWraiGC1RCu76Vb2BbjLnUbdPurv2AEKOhPrTfNd4Q0a4Zj37VXhtoIJ5GKk56Zq2HAlRUXk8H2qIjbsTR2KXNukcwyUXeuTkE1LDbM6rLJwy8bfQVEt1FG8yIrtJGc+1OhmluJEYgq54YZ4xQ3YqLuRzxo0okTkDgVUu2Nwr5A8wEYx3q8D+7ZVOIxkE461DMyAfuVO4YxkdaL3E9zM3uts6tGC+7bk9hipLq51q50xbK91a4udLR1ZbZ3JQEfdOPbtU8skTRSqyEDI5p0iGJgqL8jDOT7VSJk1bUpXs0kwSCMAkDqBxwAa0PGnjDTdbl0VLazNk1nCVmLJjeTwAMduD19azmS4jlMyYaMn06U9dX0yw8Oa/YXFj9o1S6ZGgmC8L61SIlquYzro+RiB1BT361Q1a2+13UAAxCiZPpU2TIgnugWKjG0HrTWliWISMCDuEa8GnGJkVp3ms7q2udMuJra9tfnimgba69uDVZrq4867u5557m9um3zTSPl3b1J7mrd7I8Eb+aq7TyrA1XKRxyNIMFiucEZFVdmbgtyj5zxuY9hO4A5JzRSS3ysS1vE7SZ28JxRWqM5H1gzeaIgRxjBHvRFJ5EsmBkbTgHpXnnws+IUHiyAWGoskWtouWXtdKO6+jeor0aZXjKpKB97aT2FedUjKDszeFSEojmkk8iNkORjmnfa3ls3mRR5cR2M2fu1HPIYXC4wD+tUpyG0XWYIcr5sJIx2Yc1MNXYfLFxvbYuNO9vLCZwPLlQ+We596LgIGDJ/F1rOvJ0vPDHhu/Vj5fyo7exXb/6EtWpnRIl6sT0PrVTXK7ChaVmipcRMJd6gAfypDBHPJvkRGYjGSKklcSgAEA9/epVjDRbicbe9QdbnZGSY4raYmNFQHIJAqCGBbaVm+Zlc55PAFa93B5kKmPGB+tQ3ybJkChcOo4pm6q8yKsihsFEBFUZxu+V49oz96teeNVO37p6HFU7q3JQBWyQeRVrYuMr6M5m+thF5mE4Pcc1iapCIYgyvlCvNdpLbB1YK37zH3a5m6EaOyyjcQeV7UxTgctrVgNRiTyflaEB1Prmm6FehAbe8Ul4/lGR1rSgiudvmlP3MmV4rOuY2t5TcBCxXgjHNaJnPKB0k1ppU1ixlXM9ZFwfsNvDLb+Y0QOCg6r71NpN5Feu6soV/Q8V0jWskFqSqxSscHtgj0qxNWPJPiJdCfVrS4XcCYR3rsrPUpLvRoHjjkaWCIbyp5qh8SfDRuNOh1exUKI1Ili9PerHwd8W3OjWt/CtrHcrOoUb1BI4I6ntWy+FHHLRtlvTbtSB5qk8YB9M+9Q3Nwtx4ktJLbKiMbeehq21gY9a05LpvLjuJVRyBnG49vpms/xNpKaP4g1uzs75bpbYhkkHr1xSauiFM6rzJGhkGQX7gjpWRcGbe8RC7mO5W+lS+HJPtGmCdnZnI5P4VNPGuwO3UcjNZ8tjolPYi0e9nilSN8kZPGK2ILhPs87yIXzkDI6VztnMyXAYHPzYLH+laRneMpFF856lTRa5cZFxJImscxqzK3BBNQxBWQyIQp+4Mmm32qJaQcADHIXb1qDT7hL6LzYWBBPzDsDStYTmnoWsFpAN/wAxHPvVK5w1tIuOOhzVycCWcRgEMB1FQXQ3OsZAyQce9UiZHmGs7otWi8wsIpGwQOK1zF5CbBGoL8Bh1x71F4styJDnaWUbs+mK0NPnXUNMt5BjeV7dyKtHM9yOyLZ8kzgOOMHvWs0h+zsjLgjjL1zs11HG+/aTIDgEVpWd6Jx5Eg3ORnJpjWmpd+7GFO3seKZdEISsbqhcgrnuKY+xmJJwAAPoapSsyylWUyKF3Z9KAi9SS93yy27K8UXl5LBSRke9Z4mT7d5hVtm7b1pk92HaN4o9wZSMA9aotcZDNEpTb1U84qCzo5HEDFQmQQGUDooNQRTBLs+UuR1NZlteSPK2+MuFUfNnHHrW5asqW7yyIoC8j/69UKcrk892dwZTyMcCmmSZ5PLtovLyOZMetUbGSW8ujLIojh6r6MK2bKVd8jKxAC9xxUCjsYOpoEnt8yeZyFYHrmt6IGNcQADt+dYchFxqISQgtuyPeti5ZI9p3FWHUChnRFodczfZ4lEa7n3jJqO/utvCqrMevPSq0krZZTyW5WrAjjdUuCuNnyn3461I+flKtshuJ5Qy5IIwa6GGMOOFYrH1x61haEY5RcSyORiQqCK03uEt5BGkhG7kc8UmF76kqlPn+tQ3kf8ApjyQyvncMHPtTi6RAmcZLjeMd6LeYSKkgT5CeD2NIpEc1xJaxymOMbivzH1qWwvRdMD5QXCglu1ReXIb2fcNyleh7UGMpbBY22O2V4oKUrEkOoR3U0iEgBThc9M+tXrv/RUDM6byPl96yoUg8yFpcb4+CoHU0l6ZZZpJJXBIGY1H8OKB3uTQoXhkZlbd0GfWpLhiqksBuUdTVPSL2Wdl8xMJGclhS6jdrdSgRHKM+Dx+lUjKYiSMrgyLmPHK1m6gJjOqWcLSXk7BY41Gcn0Oa1Lkwl9sJKlFw4f1qjdRTxywXdmwa4t3EsZPIyvrQQQa5p/ijw0IX1zQZ44XBbdtDBT7lTx+NVdNlj1Gza5yd2fu9hXp/hb44R4nh8Z2P2d/mkhe3TMbjHRlY8mvMJ9ZW91PUNXmhFrHeXDzJEABiM9F44rWUVFaGNNyT940tO8C3eteD9S8TjWIILey3H7Iytk7e2exPauW+2K8CB4QMLkso5OKkkHnLMkN7OlszCSWFJCEf8O9VpJYluX8pSEIGechR6VILm5rs6nT/HtppHg1dJh8PWcmqvIWW9ZBu2nvn1orgdQvTHFtRkYsTgd1FFbwWhy1WuYztH1CfTNRt72znMFzbuJIpAM7WHT8K+r/AAJ4stPGPh0y2r7Z4NonidvmiPr/ALvvXyHXReBPE9z4S8Q2+q2Y8zy/llhJwssZ+8p/p6GitSVRGVKpyM+v5MSIVOfMX2qPSYUa/wDJdgUmUqfyrN0fXrHXvDkOqaXKTBLwSwwykdVb/aH61ZsXilmL2742kHIryEuWXvHrU7yg5LYo29s1h4O1HSWO6SyvsxA9dhO4Y/M1esrlZYArgbj69qln8ua6mlBy+7BJ78YzWfOhU740waKsuaRpRhFR1CRDb+YVO7j8qdaXLHCnv2oVgyAv171UcJFKJEfv0qUzoUOZbGwu0h8sMAcDNQKDOm2TBC9KptPGG3dzTptQEYXamG7/AEqk0QqUk7Ika3VlBZiCRuJzWXPfxICqEPJnHy81ZD3eoS+VbR4ic4ZyOgrVttPsNPhWKKJHkJ5cjkmtEjTnVL49TBjSeZS7qEyOC3BpW0q2a2ZpgrS9QBWxNZmfcGJXHrUH9nCHLJufjrVpC9vHuZMPh5Lg+YTtVAflHT6021sba0naO8hQAjh8VvCV0QeXwhGG9jWbqSRSWyyEg7DkEnOaRUJORmav4csr5GeAiBh3XiuY09G0bUs3he5A4WMjIauzt2LMoCsVI5IrK1W3WScMcDaCcjrVKTLcUlrqZjzQXNvNGcIrqT5Z9DXjlhqFz4d1uZCuyJnwVP8AdzwRXq14VSCSRFLEc7sdBXKahpkfiHwvcy7Al9YlpFbHLr6GumEuh52JhdJo6Q3EGs6XmMgjbuzn0/lXP6bChXUYSd0205IbOTWB4H1Iw+bDNJiJxt4PStuyngtdbuYY2H71dyg9Wq7M4ro0fBF5IEa3cgNGcHPpW/ctvmyBhOlcjo00cHiII6487JP1x2rqbje1rjd84GRipZsmrFNdrXDIQflOV+ta8c3lIsjplsEA461n2uNitMMSHpn+taUc7vbxqUGwcFqk1TsWfCWqabY+K/M1nYbWS1MaFlLKjk5ycVD4mOjnXLz/AIR5lisHVZAkaFUEuPmxnnFV3t4CXWREYD7oIpIUhQDCoIsZAHUmgnkTncIjlVLthiOTUczh4xHsJZjwwp63MSIzSJvfPyL6VVubrymYquwYyM+tNDkzi/F0saQTFQ3mE7Aaq6NdSfZU42lBt9OKq+I7hZZWiyzEncR71u6fBZi1TzA2GTsec1RgyNpYRtidCX+8cd6r3JCP5saBABnPtWnHBEYwUOZB8vzGopIUSLbIznJ7cCgCITyXCIIwEyOfemNHcSh4Q3lE/wAR9KllESqJEbbGvGGPQ1VS8cBxgyRt1OOopXAtafaiJFiOJOmXB/OqesWj204ntl/dj7w9ajGovDcRrbRFbbPz/StN7x58xMqm3YZBHWi4e8Z24TwCWNMALgY7EetQB5LOWRrhfMhK5kUGnRuLT9xIrbi2QR0xWhK8TsjfKEC/OP71Mss6bqEdyYY0wqKNu0fpV+2u3iHkOo8o5JOK5TA0+88yMcSfdrokJubXOcREZyKiwIp6e6S6tOSB5Yxs3etaWoDzlaGLCEYJPqaxtLWQakULqwY7VH933rZvY3ij/eYJwRkUWKRWhiYTMrOPOZSUYnhRVgKFs+WySOTngmqqxxSRksZFcZjyp/vU62hFtbfZLt2aFfusTkkCkxs0NLtYvJkMZyD1BPGanmES/LtAwmOe5qjbMFhQYwHPygd6mkuoYEfzw0z5ChQM4zSsXcaJTJcQJL80W3Dj3qG7Rru7NvuZY15O3irBurdpvsoCqzDcSeMVNAyi3kkXBZjjd6UmrjUrFhp42McSMNypyfUfWpgIhbhmcHtWaLeKOAlGZ33ZGPSo4rtLiR1wEKDABqfh2G7svwBTvlVMlenPWqrXbDekqqUbofT1qRJYyrQ2+TLja2OlVLmRoL6GBYw/IJJ6D1p7oS0ZJbkW4aONlBPbuac6+X5aKm5i248dKdFbK+oCSVlDg7lx6elS3UqQzSMUbDdOe9Edi20U2tgL9llfl1DEZ96p3ksenzPKznYpxt6jFRarfpZAXDkFuh5ycVjtHcaoxaUMlocMAeCarlM5THanqaXUwWCHzUToFXPFUJ4ZWlle5370XKoPu7e1ajOlnCyWkJ8xfvEDoKhWV5Codx5flYJ7k+la8qMpSuYzPMI/3YADkHIpt5OtvEm4YHTbnnNa+YreB55h+7UdO/4Vx+oXP2q6klxgMeB6CrjG+xhWnyqxDI+5mPcnNFRmit0cTdxKeCAuMZplLnikI734U+NB4X1cpqDSvpVyNsyg58tu0gHt0PsTX0ZYNCkouLWVJbedBIkkZ3LIp/jHtXxuGxXq/wAFPF0NhPLousXTR2U+Dbbz+7jkJ5yeoB/LNcmJoKXvLc78JiHB8j2PoCAsGbLIN2Oe1Jcuqsc42+tRBSQ+8EEc8nk0yaAz2mI8lq8p3vY9FU1e99CKcqCuxhtPOaqEgoQ7DBPpQ0MibVIyuMH2NLHZSypsbgHofSqikzrVoLmuR2ttJeTmOFSy9fM7Vu2WmQ2rK1wplx39at2UUdta+XECFC4LD1pFKxhSZMgnBB71vCCOKeJnLRPQk3r5n7mILDnnb2p9zaKZD5Tqw6jNNiAjSRUYhZOtRhPKTf5mT/t8YrflRzdbIngjBcxsATjrmmTkyJtCqu04wD1qO2vIllyNh9easSmDd5oKkEZ4qrJCalGWpj6qo2xhcKV6qO9ZNuVZXV2/dDrmtm9MUjD5vlHH1Nc7qIC3bCI8Y5HasJaHqYbVWZKkwEEjJhVXoMVi6vdBYEKFTNI3T2q1PdbYQUHyMOawn2y3KOScKDtP/wBahK5rU0VzH1+8aC0khZfLO3DY71n+A75P7O1ATMHLIwzjoADWX4t1dTcraxAyTu2ZO4AplndRab4f1CQRhJHBVcDrkV0Q0PMrS5kzgbed4JNyKSCTkVJPd3bXAuN5WQDaCOwpmNgiZVJOMkVMymUbwOB19q6LnmuOu520lk0djYalFuMsZBI7multbpZpSZX2MVziq+jxtc6XCjYICila3lMmNoEm/jHdaxludcYuxpNJHNhz2AB5xirkTxMzRqxNvw2B1zWJcEf3O/Wp4pFIAjYq2csO2KSZqlc15/JduchWHWoyqlUeEBpBxt7AVTlmjAVdzMvY4pBdRjcQxVx19xTeoDLpmCl1Q5VufasPUb7L7JpCDHn8as6pqyQyhZWPlgjOPSuU1GabUrhzbxnyWfhvUU0RJlR42udTSUMSHODkV09xZusKOp3oMcLxWbd2xs44HDkKuAR61uCeR1BDN5QwMn0qkzJ7mfGGVmZjsdjxuNWGKvEMuu8ckUlwY5ZAxHQ5GRTIljWRnYbiOV29BSbGhJoBLCN6gLuzwetSokaF41jyMY2jqKcsiPCcoc7sk/WmxSqJ2ljzujbJY/Spa6gIbNQDEqfMCAVIxn3rGmhuLKZ4ucg5Cjnir+pXk8lysytlnbl+nFQ3XmNJHImWRjgkVJpcrvKBLGJeS469cVPAd8UoDArGcFsdBSGAQ3MckPzRLxs9KrPHNao+7CB8nPY1oFzSaO3lLIZQ8YU7eOSfQVU025MSG3Sc5UkKuOvtUFk+xkLMm8HKgH9aNStRZ3X2mJ3DScnA4GetAjas3LXhuBtjTG0D1PrWjKpuI3O7y2A6HvVHTUhkQbcLGgzz3rSkiV95VlcBRlgentS3K8zGklfdtBGWYEY9qt3AidjLIx5XlPSmTxR8eVkFW+96Gq0kgIbz1KqxwKlqwJvqakkZit7dYMN3Ge1RyWzREFBunk5bPAprTogCqGGOmOaZC8n71rl/klYBATzSuUXBB50rSSAFVT53A5oieJHWPftjGWxiqDXUttKw5II2j0pMSyS7ZGUBx1B/Skxou2OPtU88/MKnCHPBpYYo3kdwQEPPvVeOJTsgZmMarnA9ant4/NcA5CLwD61LNEyayEaPI6AFmPyt6+1TLHbwfLPuErn72KiW82SiC2jUovJJHQ+1WLq984ojj7vPPahCa1K7ukb4OWPr3FUNYvvsQXc4eVxlEPaq9xqa25lkZtzh+O9Y0MMuoal9puiwBGF/2fwqorUl6D7FPt9w1zfE7EHCFeCfWr+oXhnWCBCI4YySXx1pwaeWWCys7ae5mfPyQpuYgd8elVI5IbmSaCYlUhH7zjke31qrGTkhJSiQsPMyneQdD9av6XYaLc6Jf3+pap5NzEMW1mEOGP8Afz6VmOrT6azwwSDTreXyvMK8eYRkLXOeIL0ErbxHhRhiD+laJXM5yUYalPUr1piYlcmJTx7n1rOoBozW6VtjglNyd2JRRRTJCiiigAp6sR0NMpcmgD3j4O+Np9Stv7E1OYy3UCbrZ26tGByCe5A6DvXqUV3sG+Lla+PbK8uLG7iurSVobiFg8ciHBVh0Ir6h+FniK28c6EzXPkQavakLcxocGQdpQvZT0PofYivOxOG97ngephMWrclQ3mL3CMxIXnPFTRyNHPHGQzR92rcTTEESlSAR0BqtNdx22U8oF1bGccVzqi92dXtue8Yq5LY3kYeSOQAJjpRPao774Ru79aZ9uDqXQKGPBFL9slRBuTIHtW0UlojmcJX5rWFOY2AmGwcfjVm/W0uEVHPyFeoqvHdx3fzxKVboVanSo8inzU6Hse1aLsEn1MuXTooMrBIXBHGPeqsscttFyX6cV0KLFKg8lNoXg04WRnB8w/L60SgbLEJWbONNw6MBIePU9KqzuouMRtvLDJbsDXV6hoUchTy3yGzwSK43W9LurIu0P3c54rncZLc9KjVp1dFuU97QpiRl8tQc565rBlknjs7+6ixmFGdQe/FK1wPtfl3bMCfXpUfieV7Lw/e3CxlkaMrlTweK1p72M8RdRseW6Y0dw5nlLfaZCxZmPAqfVwolggRmKKNz5PXNV9I2vZ+UVAPOCferl7HskiCcgrtznJrpaPK1sZV5Yi2ZpYmJhboD1FMjYoCcAR4zz3rqmQz6PNEIlZwnyu1cjtaS3KsjFgOg9apMx5ddD1LRI2awt5I2+R1GPatNIWDkq4JUYyaxvDk7JpVuG/gUblxiuiDFrZmjVVLeorKR0Q2IJbVnjCb1Ix261jXMM9tu8lSWJ5JPaugQGIxogDtIvLZ6VWnUwYRlErg7iR3FSir2OVn1C4iSMMj4AJwRyD/hWU2p3motiD9zIvBDd66zVU80Rz7NvPNc2T9l1WYxpjctXEzk2Oh0Zpyl3ezb2boqnvV8Dyo2WBFCL8vIq5p0bylS4AQLwfQ1HPcLESoTcSc5BxVE6soXrs1pkMnAxhhzmrFjKv2YQNIm7jPam/PJndECG9TWx8NfDFr4v1q7sbu5aDyoGm3RAMwbOBgHqPWgiTsZ87kuyxruwOoHApnlRlthbHGWI4xTrrw7r+i3d/aX8J8uCQqJQfvjPDD2NLIjsAHwPl5NKUWh05J6lWBy8+yPmPg7vWlulCqzxD5nOWApGXeoW3YDZ1I7/hU1iHmdIo0UswPDnDH3FJvQp7lAMCRHc7V3DIz2FOkVnCwWkigJ8xBHJq9esZPLR1VRBnBPUis+a8dWYW8KmSMYPPJFVZDWoy4ge1sIrsTIZpXZDD/HGB3PbBqsb+a4tmjnVcjgDFSyFGdPNTcxGZAcjFQtPGb5TbYERXhc5JoHYj8lBKFXgsPlIHWrS3AW1kjnZXXGFbFVbpmmaPJCrHnaKbFBEtt5Y+Y7s8nFIVzY0BkuYNshG4NkAVt/aFETRCE4PXtXFmYaXexSqd0bHkdMCunFyznzY/3kJxx3qWmjSOxNfRrtjKdCfmUdx6VXlVp7dkdcDcAq+gqe5Vm3KpKqRlVAzVaNjF5Ykz8x60tWDaIp5HhkTylLkHBGO9SSxx3F4jSSMrRr09DVeW5d5lIYbYxtzjg0mmAXNxPuBDngehpWBFmeQr+7Vdx7Z71HK5cOArR7cZHpSr8yne2HjOD71JdzpGJI4owQ4GS3pSKRahjZZ4oxjDR/eFCT+QkiTfdBxkcGobW7EKQLnL49e1JqF3JGkjMFf/ZA7GqVrCbsyaS5DRk26DceQf61mXt04VlkkHmHr600ky26mSQxlOQAvWo7OzjWRmKs8rdz0NJRE56lIRKjKSMhuSD3rUdCskbRA5ZMZHQYqS3tU8yUk/OnXPI/Cp7a0hutB1m9EojezeNBGx5cMcHFOxHM7ieFfFl94Z8TRXejWkF7MsbK4kzt5xnoc9qxmL3t1d3lxGkYnkaRol67icn8BUlvFbWgMVoPLkYcMTkmszVr/wDs5AjwkzYIB3df/wBVaJX2FJxirsh1fW7m00M6JE+bV5jc477umfrXJls9evrSyStI5ZzknvTM1vGNjz5zcn5CUUUVRAUUUUAFFFFABRRRQAVq+HdavdA1i11HTpninhYH5TjcvdT6gjgg1lUo60eoXsfbfhHxLb+MPD8Gr6fH5cEpKPCTloZB95SfT0/+vW0thFKh3fePODXxz8OfHOo+CtZFzalprOUgXNsWwsq+o9GHY19j6DqNtrmh2Gr2hY215EJYyV2tySCCPbGK56lJM2jVaWj1M280vy32xY9cjtU1myAeWwDdsnrWvLCrEYyKxtQt/stz9oQDHQ1h7PlOunVdTRvUtSQxGQOirnocVZitQshcncvpWdDOVUApxJ901rhgIY2BU4+8PWtIJNmNVtCG2jEbeX8pb0qC3jeEP5yqT7dDVuOJFYspfcffinkZ4OK3dO5ipPqZki+agBgVcfdK9RWfqNtutmEgwAK6GRdyfSsS6LGdo2YY9K5qsTpw03zXR5t4l0OG8PH7twOGFcvpxNxZ3/h/UTkvG3lSHu2OK9S1GzCxsvUf3q8u1uM2GtxFs5bkEkYrlT5ZXPebVWn5nlljGbbUJLO43CSJ9jAe3Wtu5twU2+UQUOVYd81FrFuYvGl3sIKyHzCx7561pQwtHErliyOSF5yR7Gu2+lzyrW0KWnyNDcAyoxB4KnpijxRp4W1F7alY0X7wX9KVlnSZ42Kjf0HtWk8TT6XNZOobenGOoNNEPVaFbQdTFwsIkXZ0X5fp15rrbSR1mJZsxkZA9PauN0PxTcaV4duPC89lblJLoP55UeYMcdevauks58qFGCsikx+9TKNyKUraM1vNUypLwVztAFR3PmK+1dpJBOQevtVVCAwCIRgfNzgZqJj+7zGcnOOv3TS5bGt7kNx51ygRyAdv8NYN9C41EqCGYryO1bFzIVjdyxx0HqKzYlDSmQndgAgn1pomSJtGuGPmR5JMfO008Qs7PI5Of4VqnYSxjVroNiNiOgPFdHJPZva2TWMTb0TbOWP3m9QPSmTsVziELujG7b0HSszSLe+sNUg1PQ7ho72CQlvUqeq/Sr88jgurAhTxxWfel7dzLG7ZYYbacGmiZaqx3viHx02vaMYJLdY7gHDseGcDsPauQeZTA6s67+u3v9KZYTCa0YjAPGWbqB7Vr67I+uW76jpdikQtFVJCMLx6kU3qKCsc87OoUqsUXmfdK9aV38i4QswEqcqw9abJGbd99wwRUHfnOTU1pawXF3Gb6UW0EsmDIxztX3x1qOU10KU08lyUG2MMuc5PX3pGCRTrOVJZl+b2q1qEemxarNb6dei6traT93KAR5gxzUMtwzRyO8J2vwCMfd9aocERanbLK8M7XLDf95fpWZe6dEgRoJQoHfPTNT3KXd2yywgKM7VX19TVwWvnFsp8qfeO4Dn2qbjkrGGxePI8wPtH3vWp1dJGOxdwApz2wlbcMeXkgLjGD7+tVpbY7yVfbtHJzVGbQ29SRo0RsBVBH0qfQ757IeXKxeF/lBP8HvT1DzQAMA0ZyN1VJoXto41KgxE7SfUUmCdjtbS6hAR3kJc9Fqa4MKTB55COMoAOtcTbXrj5A/yggKx5rXj1QyyAOgbyzjkVKRV7lqSFZY3aRWjT7yBe9Twp5ceyMgbvmB74qvJO84ZQmABnGRyKz57m5jiJkheJDwrZH9KGrF9DS1O3c4kjlVT6A1m3tw7iM5G7IXr29ajkjlusxrJjCZ8zNQG2YKZJHyRgKQOpppCbInmmLF0BBI2Ant71dt76TyNwKvJjy2X1x3pZ4JCflYIpUZqpPYTLxERk/MSBjihoVzcivikcr3EWXABCqKW3ukYb23RhgWwewrMgmFvGPNVpC3BOaW4kWVlaJGG0YIPXHpTSsJ9yxPcztIfs7qsJxyTyaJ7mC1YmZhK5IyB09qxnM0jHaMRrxjuKrzYMMkzB3VCNxY8UrXYc6S1LusX0QCXCgR4OAq/xVyd3cSXMxkkYn0zzgU+8nMzkL8sYOVWqpPNdEI2OGtU53oBOTmkooqzEKKKKACiiigAooooAKKKKACiiigByHDDnvXrvwZ+KsvhaePSNbkebQJmyDnLWrc8r/sc8r+IryCnocPQ1dDR+gFvdQ3UKy2sqSxyKHR16FD0I9jVPU2/ctHkEnqfQV4T8CfiLawJB4e1ufZMGxaXUr/Iyn/lkx7Y/h/8A1V7bcuscjmQYY5yDzgg461zVHpax1UYrm0MuCVxBtlblW4b1FaenXI+1KM7kIwa5nVLgBz8wwT2FSw3QSMGEkSY61zQnys9OeG5oXSO6DrvI3YAoZgEJHPNc9b3Uj2a+dJ82etaD36CJPLOcda6lUTPLlh5xdkX2dSc56CsPVG/0tHA+Tac1Yku0eKYkbQ2CD61FKVnhTIOPU1nN8xpRhKm9TDuhtJyTjFeN+M2a91/9ypwgxu9K9P8AGOqRaRZNNPIqoqhUHdia8dv/ABDHHaymOIPeOpyf7vPT61yqPMz24yUKRgXYFzqczyEllUKDmr1vHIsKyHJVuCM9COlZNiu3DO7NI/OB/DXRaZEIo2/eqDncMjmutbWPP+K7Mm/SZbgyp8xDAAE9K3LB2Z1QEcHOR2qj4ot/skP2mMsAcFh6mrXh2NZ7N5fOAD9qq5jrcyfFelhJRfQP5iE4kA6g0mgaxs2wupxGpZfpW/d6cG064i8wYlXkLXn9tI0cgQv5bRkru7kULUmppqj0yG8NzCdqqr8H6ik5hDFNuxsHbnpXBx6vJBIBHIOD8xyeVpo1q4aPEjyFg2dw6U7EpnYXxLXDMG2DFZtxJcNOmn6VEby7dSxVf4aw/P1S+ClWATPcmtXw/Z3umXgvre7lh1BM/vY2wQD2p2QnJmdp8LR6xDc3LsjtKyOhXoQK7MSBQu1ckjgiua1K3nFyk4fzJUO+RuvJ7t61sh5Z2tjnapKqXTjAJxmkxpl4NI2S7Ar6etU5hIWbBDYB/DjpV3xJo7aFq81taarbX8LYkRojkDIGRmsS+WZ0cxHyxn5mHXp2qWy0yC1upk53psTls9/atKW5uI9OnWz3IJ8F0BznkYFZFjHBcRbQSMdRnH41NPPNYSIskjm22nGeppphY6TV4tHXwVos1lI8mtTSEXKFchVGe9VfC0dtPrFrFrQ8yyYlTzjk9DVHSZoZisjccHCLzimy3WxGSBR50jY+bgKPWgHE1td0F9C1Z7J/KuYHzIvlvkKD2OKw5lnVd0ahVH3QR2q75croZFnkxt5PqaWZykaNPJ0+Xn0qblQZkl7ya5AWUx25+bao+6apzRXHzhJP3jHefcVtp5Xl+ViQIrEh/XNVbmElU8uM7MfeXqeaLFt3KkSyCJAZCPU+9VrwvHKBITJnqcYGKvWjiUyJK+AW5DH0q8bWFCC6yOjDqT/KqM3poc8LgxxHa2Ez09Kml1IOxjcKy9s1YuLCFeNrMrN1z1HpSrHss7uAWURVyMSyDLJg9VoJMd/lc/ZsCTIO3tQJ7iKdi65QH5yKvGGHZ5jPsuv4gOgp1tGrBkllOD29aYWFsriW7fdCwTPB7kCtiOAiD5B5iBgCT/FXNTQvFcCSBhFH0IBrS0XVXWQwSMFRejZ61LVx3NEJ5D4YYz2qvt8ltknz4z9Oa1JXjupFYfNHGm9s9z7VRnh86KQhnWNDuTJpbAhqNLcIwjRfOUY/CnQrIwDuDJldpIPTFUZJLpJPMtpCDuxnv0pvnyiOcIXXI+bB6nuaadxkt1Nu3sAo2jGDVF7goBHbANnknPNOjZAxDMWCY3Z5yKhBhJlKOokcnbx1qraA30HyM7RZVzEAf3hrF1G/MqmCIkw5yT64qXVrwFPIUhiQN59xWPnnJrSEdLnJWqfZQN96m0p60laHOFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFKKKKfQCSD/AF8X+8P519wan0H/AFzX/wBBFFFc9bY68L8Zx+sdV+tSWn3T9RRRXmP4j6ZfAbQ/48h/vip7P/XSUUV0LY4Z7ssP9xf96ppf9UKKKo5ZHi/xl/5C9j/uj+deWS/6y4/67UUVMNjoq/CTWv8ArzW9afdb6iiitjnjsXPGP/IFn/3VrM8Hf8gw/U0UUEPc6VP4/p/SvKr3/kLXH++aKKqG5FTYYnQ1NYdW/wB40UVZgjptK/48x9auxf6x6KKCmUpf9XeVc/5cbb/dFFFJlR2Ebp/wGpH/ANWP900UVDNEY2m9birWu/6mP/dFFFNAQ+HvvtVjUP8Aj4SiimJGiv8Ax6N/wGq19/q2ooqAiSQ/db6CpLL/AI8F/GiirLMO6+/N9RW43+qtv+udFFBD3KneL/fp17/qJPrRRQUc/f8A33+gqJf9YPoKKKCWXH/49x9azf4h/wAC/nRRQSdDpH+qX/cq5d/6gUUVMhooSf6gVGn/AB5XP0oopoZl3X3/APgH9Kitf+Pi0/3TRRVIiexiXX+tb/eP86hFFFbrY4ZbiUUUUyQooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The image obtained at the time of endoscopy reveals a typical GOV (gastro-oesophageal variceal) lesion. The GOV nomenclature is used for varices that are continuous from the esophagus to the stomach (GOV1 include those that extend less than 5 cm from the GE junction, whereas GOV2 extend for further than this length [this is an instance of GOV2]). The large grape-like structure appears to emanate from the GE junction, typical of GOV lesions. Gastric varices can also be isolated, often when they arise as a result of splenic vein thrombosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_10_25766=[""].join("\n");
var outline_f25_10_25766=null;
var title_f25_10_25767="Precut (access) papillotomy";
var content_f25_10_25767=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Precut (access) papillotomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/10/25767/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/10/25767/contributors\">",
"     Martin L Freeman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/10/25767/contributors\">",
"     Kapil Gupta, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/10/25767/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/10/25767/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/10/25767/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/10/25767/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/10/25767/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precut papillotomy (or sphincterotomy) refers to a variety of endoscopic techniques used to gain access to the bile (or occasionally the pancreatic) duct. In most patients, precut papillotomy is followed by conventional sphincterotomy, which permits completion of therapies such as stone extraction and biliary drainage. However, precut papillotomy is sometimes used to gain access to the bile (or the pancreatic) duct for diagnostic cholangiography (or pancreatography) alone, a practice of increasingly uncertain justification given the availability of MRCP EUS and intraoperative laparoscopic cholangiography to diagnose biliary disease. Thus, the alternative term access papillotomy is probably more accurate [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Precut techniques are most often used after conventional methods of biliary cannulation have failed or, in a few centers, as a preferential technique for performing biliary and pancreatic sphincterotomy over a pancreatic stent in patients with sphincter of Oddi dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/2\">",
"     2",
"    </a>",
"    ]. Use of precut varied from none to as many as 38 percent of all biliary cannulation attempts in different reports [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/3-24\">",
"     3-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of access papillotomy is highly controversial, with widely variable opinions as to its appropriateness, safety, and preferred technique. With advances in techniques and equipment for biliary cannulation, access papillotomy is seldom necessary. When it is performed, it should generally be limited to patients with a definitive indication for biliary therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several techniques to perform precut papillotomy. Success and complication rates of precut techniques are highly variable and depend heavily upon the experience and skill of the endoscopist, the indication for the procedure, the risk profile of the patient, anatomic variations among patients, and technique-related factors such as use of pancreatic stents [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Common techniques",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Free-hand needle-knife",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most widely practiced technique is the free-hand needle-knife, in which an incision is made starting at the orifice and extending cephalad for a variable distance. The original description of the technique involved using an upward sweeping motion with the elevator. However, improved control and safety can be achieved by loading the needle-knife by upward traction on the endoscope. Performing practice movements with the needle out (in the direction of anticipated cut) but not in contact with the mucosa can help in making sure of the direction of the cutting needle (",
"    <a class=\"graphic graphic_figure graphicRef76180 \" href=\"UTD.htm?25/34/26150\">",
"     figure 1",
"    </a>",
"    ). Having the duodenoscope in a shorter position can also assist in controlled transfer of movements.",
"   </p>",
"   <p>",
"    A variation of the needle-knife technique involves making a puncture into the papilla above the orifice (often referred to as fistulotomy) and then cutting either upward in a cephalad direction or downward toward the orifice. A theoretical advantage of fistulotomy is that it spares the pancreatic orifice (",
"    <a class=\"graphic graphic_figure graphicRef76007 \" href=\"UTD.htm?38/8/39044\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Any of the above techniques can be performed after placement of a pancreatic stent (",
"    <a class=\"graphic graphic_figure graphicRef68914 \" href=\"UTD.htm?29/50/30502\">",
"     figure 3",
"    </a>",
"    ). Pancreatic stents are increasingly used to reduce the risk of post-ERCP pancreatitis in a number of settings, particularly for difficult cannulations and prior to needle-knife precut papillotomy. Pancreatic stents serve not only to protect the pancreatic sphincter from injury, and maintain pancreatic drainage during and after the procedure, but may also provide anatomic guidance to the location of the bile duct. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Pancreatic stenting'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Various factors influence the use of precut technique at endoscopic sphincterotomy. One group reported that the need for precut papillotomy was increased in malignancies and less common in patients with bile duct stones. Use of a precut technique was also more common in patients with an anatomical abnormality of the papilla and in duodenal stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Traction sphincterotome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second major approach involves use of a traction sphincterotome. As originally described, a specialized short-nosed papillotome is wedged into the common channel in the direction of the bile duct allowing the endoscopist to perform what has been referred to as a \"papillary roof incision\" [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/4\">",
"     4",
"    </a>",
"    ]. A report that described use of this technique in 123 patients achieved successful cannulation in all the patients in whom conventional cannulation techniques had failed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A now more commonly used variation of this technique involves intentional seating of the tip of a standard traction papillotome into the pancreatic duct and cutting through the septum in the direction of the bile duct, an approach often referred to as \"transpancreatic precut sphincterotomy\" (",
"    <a class=\"graphic graphic_picture graphicRef52970 \" href=\"UTD.htm?5/48/5894\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/12\">",
"     12",
"    </a>",
"    ]. Some series have shown efficacy and safety of transpancreatic papillotomy to access the bile duct [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Novel techniques",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Intramural incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intramural incision technique has been described in a small number of patients. A false tract is created with a guidewire, permitting placement of a papillotome though the intramural portion of the papilla and unroofing of the biliary orifice [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. This technique is applicable mostly to patients with prominent papillae in whom partial biliary cannulation has been achieved. The safety and usefulness of intramural incision has been demonstrated in patients where a false tract has been created after attempt at biliary cannulation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Ultra-small sphincterotome",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ultra-small-caliber sphincterotome (1 mm diameter) introduced through a 6F or a 7F catheter has been evaluated for achieving conventional or precut papillotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/32\">",
"     32",
"    </a>",
"    ]. In one report, it allowed for successful cannulation in 98 percent (53 out of 54) of patients, with selective cannulation in 24 percent and precut in the remainder [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Suprapapillary blunt dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suprapapillary blunt dissection involves creation of an initial linear cut over the mucosa of the infundibulum of the papilla with a needle-knife papillotome. A small ball of cotton held with a forceps is used for blunt dissection down to the bile duct, with subsequent needle-knife access. In one of the largest reports, this technique was used in 48 of 1057 attempted cannulations with success in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/33\">",
"     33",
"    </a>",
"    ]. Pancreatitis developed in 8 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Endoscopic scissors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic scissors have been used to cut through the papillary roof or septum without cautery to gain biliary access. In an initial report, this technique was successful in 8 of 12 attempts without any complications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/34\">",
"     34",
"    </a>",
"    ]. Although the idea is innovative, data are limited, and the instrument used is a prototype that is not widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Endoscopic ampullectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ampullectomy has been performed for gaining biliary access when other methods have failed. In a series of 10 patients with malignant lesions involving the ampulla and protuberant ampullae at ectopic locations, cannulation was achieved in 100 percent, although 10 percent had significant bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13897?source=see_link\">",
"     \"Treatment of ampullary adenomas\"",
"    </a>",
"    .) This technique is somewhat radical and seems appropriate only in extremely unusual circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple reports have described the efficacy of the various precutting techniques. In several reports, precut techniques were performed in 4 to 38 percent of all cannulation or sphincterotomy attempts, with immediate success rates from 35 to 96 percent.",
"   </p>",
"   <p>",
"    These results must be interpreted cautiously. Only immediate success at cannulation represents true success, because repeat ERCP without precut may also have been effective. Using a variety of techniques with or without precutting, expert endoscopists are now able to achieve biliary cannulation in &gt;99 percent of cases during first attempt, as long as the major papilla can be reached with a duodenoscope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications have been reported in 2 to 34 percent of precuts, a rate that is generally higher than reported in patients undergoing standard sphincterotomy. A meta-analysis and a number of multivariate analyses have suggested that precutting is an independent risk factor for overall complications, and particularly for post-ERCP pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/11,19,36,37\">",
"     11,19,36,37",
"    </a>",
"    ]. Severe post-ERCP pancreatitis occurs disproportionately more often after precuts performed in the conventional fashion without a pancreatic stent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/11,36,37\">",
"     11,36,37",
"    </a>",
"    ]. In addition, rates of perforation were significantly higher in another multicenter study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/20\">",
"     20",
"    </a>",
"    ]. Bleeding is not consistently more common after precut papillotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/3,38,39\">",
"     3,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differences in complication rates in part reflect variability in the rigor of data collection, definitions and patient characteristics. Complications associated with ERCP, especially pancreatitis, depend heavily upon patient-related factors, as well as technique and operator characteristics. Thus comparison of outcomes of precut with standard ERCP is not straightforward since the indications for the procedure, anatomy, and patient characteristics often are very different in patients undergoing precut compared with standard sphincterotomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=see_link\">",
"     \"Post-ERCP pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In other words, endoscopists often elect to perform precut techniques in patients who are actually at lower initial risk of complications (eg, those with true obstructive jaundice and prominent papillary landmarks). By contrast, standard sphincterotomy is more often performed for more marginal, high-risk indications such as suspected sphincter of Oddi dysfunction. Thus the complication rates of precut papillotomy may appear deceptively low when compared with standard sphincterotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Complications rates with different techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only limited data comparing specific precut techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/3,12,13,20,38-41\">",
"     3,12,13,20,38-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized study compared fistulotomy starting above the orifice with conventional needle-knife starting at the orifice in 153 patients with suspected choledocholithiasis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/20\">",
"       20",
"      </a>",
"      ]. Rates of pancreatitis were significantly lower in the fistulotomy group (0 versus 8 percent), although overall complication rates and success at initial cannulation were similar [",
"      <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/20\">",
"       20",
"      </a>",
"      ]. Despite the theoretical advantages of fistulotomy in sparing the pancreatic orifice, the technique may not be feasible in patients with a very small or flat papilla, or in patients at high risk for post-ERCP pancreatitis.",
"     </li>",
"     <li>",
"      Another study looked at the two techniques of precut [",
"      <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/38\">",
"       38",
"      </a>",
"      ]. There was no difference in success rates or complication rates between the standard technique starting at the orifice and modified technique, in which the cut was made at top and extended downwards towards the orifice.",
"     </li>",
"     <li>",
"      Two initial reports of the transpancreatic precut technique from a single endoscopist described complication rates comparable to standard precut techniques [",
"      <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. However, a subsequent large series from Japan in average-risk patients suggested that, while usually successful, transpancreatic precut was associated with a significantly higher risk of pancreatitis than standard sphincterotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective series (n=116) of pancreatic sphincterotomy using a precut technique reported relatively high success (85 percent at initial ERCP) and low complication rates (12 percent, mostly mild to moderate severity, although two were retroperitoneal perforations) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial compared transpancreatic precut with needle-knife papillotomy (sometimes with, and sometimes without a 5 to 7 French pancreatic stent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/40\">",
"       40",
"      </a>",
"      ]. The rate of successful biliary cannulation was significantly higher (100 versus 77 percent) and complication rates somewhat lower (4 percent versus 18 percent) with the transpancreatic precut approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The success and complication rates of needle-knife precut as used in this study are difficult to interpret because of inconsistent use of pancreatic stents. When they were used, relatively large caliber pancreatic stents (up to 7F) were used. This may have interfered with biliary cannulation and increased pancreatitis rates compared with small caliber stents (3 or 4F), which are currently favored [",
"      <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      While the transpancreatic precut method may be fairly safe in patients at low risk for complications (such as those with obstructive jaundice), caution must be advised regarding this technique in patients at high risk for post-ERCP pancreatitis since performance of a partial pancreatic sphincterotomy without a pancreatic stent can be hazardous. Placement of a pancreatic stent may be advisable in higher-risk patients undergoing this technique; unfortunately, it is not always possible to identify high- and low-risk patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=see_link\">",
"       \"Post-ERCP pancreatitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study suggested significantly fewer complications and greater success at bile duct access using needle-knife over a pancreatic stent compared with a freehand needle knife technique [",
"      <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial suggested that endoscopic ultrasound (EUS) rendezvous may be safer and more effective for bile duct access than precut papillotomy using a traction-type papillotome [",
"      <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/43\">",
"       43",
"      </a>",
"      ]. This study needs to be interpreted cautiously as the pancreatic stent-protected needle knife technique was not used for precut papillotomy, and this center was dealing primarily with patients with a dilated bile duct and had significant experience with EUS rendezvous.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Are complications due to the precut?",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has often been debated whether complications of precut are due to the precut itself or the antecedent cannulation attempts. A meta-analysis of six randomized trials with 966 subjects examined this issue [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/44\">",
"     44",
"    </a>",
"    ]. The meta-analysis included trials in which patients were assigned to early precut implementation or persistent attempts at standard cannulation. Post-ERCP pancreatitis was significantly less common in the precut group compared with the persistent attempts at cannulation group (3 versus 5 percent). However, the overall rate of complications including pancreatitis, bleeding, cholangitis, and perforation did not significantly differ (5 versus 6 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PANCREATIC STENTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, accumulating evidence has suggested that prior placement of a pancreatic stent can reduce the incidence of post-ERCP pancreatitis in a number of settings including, precut papillotomy for any indication, after biliary sphincterotomy in patients with sphincter of Oddi dysfunction, or after difficult cannulation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/2,36,45,46\">",
"     2,36,45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to protecting pancreatic drainage during the incision and subsequent manipulations, a pancreatic stent provides invaluable anatomical orientation while the papilla is dissected. With a stent in place, the area can be probed with confidence with a guidewire or catheter until the bile duct is successfully cannulated with a substantially lessened risk of inadvertent partial laceration or thermal injury to the pancreatic sphincter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22983?source=see_link\">",
"     \"Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a limitation of this approach is that it may sometimes be difficult to place a pancreatic stent, especially for endoscopists with limited experience at pancreatic endoscopic therapeutic techniques. If the pancreatic duct has not been cannulated and papillary anatomy is clear, it may be best to omit attempting a pancreatic stent and to avoid pancreatic duct manipulation altogether.",
"   </p>",
"   <p>",
"    If pancreatic stents are placed, evidence now supports using small caliber (3 or 4 French) stents rather than 5 or 7 French stents, because the risk of causing duct injury and post-ERCP pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/36\">",
"     36",
"    </a>",
"    ]. Pancreatic stents must be documented to pass by X-ray or removed endoscopically, preferably within two weeks, to reduce risk of duct injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22983?source=see_link\">",
"     \"Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ENDOSCOPIST'S EXPERIENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are substantial data to support that high volume endoscopists have lower overall and severe complication rates for therapeutic ERCP in general [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/1,2,47\">",
"     1,2,47",
"    </a>",
"    ], but there are fewer data regarding precut papillotomy. There is probably no procedure in interventional endoscopy that requires more precise technique than precut papillotomy. It is important to remember that the published literature is primarily derived from specialized centers, and that the practicing endoscopist may not be able to achieve similar results.",
"   </p>",
"   <p>",
"    The few data on outcome of precut papillotomy in the hands of practicing clinicians outside specialized centers suggest that it may not be as safe or effective as in published reports. In one study, for example, practicing endoscopists performing not more than one sphincterotomy per week were found to have a first time bile duct access rate of only 52 percent using precut techniques, with a 24 percent complication rate, a",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio that is hard to justify [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/1\">",
"     1",
"    </a>",
"    ]. Although their complication rates may or may not be substantially lower, expert endoscopists are much more likely to succeed at initial bile duct accessing after precut (90 percent successful bile duct access during initial precut attempt for high volume endoscopists) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25767/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Success and complication rates of precut papillotomy techniques are highly variable and depend heavily upon the experience and skill of the endoscopist, the indication for the procedure, the risk profile of the patient, anatomic variations among patients, and technique-related factors such as use of pancreatic stents. The decision to perform precut papillotomy and the controversy surrounding the technique are related to a number of factors including the strength of the indication for biliary access. There should be a clear indication for endoscopic therapy, such as clinical evidence of cholangitis, demonstration of a bile duct stone at magnetic resonance cholangiopancreatography or endoscopic ultrasound, or abnormal sphincter of Oddi manometry. Endoscopists should be familiar with techniques of precut papillotomy, and weigh their own likelihood of safety and success against the option of terminating the case and referring the patient to another more experienced center, or performing an alternative imaging or drainage technique.",
"   </p>",
"   <p>",
"    Once the decision has been made to use a precut technique, it may be advisable to tailor the technique to the individual patient's anatomy and risk profile. For example, a bulging papilla with an impacted stone generally does not require a pancreatic stent, and the decision to proceed to needle-knife might be made quickly. By contrast, a young patient with a normal pancreas and small papilla who has undergone pancreatic instrumentation might be more suitable for pancreatic stent-protected needle-knife or transpancreatic precut followed by a pancreatic stent.",
"   </p>",
"   <p>",
"    The need for a precut papillotomy should be guided by the following considerations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The strength of the indication for biliary therapy",
"     </li>",
"     <li>",
"      The urgency of obtaining biliary drainage",
"     </li>",
"     <li>",
"      The anatomic feasibility of obtaining bile duct access",
"     </li>",
"     <li>",
"      The experience of the endoscopist with precut papillotomy",
"     </li>",
"     <li>",
"      The ability to place a pancreatic stent in higher risk circumstances",
"     </li>",
"     <li>",
"      The possibility of referral to an expert endoscopic retrograde cholangiopancreatography center",
"     </li>",
"     <li>",
"      The availability and safety of alternative approaches",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/1\">",
"      Vandervoort J, Carr-Locke DL. Needle-knife access papillotomy: an unfairly maligned technique? Endoscopy 1996; 28:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/2\">",
"      Fogel EL, Eversman D, Jamidar P, et al. Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy 2002; 34:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/3\">",
"      Akashi R, Kiyozumi T, Jinnouchi K, et al. Pancreatic sphincter precutting to gain selective access to the common bile duct: a series of 172 patients. Endoscopy 2004; 36:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/4\">",
"      Binmoeller KF, Seifert H, Gerke H, et al. Papillary roof incision using the Erlangen-type pre-cut papillotome to achieve selective bile duct cannulation. Gastrointest Endosc 1996; 44:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/5\">",
"      Boender J, Nix GA, de Ridder MA, et al. Endoscopic papillotomy for common bile duct stones: factors influencing the complication rate. Endoscopy 1994; 26:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/6\">",
"      Bolzan HE, Spatola J, Gonz&aacute;lez J, et al. [Precut Vater's papilla. Prospective evaluation of frequency of use, effectiveness, complication and mortality. Cooperative study in the northwest of the province of Buenos Aires]. Acta Gastroenterol Latinoam 2001; 31:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/7\">",
"      Booth FV, Doerr RJ, Khalafi RS, et al. Surgical management of complications of endoscopic sphincterotomy with precut papillotomy. Am J Surg 1990; 159:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/8\">",
"      Bruins Slot W, Schoeman MN, Disario JA, et al. Needle-knife sphincterotomy as a precut procedure: a retrospective evaluation of efficacy and complications. Endoscopy 1996; 28:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/9\">",
"      Dowsett JF, Polydorou AA, Vaira D, et al. Needle knife papillotomy: how safe and how effective? Gut 1990; 31:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/10\">",
"      Foutch PG. A prospective assessment of results for needle-knife papillotomy and standard endoscopic sphincterotomy. Gastrointest Endosc 1995; 41:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/11\">",
"      Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/12\">",
"      Goff JS. Common bile duct pre-cut sphincterotomy: transpancreatic sphincter approach. Gastrointest Endosc 1995; 41:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/13\">",
"      Goff JS. Long-term experience with the transpancreatic sphincter pre-cut approach to biliary sphincterotomy. Gastrointest Endosc 1999; 50:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/14\">",
"      Harewood GC, Baron TH. An assessment of the learning curve for precut biliary sphincterotomy. Am J Gastroenterol 2002; 97:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/15\">",
"      Huibregtse K, Katon RM, Tytgat GN. Precut papillotomy via fine-needle knife papillotome: a safe and effective technique. Gastrointest Endosc 1986; 32:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/16\">",
"      Kasmin FE, Cohen D, Batra S, et al. Needle-knife sphincterotomy in a tertiary referral center: efficacy and complications. Gastrointest Endosc 1996; 44:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/17\">",
"      Katsinelos P, Mimidis K, Paroutoglou G, et al. Needle-knife papillotomy: a safe and effective technique in experienced hands. Hepatogastroenterology 2004; 51:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/18\">",
"      Leung JW, Banez VP, Chung SC. Precut (needle knife) papillotomy for impacted common bile duct stone at the ampulla. Am J Gastroenterol 1990; 85:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/19\">",
"      Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/20\">",
"      Mavrogiannis C, Liatsos C, Romanos A, et al. Needle-knife fistulotomy versus needle-knife precut papillotomy for the treatment of common bile duct stones. Gastrointest Endosc 1999; 50:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/21\">",
"      O'Connor HJ, Bhutta AS, Redmond PL, Carruthers DA. Suprapapillary fistulosphincterotomy at ERCP: a prospective study. Endoscopy 1997; 29:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/22\">",
"      Rabenstein T, Ruppert T, Schneider HT, et al. Benefits and risks of needle-knife papillotomy. Gastrointest Endosc 1997; 46:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/23\">",
"      Rollhauser C, Johnson M, Al-Kawas FH. Needle-knife papillotomy: a helpful and safe adjunct to endoscopic retrograde cholangiopancreatography in a selected population. Endoscopy 1998; 30:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/24\">",
"      Tweedle DE, Martin DF. Needle knife papillotomy for endoscopic sphincterotomy and cholangiography. Gastrointest Endosc 1991; 37:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/25\">",
"      Horiuchi A, Nakayama Y, Kajiyama M, Tanaka N. Effect of precut sphincterotomy on biliary cannulation based on the characteristics of the major duodenal papilla. Clin Gastroenterol Hepatol 2007; 5:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/26\">",
"      Linder S, S&ouml;derlund C. Factors influencing the use of precut technique at endoscopic sphincterotomy. Hepatogastroenterology 2007; 54:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/27\">",
"      Kapetanos D, Kokozidis G, Christodoulou D, et al. Case series of transpancreatic septotomy as precutting technique for difficult bile duct cannulation. Endoscopy 2007; 39:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/28\">",
"      Weber A, Roesch T, Pointner S, et al. Transpancreatic precut sphincterotomy for cannulation of inaccessible common bile duct: a safe and successful technique. Pancreas 2008; 36:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/29\">",
"      Halttunen J, Ker&auml;nen I, Udd M, Kyl&auml;np&auml;&auml; L. Pancreatic sphincterotomy versus needle knife precut in difficult biliary cannulation. Surg Endosc 2009; 23:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/30\">",
"      Burdick JS, London A, Thompson DR. Intramural incision technique. Gastrointest Endosc 2002; 55:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/31\">",
"      Misra SP, Dwivedi M. Intramural incision technique: a useful and safe procedure for obtaining ductal access during ERCP. Gastrointest Endosc 2008; 67:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/32\">",
"      Seifert H, Binmoeller KF, Schmitt T, et al. [A new papillotome for cannulation, pre-cut or conventional papillotomy]. Z Gastroenterol 1999; 37:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/33\">",
"      Hashiba K, D'Assun&ccedil;&atilde;o MA, Armellini S, et al. Endoscopic suprapapillary blunt dissection of the distal common bile duct in cases of difficult cannulation: a pilot series. Endoscopy 2004; 36:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/34\">",
"      Heiss FW, Cimis RS Jr, MacMillan FP Jr. Biliary sphincter scissor for pre-cut access: preliminary experience. Gastrointest Endosc 2002; 55:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/35\">",
"      Farrell RJ, Khan MI, Noonan N, et al. Endoscopic papillectomy: a novel approach to difficult cannulation. Gut 1996; 39:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/36\">",
"      Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004; 59:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/37\">",
"      Masci E, Mariani A, Curioni S, Testoni PA. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. Endoscopy 2003; 35:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/38\">",
"      Kaffes AJ, Sriram PV, Rao GV, et al. Early institution of pre-cutting for difficult biliary cannulation: a prospective study comparing conventional vs. a modified technique. Gastrointest Endosc 2005; 62:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/39\">",
"      Kahaleh M, Tokar J, Mullick T, et al. Prospective evaluation of pancreatic sphincterotomy as a precut technique for biliary cannulation. Clin Gastroenterol Hepatol 2004; 2:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/40\">",
"      Lehman GA, Sherman S. Pancreatic stones: to treat or not to treat? Gastrointest Endosc 1996; 43:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/41\">",
"      Catalano MF, Linder JD, Geenen JE. Endoscopic transpancreatic papillary septotomy for inaccessible obstructed bile ducts: Comparison with standard pre-cut papillotomy. Gastrointest Endosc 2004; 60:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/42\">",
"      Kubota K, Sato T, Kato S, et al. Needle-knife precut papillotomy with a small incision over a pancreatic stent improves the success rate and reduces the complication rate in difficult biliary cannulations. J Hepatobiliary Pancreat Sci 2013; 20:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/43\">",
"      Dhir V, Bhandari S, Bapat M, Maydeo A. Comparison of EUS-guided rendezvous and precut papillotomy techniques for biliary access (with videos). Gastrointest Endosc 2012; 75:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/44\">",
"      Cennamo V, Fuccio L, Zagari RM, et al. Can early precut implementation reduce endoscopic retrograde cholangiopancreatography-related complication risk? Meta-analysis of randomized controlled trials. Endoscopy 2010; 42:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/45\">",
"      Singh P, Das A, Isenberg G, et al. Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials. Gastrointest Endosc 2004; 60:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/46\">",
"      Hookey LC, RioTinto R, Delhaye M, et al. Risk factors for pancreatitis after pancreatic sphincterotomy: a review of 572 cases. Endoscopy 2006; 38:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25767/abstract/47\">",
"      Varadarajulu S, Kilgore ML, Wilcox CM, Eloubeidi MA. Relationship among hospital ERCP volume, length of stay, and technical outcomes. Gastrointest Endosc 2006; 64:338.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 675 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_10_25767=[""].join("\n");
var outline_f25_10_25767=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Common techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Free-hand needle-knife",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Traction sphincterotome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Novel techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Intramural incision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Ultra-small sphincterotome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Suprapapillary blunt dissection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Endoscopic scissors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Endoscopic ampullectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Complications rates with different techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Are complications due to the precut?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PANCREATIC STENTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ENDOSCOPIST'S EXPERIENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/675\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/675|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/34/26150\" title=\"figure 1\">",
"      Free hand needle knife 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/8/39044\" title=\"figure 2\">",
"      Precut fistulotomy 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/50/30502\" title=\"figure 3\">",
"      Precut over pancreatic stent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/675|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/48/5894\" title=\"picture 1\">",
"      Transpancreatic precut",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/63/28666?source=related_link\">",
"      Post-ERCP pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22983?source=related_link\">",
"      Prophylactic pancreatic stents to prevent ERCP-induced pancreatitis: When do you use them?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13897?source=related_link\">",
"      Treatment of ampullary adenomas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_10_25768="Attenuation artifact in SPECT radionuclide myocardial perfusion imaging";
var content_f25_10_25768=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Attenuation artifact in SPECT radionuclide myocardial perfusion imaging",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/10/25768/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/10/25768/contributors\">",
"     Gary V Heller, MD, PhD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/10/25768/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/10/25768/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/10/25768/contributors\">",
"     Ami E Iskandrian, MD, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/10/25768/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/10/25768/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/10/25768/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of radionuclide myocardial perfusion imaging (rMPI) with single-photon emission computed tomography (SPECT) for the diagnosis and risk stratification of coronary heart disease (CHD) is well-established. However, the full clinical potential of rMPI has not been realized due to numerous factors producing artifacts. These artifacts degrade image quality and increase the risk of misinterpretation of the results [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Soft tissue attenuation is one of the more common causes of rMPI artifact. The heart is surrounded by tissues of varying densities (eg, bone, lungs, and breast). Radionuclide imaging of the thorax results in nonuniform myocardial photon activity due to these intervening structures. Unpredictable artifact may arise when the body habitus differs significantly from expected gender-specific patterns. Photon attenuation and the resultant artifacts are affected by several factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Body size",
"     </li>",
"     <li>",
"      Depth of the heart in the body",
"     </li>",
"     <li>",
"      Gender",
"     </li>",
"     <li>",
"      Patient position under the camera.",
"     </li>",
"     <li>",
"      Radiopharmaceutical tracer (eg, thallium versus technetium) and dose of the tracer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Soft tissue attenuation may result in an apparent fixed or reversible perfusion abnormality. Because it is caused by fixed anatomic structures, attenuation artifact is usually present both on stress and rest imaging. It is therefore interpreted as a fixed perfusion abnormality, resulting in incorrect diagnosis of myocardial",
"    <span class=\"nowrap\">",
"     scar/infarction.",
"    </span>",
"    However, if the position of the patient, and thus the tissue causing attenuation, is different during stress and rest imaging, soft tissue attenuation may produce a reversible perfusion defect mimicking ischemia.",
"   </p>",
"   <p>",
"    In either case, attenuation artifact causes an increase in false-positive studies, resulting in decreased specificity for the diagnosis of CHD and a decrease in the confidence of the referring and interpreting clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. False-positive scans may lead to unwarranted further testing, including cardiac catheterization, resulting in increased costs and the potential for patient morbidity. Paradoxically, a high frequency of attenuation artifact may cause the interpreting clinician to disregard true perfusion abnormalities, assuming artifact instead, thereby reducing sensitivity of the test. Consequently, patients with CHD may be missed or go undertreated.",
"   </p>",
"   <p>",
"    Sources of attenuation with SPECT rMPI and ways to interpret or eliminate attenuation artifacts will be discussed here. The clinical uses of SPECT rMPI are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SOURCES OF ATTENUATION ARTIFACT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are multiple sources of attenuation artifact, our discussion will focus on the following common sources in detail:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diaphragmatic attenuation",
"     </li>",
"     <li>",
"      Breast attenuation",
"     </li>",
"     <li>",
"      Liver attenuation",
"     </li>",
"     <li>",
"      Attenuation due to obesity",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diaphragmatic attenuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attenuation from the left hemidiaphragm can reduce photon counts in the inferior wall. This artifact results in a perfusion defect in the inferior segments which generally correspond to the right coronary artery (RCA) territory. Diaphragmatic attenuation is estimated to occur in up to 25 percent of myocardial perfusion studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diaphragmatic attenuation is more common in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Men compared to women",
"     </li>",
"     <li>",
"      Abdominal protuberance (eg, ascites, or peritoneal dialysis)",
"     </li>",
"     <li>",
"      Elevated left hemidiaphragm",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Use of thallium as the radiopharmaceutical tracer (compared with technetium)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Breast attenuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast attenuation decreases counts detected in the anterior, anteroseptal, or lateral walls depending upon the position of the breast. This results in perfusion artifacts anterior or anterolateral segments, corresponding to in the left anterior descending",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    left circumflex artery territories [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/6\">",
"     6",
"    </a>",
"    ]. Soft tissue attenuation from breasts may produce artifacts in up to 40 percent of myocardial perfusion studies in women [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Breast size, breast tissue density, and breast position relative to the heart may affect the extent and severity of soft tissue attenuation. Large, pendulous breasts that tend to lie closer to the lateral chest wall are more likely to attenuate the lateral myocardial wall, whereas small breasts that lie over the anterior chest wall may attenuate the anterior or anteroseptal walls of the myocardium. A combination of these characteristics may result in both anterolateral and anteroseptal attenuation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attenuation artifacts of the anterior and anterolateral myocardial walls may also occur in men with gynecomastia or significant obesity. Women with breast implants require special consideration as artifacts may intensify.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Liver attenuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue attenuation due to increased radionuclide tracer in the liver (ie, a \"hot\" liver) may distort counts detected in the inferior wall, resulting in artifactual perfusion abnormalities in the left circumflex or right coronary artery territory [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because exercise enhances the clearance of tracer from the liver, these artifacts may be less common with exercise stress than with vasodilator or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress. To provide tracer clearance from the liver, it is advisable to wait longer (at least 45 minutes) prior to imaging patients after pharmacologic stress testing compared to waiting 15 minutes following exercise. Combining exercise with vasodilator stress reduces liver activity in comparison to vasodilator stress alone and patients may be imaged earlier [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Attenuation due to obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue attenuation and scatter of photons due to obesity may reduce the diagnostic accuracy of rMPI. This was illustrated in a study of 607 patients with thallium-201 SPECT imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/13\">",
"     13",
"    </a>",
"    ]. Obesity (body mass index of &ge;30",
"    <span class=\"nowrap\">",
"     kg/m2)",
"    </span>",
"    was associated with a significantly lower accuracy for diagnosing coronary heart disease (86 versus 92 percent for nonobese patients).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     METHODS TO IMPROVE ARTIFACT RECOGNITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While it is difficult to entirely eliminate the attenuation of photon counts due to soft tissue, with single-photon emission computed tomography (SPECT), soft tissue attenuation can often be recognized and distinguished from true myocardial perfusion defects, thereby improving diagnostic accuracy. Several methods have been developed to improve artifact recognition, with varying degrees of success. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Review of planar images",
"     </li>",
"     <li>",
"      Quantitative analysis",
"     </li>",
"     <li>",
"      Breast markers",
"     </li>",
"     <li>",
"      Prolonged acquisition",
"     </li>",
"     <li>",
"      Higher energy radiopharmaceuticals (technetium-99m versus thallium-201)",
"     </li>",
"     <li>",
"      Prone imaging",
"     </li>",
"     <li>",
"      ECG-gated SPECT imaging",
"     </li>",
"     <li>",
"      Attenuation correction",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Planar images",
"    </span>",
"    &nbsp;&mdash;&nbsp;Review of a cine loop of planar rotating images may identify potential problems due to soft tissue attenuation, motion, abnormal lung activity, and other incidental findings (eg, neoplastic lesions). The planar images provide valuable information about the proximity of soft tissue to the myocardial structures to alert the readers of potential areas of soft tissue attenuation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Quantitative analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of quantitative perfusion SPECT scans may assist in differentiating attenuation artifacts from true perfusion defects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/8\">",
"     8",
"    </a>",
"    ]. Normal databases have quantified gender-dependent myocardial perfusion distributions in normal populations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/15\">",
"     15",
"    </a>",
"    ]. Based upon the degree of variation of the study from expected patterns, abnormality criteria have been developed that may serve as a second opinion in differentiating between coronary disease and attenuation artifact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Breast markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast markers (eg, intravenous tubing filled with radioactive materials, thallium-201, or technetium-99m) outlining the breast have been used in the past to delineate the relationship between breast tissue and myocardial structures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/6,8,16\">",
"     6,8,16",
"    </a>",
"    ]. Breast markers were primarily used with planar imaging. In the era of SPECT imaging, this procedure is rarely used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prolonged data acquisition",
"    </span>",
"    &nbsp;&mdash;&nbsp;When significant soft tissue attenuation is anticipated or encountered, a prolonged duration of data acquisition, which allows for greater isotope detection by the camera, may reduce the potential for attenuation artifacts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Use of technetium-based imaging agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technetium-99m has advantages over thallium as a radionuclide tracer for myocardial imaging. Technetium-99m has higher emission energy (140keV versus 78 keV) and a shorter half-life (six hours versus 72 hours) that permit administration of a higher dose. These qualities result in improved image quality and contrast, and less soft tissue attenuation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential utility of technetium-99m was initially illustrated in a study of 13 patients with a false-positive thallium studies as shown by normal coronary angiograms [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/18\">",
"     18",
"    </a>",
"    ]. Repeat imaging with technetium showed an inferior perfusion defect in only one patient.",
"   </p>",
"   <p>",
"    Despite this advantage, attenuation artifact continues to be a significant problem with the use of technetium-based agents. A recognized downside to technetium 99m-based imaging is the increased frequency of liver and gut activity in contrast to thallium-201.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prone imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of prone imaging can reduce diaphragmatic attenuation and improve inferior wall image quality. The rationale for prone imaging is that the heart shifts slightly superior and the diaphragm is more inferior in the prone position, increasing the distance between the diaphragm and the inferior wall of the left ventricle. Thus, in a study in which an inferior perfusion abnormality is observed on supine imaging but not on prone imaging, the abnormality should be considered to be due to attenuation, and the study can be considered normal.",
"   </p>",
"   <p>",
"    It is recommended that standard supine imaging be performed first, followed by prone imaging if there is concern regarding inferior wall attenuation. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Diaphragmatic attenuation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most experts recommend selective prone imaging in patients with inferior perfusion abnormalities on supine imaging, but some favor imaging all patients in both supine and prone positions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Combined imaging (prone, supine) requires additional camera and technologist time reducing laboratory efficiency. In addition, as mentioned previously, prone imaging may occasionally create fixed anterior or lateral defects, which may represent attenuation artifact. Just as supine position may produce a lateral hot spot, prone imaging may result in a septal hot spot, as the septum lies closer to the detector in the prone position.",
"   </p>",
"   <p>",
"    The prognostic value of prone imaging was assessed in a series of 3834 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/20\">",
"     20",
"    </a>",
"    ]. All patients underwent stress testing with rest thallium 201 and stress technetium 99m-sestamibi rMPI in the supine position; those patients with an inferior defect also had prone imaging. At a mean follow-up of 24 months, patients with inferior wall abnormalities on supine imaging that were absent on prone imaging had a low risk of subsequent cardiac events that was comparable to the risk in patients with normal supine-only studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     ECG-gated SPECT imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECG-gating refers to the process of acquiring images on successive beats at multiple points in the cardiac cycle. Based upon timing related to the QRS complex, a moving image of a sample ventricular contraction is reconstructed. Using this technique, both left ventricular (LV) and right ventricular function can be assessed.",
"   </p>",
"   <p>",
"    ECG-gated imaging, also called functional imaging, may help differentiate between myocardial infarction and attenuation artifact (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59383 \" href=\"UTD.htm?4/38/4704\">",
"     image 1",
"    </a>",
"    ). Normal regional function (ie, normal wall motion and myocardial thickening) in an area with a fixed defect on perfusion imaging can be classified as a soft tissue attenuation artifact, whereas abnormal function in conjunction with a similar fixed defect would be compatible with myocardial infarction or myocardial stunning. In contrast, this gating technique is not useful in determining whether a reversible perfusion abnormality is due to CHD since the gating procedure is acquired 45 to 60 minutes later at such a time that a wall motion abnormality due to ischemia has most often resolved and will not be observed. Similarly, this technique is not useful in \"stress-only\" or acute rest MPI studies.",
"   </p>",
"   <p>",
"    The potential value of ECG-gated imaging has been illustrated in multiple studies, including one study of 180 consecutive patients with fixed myocardial perfusion defects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/22\">",
"     22",
"    </a>",
"    ]. Among the 102 with ECG or historical evidence of a prior myocardial infarction, 96 percent had abnormal function on ECG-gated imaging, whereas only 23 percent of patients with a fixed defect but no prior infarction had abnormal defect function. In patients with normal function on gated images, 91 percent of the fixed defects could be accounted for by soft tissue attenuation.",
"   </p>",
"   <p>",
"    ECG-gated functional imaging also improves reader confidence. This was illustrated in a series of 285 consecutive patients, in which the number of borderline readings was significantly reduced by the addition of gated images [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/23\">",
"     23",
"    </a>",
"    ]. Among those with a low likelihood of coronary heart disease (CHD), the addition of gating significantly increased the \"normal\" interpretation from 74 to 93 percent. In patients with known CHD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    previous myocardial infarction, the addition of gated images increased the \"abnormal\" interpretations from 78 to 92 percent, although this difference was not statistically significant.",
"   </p>",
"   <p>",
"    ECG-gated LV functional data also add prognostic information. As an example, in a study of 3207 patients who underwent rMPI with ECG-gating, patients with an abnormal ECG-gated myocardial wall motion score had an annual event rate (nonfatal myocardial infarction and cardiac death) of 6.1 percent compared with 1.6 percent for patients with a normal score [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/24\">",
"     24",
"    </a>",
"    ]. An abnormal ECG-gating score was associated with an adverse prognosis regardless of the perfusion data. Conversely, those with normal perfusion and wall motion had an excellent prognosis (",
"    <a class=\"graphic graphic_figure graphicRef72140 \" href=\"UTD.htm?14/62/15342\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In contrast to its utility in distinguishing prior infarction from artifact, gated imaging cannot differentiate ischemia (suggested by a reversible perfusion defect) from artifact because the wall motion in the region with the defect is often normal in both circumstances. In addition, ECG-gated functional imaging cannot be used to differentiate attenuation artifact in circumstances in which only one image is available (eg, emergency department imaging for acute chest pain, stress-only imaging).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ATTENUATION CORRECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attenuation correction refers to automated methods that adjust the intensity of the myocardial perfusion image to reflect the estimated magnitude of soft tissue attenuation on different regions of the heart. Attenuation correction methods include either line-source or computed tomographic (CT) techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Artifacts due to soft tissue attenuation may be improved by various techniques of attenuation correction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/25\">",
"     25",
"    </a>",
"    ]. In order to apply such methods, it is necessary to create a patient-specific attenuation map [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/26\">",
"     26",
"    </a>",
"    ]. An attenuation map represents the degree of photon attenuation across different areas of the thorax.",
"   </p>",
"   <p>",
"    Transmission imaging is one means of creating an attenuation map. With this method, an external source of radiation (eg, technetium, gadolinium, or x-ray) is positioned on one side of the patient and a detector on the other side [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/25\">",
"     25",
"    </a>",
"    ]. The distance between the source and detector is known, and from the measured intensity data one can calculate the degree of attenuation across the thorax. By obtaining a number of these measures at different angles, a \"map\" of attenuation across the thorax is generated. The attenuation maps are then integrated with the raw myocardial perfusion images to reconstruct image data with attenuation correction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different camera systems have been designed with various geometric arrangements of transmission sources, including",
"    <span class=\"nowrap\">",
"     point/line/sheet",
"    </span>",
"    sources or a scanning line source [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/25,27-32\">",
"     25,27-32",
"    </a>",
"    ]. The most common configuration for transmission imaging uses a gadolinium-153 scanning line source with dual-head 90-degree detectors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/25\">",
"     25",
"    </a>",
"    ]. As the scanning line source system moves and generates transmission images opposite the external source, images are simultaneously acquired through an electronic window in the detector that moves in a direction opposite to the line source [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such an arrangement makes cross-contamination less likely. However, the scanning line source system is geometrically complex and less sensitive. It requires strict quality control and system maintenance to ensure precise movement of the line source and electronic window as well as source strength [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/29\">",
"     29",
"    </a>",
"    ]. Computed tomographic (CT) imaging is increasingly being used to create an attenuation map. Several camera systems now offer this option with emerging validation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/30-33\">",
"     30-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Clinical data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attenuation correction improves the relative uniformity of radionuclide tracer distribution in patients with a low likelihood of coronary heart disease (CHD), resulting in an improvement in diagnostic accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/34-38\">",
"     34-38",
"    </a>",
"    ]. In general, attenuation correction results in fewer false-positive tests, which is demonstrated by improved specificity and higher rates of normal studies in control populations.",
"   </p>",
"   <p>",
"    The diagnostic value of attenuation correction is demonstrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 60 patients with known CHD and 59 controls, the addition of attenuation correction increased the percent of studies in controls that were read as normal (88 to 98 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/34\">",
"       34",
"      </a>",
"      ]. In the overall population, attenuation correction resulted in a marked increase in specificity, from 46 to 82 percent.",
"     </li>",
"     <li>",
"      In a multicenter trial involving 96 patients with angiographically proven CHD and 88 subjects with low likelihood of CHD, attenuation correction resulted in a significant higher normalcy rates (86 versus 96 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/37\">",
"       37",
"      </a>",
"      ]. However, sensitivity was not improved with attenuation correction, and for patients with RCA or multivessel disease, it was slightly worse.",
"     </li>",
"     <li>",
"      Attenuation artifact is more prevalent in obese patients. The value of attenuation correction in this population was evaluated in 119 patients (60 with BMI &lt;30",
"      <span class=\"nowrap\">",
"       kg/m2,",
"      </span>",
"      and 56 with BMI &ge;30",
"      <span class=\"nowrap\">",
"       kg/m2)",
"      </span>",
"      who underwent SPECT rMPI with ECG-gating followed by coronary angiography within 60 days [",
"      <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/39\">",
"       39",
"      </a>",
"      ]. The specificity for clinically significant CHD (stenosis &ge;70 percent) was significantly improved with attenuation correction, regardless of BMI (79 versus 50 percent in nonobese patients, and 76 versus 41 percent in obese patients).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 2002, the American Society of Nuclear Medicine and the Society of Nuclear Medicine published a position statement outlining the quality control methods for attenuation correction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/40\">",
"     40",
"    </a>",
"    ]. A number of the above studies were performed prior to the implementation of this publication [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. With improved quality control and newer generations of hardware and software, the performance of attenuation correction algorithms may improve further.",
"   </p>",
"   <p>",
"    The combination of attenuation correction with other corrective adjustments, including ECG gating, results in additive improvements in diagnostic accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/39,41\">",
"     39,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Attenuation-corrected quantitative analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial perfusion studies are usually interpreted by visual inspection. However, photon count intensity can also be measured by automated quantitative analytic tools. These automated counts are compared against values derived from databases of normal patients. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Quantitative analysis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnostic accuracy of these databases may be compromised by attenuation artifact. In addition, gender-differences in attenuation artifact contribute to the differences in normal values used in quantitative analyses for men and women. As with visual inspection, the diagnostic accuracy of quantitative analysis is improved with attenuation correction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/37,38,42\">",
"     37,38,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A gender-independent normal database for attenuation corrected rMPI was generated and subsequently validated in separate series of obese patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/38\">",
"     38",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In contrast to uncorrected rMPI studies, there was no difference in perfusion distributions between normal men and women with attenuation corrected studies.",
"     </li>",
"     <li>",
"      In the validation cohort of 95 patients, 74 underwent coronary angiography, and 21 had a low likelihood (&lt;5 percent) of coronary heart disease based upon clinical criteria. Quantitative analysis was first performed without attenuation correction using normal values from a gender-specific database (derived from uncorrected rMPI studies), and then repeated with attenuation correction and the new gender-independent normal database (also derived from attenuation corrected studies). Using the corrected images and the gender-independent database, there was a significant increase in the number of studies interpreted as normal (90 versus 52 percent in the uncorrected analysis), and in specificity (57 versus 29 percent).",
"     </li>",
"     <li>",
"      Generally, attenuation correction solutions for both line source and CT require large field of view camera systems. However, the trend in office-based practices has been towards small field-of-view (SFOV) cameras. Line source attenuation correction with a SFOV camera was validated demonstrating excellent results using a truncation compensation algorithm [",
"      <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Stress-only imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;If stress-perfusion images are normal, there is little, if any, need for rest images. Stress-only technetium-99m rMPI, when used in conjunction with ECG-gating and attenuation correction, may be more time- and cost-efficient and may increase reader confidence in interpretation of the results [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/42,44\">",
"     42,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic value of stress-only imaging was illustrated in a series of 90 patients who underwent",
"    <span class=\"nowrap\">",
"     rest/stress",
"    </span>",
"    ECG-gated technetium-99m sestamibi SPECT rMPI with attenuation correction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/44\">",
"     44",
"    </a>",
"    ]. Only the stress images were made available for interpretation by 10 experienced readers. Images were read for diagnostic accuracy in the following sequence: rMPI alone, rMPI with ECG-gated SPECT images, and attenuation-corrected rMPI with gated images. Forty-one patients underwent catheterization within sixty days of imaging. Attenuation-corrected data significantly reduced the perceived need for rest imaging (43 versus 77 percent with rMPI alone) and allowed the readers to characterize significantly more studies as definitely normal or abnormal (84 versus 37 percent with rMPI alone).",
"   </p>",
"   <p>",
"    The prognostic value of stress-only imaging with attenuation correction was demonstrated in 652 patients (428 women) with low to intermediate probability of coronary heart disease (CHD) who were being evaluated for chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/42\">",
"     42",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      None of the patients had documented CHD even though the mean pretest probability of CHD was 37 &plusmn; 24 percent based upon the risk factors of age, gender, and the type of chest pain.",
"     </li>",
"     <li>",
"      Although uncorrected images revealed abnormalities severe enough for the reader to request rest imaging in 37 percent of the patients, all of the abnormalities corrected with attenuation correction, and the defects on the original images were attributed to diaphragmatic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      breast attenuation artifacts.",
"     </li>",
"     <li>",
"      At an average follow-up of 22 months, the cardiac event rate was only 0.6 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a more recent study of prognosis among 419 patients, the same studies were compared with and without attenuation correction software applied [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/45\">",
"     45",
"    </a>",
"    ]. Similar risk stratification was identified with summed stress scores (SSS) in the 4 to 8 (mild) and 9&gt; (moderate to severe) range as well as completely normal (0). However, in patients with SSS after attenuation correction of 1 to 3, outcomes were similar to those with mild perfusion abnormalities. These data suggest that after attenuation corrected studies, any resulting perfusion abnormality should be considered abnormal and consistent with CAD.",
"   </p>",
"   <p>",
"    An information statement by the American Society of Nuclear Cardiology (ASNC) strongly recommended the use of stress-only imaging in patients without known coronary artery disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    no history of prior myocardial infarction or bypass surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/46\">",
"     46",
"    </a>",
"    ]. One study suggested that 40 to 45 percent of patients undergoing SPECT imaging are reasonable candidates for stress-only imaging with a very low return rate for rest imaging (9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/47\">",
"     47",
"    </a>",
"    ]. Furthermore, a position statement by the American Society of Nuclear Cardiology in 2009 also emphasized the value of stress-only imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from stress-only imaging risk stratification have greatly enhanced previous study. In the aggregate, over 20,000 patients who had normal stress-only imaging studies were evaluated for future cardiac events and had a demonstrated annual event rate of less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/10/25768/abstract/49\">",
"     49",
"    </a>",
"    ]. These data suggest that the incidence of coronary disease in these patients is very low. However, the stress-only study should be completely normal, and this procedure is best performed with attenuation correction, resulting in fewer rest studies being performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18686597\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because the heart is surrounded by tissues of varying densities (eg, bone, lungs, and breast), soft tissue attenuation is one of the most common causes of artifact seen on radionuclide myocardial perfusion imaging (rMPI). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are multiple sources of attenuation artifact, with the most common clinically relevant sources being diaphragmatic attenuation, breast attenuation, liver attenuation, and attenuation due to obesity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Sources of attenuation artifact'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While it is difficult to entirely eliminate the attenuation of photon counts due to soft tissue, with single-photon emission computed tomography (SPECT), soft tissue attenuation can often be recognized and distinguished from true myocardial perfusion defects. Methods employed with SPECT to reduced attenuation include the review of planar images, the ability for quantitative analysis, prolonged acquisition times, prone imaging, and ECG-gating. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Methods to improve artifact recognition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of prone imaging, in which the heart shifts slightly superior and the diaphragm is more inferior, thereby increasing the distance between the diaphragm and the inferior wall, can reduce diaphragmatic attenuation and improve inferior wall image quality. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prone imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ECG-gating refers to the process of acquiring images on successive beats at multiple points in the cardiac cycle. ECG-gated imaging, also called functional imaging, may help differentiate between myocardial infarction and attenuation artifact. Normal wall motion and myocardial thickening in an area with a fixed defect on perfusion imaging is consistent with soft tissue attenuation artifact, whereas abnormal function in conjunction with a similar fixed defect would be compatible with myocardial infarction or myocardial stunning. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'ECG-gated SPECT imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Attenuation correction refers to automated methods that adjust the intensity of the myocardial perfusion image to reflect the estimated magnitude of soft tissue attenuation on different regions of the heart. Attenuation correction improves the relative uniformity of radionuclide tracer distribution in patients with a low likelihood of coronary heart disease (CHD), resulting in an improvement in diagnostic accuracy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'attenuation correction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/1\">",
"      Singh B, Bateman TM, Case JA, Heller G. Attenuation artifact, attenuation correction, and the future of myocardial perfusion SPECT. J Nucl Cardiol 2007; 14:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/2\">",
"      Picano E, Bedetti G, Varga A, Cseh E. The comparable diagnostic accuracies of dobutamine-stress and dipyridamole-stress echocardiographies: a meta-analysis. Coron Artery Dis 2000; 11:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/3\">",
"      Kim C, Kwok YS, Heagerty P, Redberg R. Pharmacologic stress testing for coronary disease diagnosis: A meta-analysis. Am Heart J 2001; 142:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/4\">",
"      Fleischmann KE, Hunink MG, Kuntz KM, Douglas PS. Exercise echocardiography or exercise SPECT imaging? A meta-analysis of diagnostic test performance. JAMA 1998; 280:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/5\">",
"      Johnstone D, Wackers F, Berger H, et al. Effect of patient positioning on left lateral thallium-201 myocardial images. J Nucl Med 1979; 20:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/6\">",
"      Wackers F. Diagnostic pitfalls of myocardial perfusion imaging in women. J Myocard Ischemia 1992; 4:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/7\">",
"      Manglos SH, Thomas FD, Gagne GM, Hellwig BJ. Phantom study of breast tissue attenuation in myocardial imaging. J Nucl Med 1993; 34:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/8\">",
"      DePuey EG, Garcia EV. Optimal specificity of thallium-201 SPECT through recognition of imaging artifacts. J Nucl Med 1989; 30:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/9\">",
"      Germano G, Chua T, Kiat H, et al. A quantitative phantom analysis of artifacts due to hepatic activity in technetium-99m myocardial perfusion SPECT studies. J Nucl Med 1994; 35:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/10\">",
"      Nuyts J, Dupont P, Van den Maegdenbergh V, et al. A study of the liver-heart artifact in emission tomography. J Nucl Med 1995; 36:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/11\">",
"      Holly TA, Satran A, Bromet DS, et al. The impact of adjunctive adenosine infusion during exercise myocardial perfusion imaging: Results of the Both Exercise and Adenosine Stress Test (BEAST) trial. J Nucl Cardiol 2003; 10:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/12\">",
"      Pennell DJ, Mavrogeni SI, Forbat SM, et al. Adenosine combined with dynamic exercise for myocardial perfusion imaging. J Am Coll Cardiol 1995; 25:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/13\">",
"      Hansen CL, Woodhouse S, Kramer M. Effect of patient obesity on the accuracy of thallium-201 myocardial perfusion imaging. Am J Cardiol 2000; 85:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/14\">",
"      Hendel RC, Gibbons RJ, Bateman TM. Use of rotating (cine) planar projection images in the interpretation of a tomographic myocardial perfusion study. J Nucl Cardiol 1999; 6:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/15\">",
"      Eisner RL, Tamas MJ, Cloninger K, et al. Normal SPECT thallium-201 bull's-eye display: gender differences. J Nucl Med 1988; 29:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/16\">",
"      Wackers FJ. Artifacts in planar and SPECT myocardial perfusion imaging. Am J Card Imaging 1992; 6:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/17\">",
"      Bateman TM, Kolobrodov VV, Vasin AP, O'Keefe JH Jr. Extended acquisition for minimizing attenuation artifact in SPECT cardiac perfusion imaging. J Nucl Med 1994; 35:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/18\">",
"      Wang SJ, Chen YT, Hwang CL, et al. 99mTc-sestamibi can improve the inferior attenuation of TL-201 myocardial spect imaging. Int J Card Imaging 1993; 9:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/19\">",
"      Kiat H, Van Train KF, Friedman JD, et al. Quantitative stress-redistribution thallium-201 SPECT using prone imaging: methodologic development and validation. J Nucl Med 1992; 33:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/20\">",
"      Hayes SW, De Lorenzo A, Hachamovitch R, et al. Prognostic implications of combined prone and supine acquisitions in patients with equivocal or abnormal supine myocardial perfusion SPECT. J Nucl Med 2003; 44:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/21\">",
"      Segall GM, Davis MJ. Prone versus supine thallium myocardial SPECT: a method to decrease artifactual inferior wall defects. J Nucl Med 1989; 30:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/22\">",
"      DePuey EG, Rozanski A. Using gated technetium-99m-sestamibi SPECT to characterize fixed myocardial defects as infarct or artifact. J Nucl Med 1995; 36:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/23\">",
"      Smanio PE, Watson DD, Segalla DL, et al. Value of gating of technetium-99m sestamibi single-photon emission computed tomographic imaging. J Am Coll Cardiol 1997; 30:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/24\">",
"      Travin MI, Heller GV, Johnson LL, et al. The prognostic value of ECG-gated SPECT imaging in patients undergoing stress Tc-99m sestamibi myocardial perfusion imaging. J Nucl Cardiol 2004; 11:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/25\">",
"      Miles J, Cullom SJ, Case JA. An introduction to attenuation correction. J Nucl Cardiol 1999; 6:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/26\">",
"      Zaidi H, Hasegawa B. Determination of the attenuation map in emission tomography. J Nucl Med 2003; 44:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/27\">",
"      King MA, Tsui BM, Pan TS. Attenuation compensation for cardiac single-photon emission computed tomographic imaging: Part 1. Impact of attenuation and methods of estimating attenuation maps. J Nucl Cardiol 1995; 2:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/28\">",
"      King MA, Tsui BM, Pan TS, et al. Attenuation compensation for cardiac single-photon emission computed tomographic imaging: Part 2. Attenuation compensation algorithms. J Nucl Cardiol 1996; 3:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/29\">",
"      Tan P, Bailey DL, Meikle SR, et al. A scanning line source for simultaneous emission and transmission measurements in SPECT. J Nucl Med 1993; 34:1752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/30\">",
"      Fleming JS. A technique for using CT images in attenuation correction and quantification in SPECT. Nucl Med Commun 1989; 10:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/31\">",
"      Takahashi Y, Murase K, Higashino H, et al. Attenuation correction of myocardial SPECT images with X-ray CT: effects of registration errors between X-ray CT and SPECT. Ann Nucl Med 2002; 16:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/32\">",
"      Tonge CM, Manoharan M, Lawson RS, et al. Attenuation correction of myocardial SPECT studies using low resolution computed tomography images. Nucl Med Commun 2005; 26:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/33\">",
"      Kashiwagi T, Yutani K, Fukuchi M, et al. Correction of nonuniform attenuation and image fusion in SPECT imaging by means of separate X-ray CT. Ann Nucl Med 2002; 16:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/34\">",
"      Ficaro EP, Fessler JA, Shreve PD, et al. Simultaneous transmission/emission myocardial perfusion tomography. Diagnostic accuracy of attenuation-corrected 99mTc-sestamibi single-photon emission computed tomography. Circulation 1996; 93:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/35\">",
"      Kluge R, Sattler B, Seese A, Knapp WH. Attenuation correction by simultaneous emission-transmission myocardial single-photon emission tomography using a technetium-99m-labelled radiotracer: impact on diagnostic accuracy. Eur J Nucl Med 1997; 24:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/36\">",
"      Gallowitsch HJ, Sykora J, Mikosch P, et al. Attenuation-corrected thallium-201 single-photon emission tomography using a gadolinium-153 moving line source: clinical value and the impact of attenuation correction on the extent and severity of perfusion abnormalities. Eur J Nucl Med 1998; 25:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/37\">",
"      Hendel RC, Berman DS, Cullom SJ, et al. Multicenter clinical trial to evaluate the efficacy of correction for photon attenuation and scatter in SPECT myocardial perfusion imaging. Circulation 1999; 99:2742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/38\">",
"      Grossman GB, Garcia EV, Bateman TM, et al. Quantitative Tc-99m sestamibi attenuation-corrected SPECT: development and multicenter trial validation of myocardial perfusion stress gender-independent normal database in an obese population. J Nucl Cardiol 2004; 11:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/39\">",
"      Thompson RC, Heller GV, Johnson LL, et al. Value of attenuation correction on ECG-gated SPECT myocardial perfusion imaging related to body mass index. J Nucl Cardiol 2005; 12:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/40\">",
"      Hendel RC, Corbett JR, Cullom SJ, et al. The value and practice of attenuation correction for myocardial perfusion SPECT imaging: a joint position statement from the American Society of Nuclear Cardiology and the Society of Nuclear Medicine. J Nucl Cardiol 2002; 9:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/41\">",
"      Links JM, DePuey EG, Taillefer R, Becker LC. Attenuation correction and gating synergistically improve the diagnostic accuracy of myocardial perfusion SPECT. J Nucl Cardiol 2002; 9:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/42\">",
"      Gibson PB, Demus D, Noto R, et al. Low event rate for stress-only perfusion imaging in patients evaluated for chest pain. J Am Coll Cardiol 2002; 39:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/43\">",
"      Noble GL, Ahlberg AW, Kokkirala AR, et al. Validation of attenuation correction using transmission truncation compensation with a small field of view dedicated cardiac SPECT camera system. J Nucl Cardiol 2009; 16:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/44\">",
"      Heller GV, Bateman TM, Johnson LL, et al. Clinical value of attenuation correction in stress-only Tc-99m sestamibi SPECT imaging. J Nucl Cardiol 2004; 11:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/45\">",
"      Baghdasarian SB, Noble GL, Ahlberg AW, et al. Risk stratification with attenuation corrected stress Tc-99m sestamibi SPECT myocardial perfusion imaging in the absence of ECG-gating due to arrhythmias. J Nucl Cardiol 2009; 16:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/46\">",
"      Cerqueira MD, Allman KC, Ficaro EP, et al. Recommendations for reducing radiation exposure in myocardial perfusion imaging. J Nucl Cardiol 2010; 17:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/47\">",
"      Mathur S, Heller GV, Bateman T, et al. Clinical outcomes in patients undergoing attenuation correction stress-only Tc99m gated SPECT myocardial perfusion imaging for evaluation of coronary artery disease. J Nucl Med 2010; 51:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/48\">",
"      Des Prez, et al. ASNC Clinical Update: Stress-only myocardial perfusion imaging. J Nucl Cardiol 2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/10/25768/abstract/49\">",
"      Bhavnani SP, Heller GV. Stress-only myocardial perfusion imaging &hellip; it is time for a change! J Nucl Cardiol 2011; 18:836.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1476 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-189.41.172.26-6ADEC3818C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_10_25768=[""].join("\n");
var outline_f25_10_25768=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18686597\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SOURCES OF ATTENUATION ARTIFACT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diaphragmatic attenuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Breast attenuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Liver attenuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Attenuation due to obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      METHODS TO IMPROVE ARTIFACT RECOGNITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Planar images",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Quantitative analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Breast markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prolonged data acquisition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Use of technetium-based imaging agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prone imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ECG-gated SPECT imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ATTENUATION CORRECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Clinical data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Attenuation-corrected quantitative analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Stress-only imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18686597\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1476\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1476|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/38/4704\" title=\"diagnostic image 1\">",
"      Gated SPECT imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1476|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/62/15342\" title=\"figure 1\">",
"      ECG gated MPI and outcomes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_10_25769="Histologic images of healed plaque rupture";
var content_f25_10_25769=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 580px\">",
"   <div class=\"ttl\">",
"    Histologic images of healed plaque rupture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 560px; height: 425px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Cross-sectional histologic image of healed plaque rupture. (Movat, magnification x40). Necrotic core (NC) is covered by thick fibrous cap.",
"    <br>",
"     (B) Magnified image (x200) of the inset in panel A. Type III collagen is overlying the rupture site (yellow arrow).",
"     <br>",
"      (C) Sirius red staining corresponding to panel B under the polarized light, the NC is identified as a black area contained within the type III collagen layer (green under polarized light) of the fibrous cap.",
"      <br>",
"       (D) Healed plaque rupture with severe luminal narrowing (Movat, magnification x40).",
"       <br>",
"        (E, F) Sirius red stained sections corresponding to panel D under the normal (E) and polarized light (F), respectively.",
"        <br>",
"         (G, H, I) Magnified image (x200) of the insets in panel D. There are multiple layered NCs, which ruptured at various times prior to the eventual multi-layered appearance, which indicate that repeated episodes of plaque rupture had occurred.",
"         <div class=\"footnotes\">",
"          NC: necrotic core.",
"         </div>",
"         <div class=\"reference\">",
"          Courtesy of Drs. Renu Virmani, Frank Kolodgie, and Fumiyuki Otsuka.",
"         </div>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_10_25769=[""].join("\n");
var outline_f25_10_25769=null;
var title_f25_10_25770="Carbamazepine: Drug information";
var content_f25_10_25770=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carbamazepine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/8/13446?source=see_link\">",
"    see \"Carbamazepine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"    see \"Carbamazepine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F145588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carbatrol&reg;;",
"     </li>",
"     <li>",
"      Epitol&reg;;",
"     </li>",
"     <li>",
"      Equetro&reg;;",
"     </li>",
"     <li>",
"      TEGretol&reg;;",
"     </li>",
"     <li>",
"      TEGretol&reg;-XR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F145589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Carbamazepine&reg;;",
"     </li>",
"     <li>",
"      Dom-Carbamazepine;",
"     </li>",
"     <li>",
"      Mapezine&reg;;",
"     </li>",
"     <li>",
"      Mylan-Carbamazepine CR;",
"     </li>",
"     <li>",
"      Nu-Carbamazepine;",
"     </li>",
"     <li>",
"      PMS-Carbamazepine;",
"     </li>",
"     <li>",
"      Sandoz-Carbamazepine;",
"     </li>",
"     <li>",
"      Taro-Carbamazepine Chewable;",
"     </li>",
"     <li>",
"      Tegretol&reg;;",
"     </li>",
"     <li>",
"      Teva-Carbamazepine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F145636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F145593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage must be adjusted according to patient's response and serum concentrations. Administer tablets (chewable or conventional) in 2-3 divided doses daily and suspension in 4 divided doses daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Epilepsy:",
"     </b>",
"     Oral: Initial: 400 mg/day in 2 divided doses (tablets or extended release tablets) or 4 divided doses (oral suspension); increase by up to 200 mg/day at weekly intervals using a twice daily regimen of extended release tablets or capsules, or a 3-4 times/day regimen of other formulations until optimal response and therapeutic levels are achieved; usual dose: 800-1200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum recommended dose: 1600 mg/day; however, some patients have required up to 1.6-2.4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Trigeminal or glossopharyngeal neuralgia:",
"     </b>",
"     Oral: Initial: 200 mg/day in 2 divided doses (tablets, extended release tablets, or extended release capsules) or 4 divided doses (oral suspension) with food, gradually increasing in increments of 200 mg/day as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance: Usual: 400-800 mg daily in 2 divided doses (tablets, extended release tablets, or extended release capsules) or 4 divided doses (oral suspension); maximum dose: 1200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Bipolar disorder:",
"     </b>",
"     Oral: Initial: 400 mg/day in 2 divided doses (tablets, extended release tablets, or extended release capsules) or 4 divided doses (oral suspension), may adjust by 200 mg/day increments; maximum dose: 1600 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Equetro&reg; is the only formulation specifically approved by the FDA for the management of bipolar disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neuropathic pain, critically-ill patients (unlabeled use):",
"     </b>",
"     Oral: Initial: 50-100 mg twice daily in combination with I.V. opioids; Maintenance: 100-200 mg every 4-6 hours; maximum dose: 1200 mg daily (Barr, 2013)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F145612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"      see \"Carbamazepine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage must be adjusted according to patient's response and serum concentrations. Administer tablets (chewable or conventional) in 2-3 divided doses daily and suspension in 4 divided doses daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Epilepsy:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;6 years: Initial: 10-20 mg/kg/day divided twice or 3 times daily as tablets or 4 times/day as suspension; increase dose every week until optimal response and therapeutic levels are achieved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance dose: Divide into 3-4 doses daily (tablets or suspension); maximum recommended dose: 35 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-12 years: Initial: 200 mg/day in 2 divided doses (tablets or extended release tablets) or 4 divided doses (oral suspension); increase by up to 100 mg/day at weekly intervals using a twice daily regimen of extended release tablets or 3-4 times daily regimen of other formulations until optimal response and therapeutic levels are achieved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance: Usual: 400-800 mg/day; maximum recommended dose: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Children &lt;12 years who receive &ge;400 mg/day of carbamazepine may be converted to extended release capsules (Carbatrol&reg;) using the same total daily dosage divided twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maximum recommended doses:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 12-15 years: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &gt;15 years: 1200 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F145594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F11510104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Dosage adjustments are not required or recommended in the manufacturer&rsquo;s labeling; however, the following guidelines have been used by some clinicians (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     GFR &lt;10 mL/minute: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hemodialysis, peritoneal dialysis: Administer 75% of dose (postdialysis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Adults: No dosage adjustment recommended",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F11510105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in hepatic impairment; metabolized primarily in the liver.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F145559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral: 100 mg, 200 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carbatrol&reg;: 100 mg, 200 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Equetro&reg;: 100 mg, 200 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 100 mg/5 mL (5 mL, 10 mL, 450 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TEGretol&reg;: 100 mg/5 mL (450 mL) [contains propylene glycol; citrus-vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epitol&reg;: 200 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TEGretol&reg;: 200 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TEGretol&reg;: 100 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 200 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     TEGretol&reg;-XR: 100 mg, 200 mg, 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F145544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10968527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Carbatrol&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241639.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241639.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Equetro&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM328348.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM328348.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     TEGretol&reg;, TEGretol&reg;-XR:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM246796.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM246796.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F145564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension: Must be given on a 3-4 times/day schedule versus tablets which can be given 2-4 times/day. Since a given dose of suspension will produce higher peak and lower trough levels than the same dose given as the tablet form, patients given the suspension should be started on lower doses given more frequently (same total daily dose) and increased slowly to avoid unwanted side effects. When carbamazepine suspension has been combined with chlorpromazine or thioridazine solutions, a precipitate forms which may result in loss of effect. Therefore, it is recommended that the carbamazepine suspension dosage form not be administered at the same time with other liquid medicinal agents or diluents. Should be administered with meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release capsule (Carbatrol&reg;, Equetro&reg;): Consists of three different types of beads: Immediate release, extended-release, and enteric release. The bead types are combined in a ratio to allow twice daily dosing. May be opened and contents sprinkled over food such as a teaspoon of applesauce; may be administered with or without food; do not crush or chew.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release tablet: Should be inspected for damage. Damaged extended release tablets (without release portal) should not be administered. Should be administered with meals; swallow whole, do not crush or chew.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F145563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Carbatrol&reg;, Tegretol&reg;, Tegretol&reg;-XR: Partial seizures with complex symptomatology (psychomotor, temporal lobe), generalized tonic-clonic seizures (grand mal), mixed seizure patterns, trigeminal neuralgia, glossopharyngeal neuralgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Equetro&reg;: Acute manic or mixed episodes associated with bipolar 1 disorder",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F145633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of restless leg syndrome and post-traumatic stress disorders",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F145644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       CarBAMazepine may be confused with OXcarbazepine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Epitol&reg; may be confused with Epinal&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       TEGretol&reg;, TEGretol&reg;-XR may be confused with Mebaral&reg;, Toprol-XL&reg;, Toradol&reg;, TRENtal&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F145634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined, unless otherwise specified.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Hypertension (3%), arrhythmias, AV block, chills, coronary artery disease exacerbation, edema, heart failure, hypotension, syncope, thromboembolism, thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness (44%), somnolence (32%), headache (22%), ataxia (15%), speech disorder (6%), abnormal thinking (2%), vertigo (2%), agitation, amnesia, confusion, coordination impaired, depression, drowsiness, fatigue, fever, hallucinations, neuroleptic malignant syndrome (NMS), slurred speech, talkativeness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus (8%), rash (7%), alopecia, alterations in skin pigmentation, erythema (multiforme and nodosum), exfoliative dermatitis, disseminated lupus erythematosus exacerbation, nail shedding, onychomadesis, photosensitivity reaction, purpura, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypocalcemia, hyponatremia, syndrome of inappropriate ADH secretion (SIADH), thyroid function tests abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea (29%), vomiting (18%), constipation (10%), xerostomia (8%), abdominal pain, anorexia, diarrhea, dry throat, gastric distress, glossitis, pancreatitis, stomatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence, urinary frequency, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, anemia, aplastic anemia, bone marrow suppression, eosinophilia, leukocytosis, leukopenia, pancytopenia, porphyria, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Abnormal liver function tests, hepatic failure, hepatitis, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (8%), tremor (3%), paresthesia (2%), twitching (2%), arthralgia, leg cramps, myalgia, osteoporosis, peripheral neuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision (6%), conjunctivitis, diplopia, intraocular pressure increased, lens opacities, nystagmus, oculomotor disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hyperacusis, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Albuminuria, azotemia, blood urea nitrogen increased, glycosuria, oliguria, renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, drug rash with eosinophilia and systemic symptoms (DRESS), hypersensitivity, lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports (Limited to important or life-threatening): Aseptic meningitis, fertility impaired (male), hirsutism, lupus erythematosus-like syndrome, paralysis, spermatogenesis abnormal, suicidal ideation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F145567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to carbamazepine, tricyclic antidepressants, or any component of the formulation; bone marrow depression; with or within 14 days of MAO inhibitor use; concurrent use of nefazodone; concomitant use of delavirdine or other non-nucleoside reverse transcriptase inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F145548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias:",
"     <b>",
"      [U.S. Boxed Warning]: The risk of developing anemia or agranulocytosis is increased during treatment. Monitor CBC, platelets, and differential prior to and during therapy; discontinue if significant bone marrow suppression occurs.",
"     </b>",
"     A spectrum of hematologic effects has been reported with use (eg, agranulocytosis, aplastic anemia, neutropenia, leukopenia, thrombocytopenia, pancytopenia, and anemias); patients with a previous history of adverse hematologic reaction to any drug may be at increased risk. Early detection of hematologic change is important; advise patients of early signs and symptoms including fever, sore throat, mouth ulcers, infections, easy bruising, and petechial or purpuric hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dermatologic toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Severe and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TENS) and Stevens-Johnson syndrome (SJS), may occur during therapy. The risk is increased in patients with the variant",
"     </b>",
"     <b>",
"      <i>",
"       HLA-B*1502",
"      </i>",
"     </b>",
"     <b>",
"      allele, found almost exclusively in patients of Asian ancestry. Patients of Asian descent should be screened prior to initiating therapy. Avoid use in patients testing positive for the allele; discontinue therapy in patients who have a serious dermatologic reaction.",
"     </b>",
"     The risk of SJS or TENS may also be increased if carbamazepine is used in combination with other antiepileptic drugs associated with these reactions. Presence of the",
"     <i>",
"      HLA-B*1502",
"     </i>",
"     allele has not been found to predict the risk of less serious dermatologic reactions such as anticonvulsant hypersensitivity syndrome or nonserious rash.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: The risk of developing a hypersensitivity reaction may be increased in patients with the variant",
"     <i>",
"      HLA-A*3101",
"     </i>",
"     allele. The",
"     <i>",
"      HLA-A*3101",
"     </i>",
"     allele may occur more frequently patients of African-American, Asian, European, Indian, Latin American, and Native American ancestry. Hypersensitivity has also been reported in patients experiencing reactions to other anticonvulsants; the history of hypersensitivity reactions in the patient or their immediate family members should be reviewed. Approximately 25% to 30% of patients allergic to carbamazepine will also have reactions with oxcarbazepine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyponatremia: Hyponatremia caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH) may occur during therapy. Risk may be increased in the elderly or in patients also taking diuretics and may be dose-dependent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multiorgan hypersensitivity reactions: Potentially serious, sometimes fatal multiorgan hypersensitivity reactions (also known as drug reaction with eosinophilia and systemic symptoms [DRESS]) have been reported with some antiepileptic drugs; including carbamazepine; monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, and/or hematologic organ systems; gradual discontinuation and conversion to alternate therapy may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric effects: May activate latent psychosis and/or cause confusion or agitation; elderly patients may be at an increased risk for psychiatric effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic sensitivity: Has mild anticholinergic activity; use with caution in patients with sensitivity to anticholinergic effects (urinary retention, increased intraocular pressure, constipation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: May cause conduction abnormalities; use caution in patients with underlying ECG abnormalities, pre-existing cardiac damage, or patients who are at risk for conduction abnormalities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impartment: Use with caution in patients with hepatic impairment or history of hepatic porphyria; rare cases of hepatic failure have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use with caution in patients taking strong CYP3A4 induces or inhibitors. Carbamazepine may significantly induce many CYP450 enzymes, including 1A2, 2B6, 2C9, 2C19, and 3A4; use with caution with medications significantly metabolized through these pathways.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nefazodone: Coadministration yields insufficient plasma levels of nefazodone to achieve a therapeutic effect; concurrent use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Non-nucleoside reverse transcriptase inhibitors: Coadministration yields insufficient plasma levels of delavirdine and other non-nucleoside reverse transcriptase inhibitors to achieve a therapeutic effect; concurrent use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asian ancestry:",
"     <b>",
"      [U.S. Boxed Warning]: Patients of Asian descent should be screened for the variant",
"      <b>",
"       <i>",
"        HLA-B*1502",
"       </i>",
"      </b>",
"      allele prior to initiating therapy. This genetic variant has been associated with a significantly increased risk of developing Stevens-Johnson syndrome and/or toxic epidermal necrolysis. Patients with a positive result should not be started on carbamazepine.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in elderly patients; may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria). May also activate latent psychosis, confusion, or agitation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Exacerbation of certain seizure types have been seen after initiation of therapy in children with mixed seizure disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sorbitol: The suspension may contain sorbitol; avoid use in patents with hereditary fructose intolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suspension: Administration of the suspension will yield higher peak and lower trough serum levels than an equal dose of the tablet form; consider a lower starting dose given more frequently (same total daily dose) when using the suspension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not effective in absence, myoclonic, or akinetic seizures; carbamazepine administration may increase the frequency of seizures in patients with these types of seizures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bipolar disorder use: The smallest effective dose is suggested for use in bipolar disorder to reduce the risk for overdose/suicide; high-risk patients should be monitored for suicidal ideations. Prescription should be written for the smallest quantity consistent with good patient care. Actuation of latent psychosis is possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F145630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C8 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Induces",
"     </b>",
"     CYP1A2 (strong), CYP2B6 (strong), CYP2C19 (strong), CYP2C8 (strong), CYP2C9 (strong), CYP3A4 (strong), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F145553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: CarBAMazepine may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: CarBAMazepine may enhance the adverse/toxic effect of Adenosine. Specifically, the risk of higher degree heart block may be increased.  Management: Consider using a lower initial dose of adenosine in patients who are receiving carbamazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bendamustine: CYP1A2 Inducers (Strong) may decrease the serum concentration of Bendamustine. Concentrations of active metabolites may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): CarBAMazepine may increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: CarBAMazepine may decrease the serum concentration of Boceprevir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): CarBAMazepine may increase the metabolism of Calcium Channel Blockers (Dihydropyridine).  Management: Consider calcium channel blocker (CCB) dose adjustments or alternative therapy  in patients receiving concomitant carbamazepine. Nimodipine Canadian labeling contraindicates concurrent use with carbamazepine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): CarBAMazepine may decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of CarBAMazepine.  Management: Consider empiric reductions in carbamazepine dose with initiation of nondihydropyridine calcium channel blockers. Monitor for increased toxic effects of carbamazepine and reduced therapeutic effects of the calcium channel blocker.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May increase the serum concentration of CarBAMazepine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Caspofungin: Inducers of Drug Clearance may decrease the serum concentration of Caspofungin.  Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of CarBAMazepine. The serum carbamazepine concentration might return to normal within one week of starting cimetidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ClomiPRAMINE: CarBAMazepine may increase the serum concentration of ClomiPRAMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: CarBAMazepine may enhance the myelosuppressive effect of CloZAPine. CarBAMazepine may decrease the serum concentration of CloZAPine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: CarBAMazepine may decrease the serum concentration of Cobicistat.  Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): CarBAMazepine may diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): CarBAMazepine may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): CarBAMazepine may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inducers (Strong) may increase the metabolism of CYP1A2 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inducers (Strong) may increase the metabolism of CYP2B6 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inducers (Strong) may increase the metabolism of CYP2C19 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inducers (Strong) may increase the metabolism of CYP2C8 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inducers (Strong) may increase the metabolism of CYP2C9 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Danazol: May decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: CarBAMazepine may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diclofenac (Systemic): CYP2C9 Inducers (Strong) may decrease the serum concentration of Diclofenac (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: CarBAMazepine may increase the metabolism of Divalproex. Divalproex may decrease the serum concentration of CarBAMazepine. Carbamazepine-Epoxide concentrations might increase, offsetting the decreases in the parent compound.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxycycline: CarBAMazepine may decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: CarBAMazepine may decrease the serum concentration of Elvitegravir.  Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP2C8 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: CarBAMazepine may decrease the serum concentration of Felbamate. Felbamate may decrease the serum concentration of CarBAMazepine.  Management: In patients receiving carbamazepine, initiate felbamate at 1200 mg/day in divided doses 3-4 times daily while reducing carbamazepine dose by 20%.  Monitor for reduced concentrations/effects of both drugs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flunarizine: CarBAMazepine may decrease the serum concentration of Flunarizine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: CarBAMazepine may decrease the serum concentration of Fosphenytoin. CarBAMazepine may increase the serum concentration of Fosphenytoin. Possibly by competitive inhibition at sites of metabolism. Fosphenytoin may decrease the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: CarBAMazepine may increase the metabolism of Haloperidol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: CarBAMazepine may decrease the serum concentration of Irinotecan. Concentrations of the active metabolite SN-38 may also be reduced.  Management: Change to a non-enzyme inducing anticonvulsant, when clinically possible, at least 2 weeks prior to beginning irinotecan.  Dosage increases for irinotecan may be needed when used with carbamazepine, but specific dosing guidelines are not available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lacosamide: CarBAMazepine may decrease the serum concentration of Lacosamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May enhance the adverse/toxic effect of CarBAMazepine. CarBAMazepine may increase the metabolism of LamoTRIgine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: CarBAMazepine may enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: CarBAMazepine may decrease the serum concentration of Lopinavir.  Management: Increased doses of lopinavir may be necessary when using these agents in combination.  Do not use a once daily lopinavir/ritonavir regimen together with carbamazepine. Increase monitoring of therapeutic response in all patients using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of CarBAMazepine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: CarBAMazepine may enhance the adverse/toxic effect of MAO Inhibitors.  Management: Avoid concurrent use of carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mebendazole: CarBAMazepine may decrease the serum concentration of Mebendazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: CarBAMazepine may increase the metabolism of Methadone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylfolate: May decrease the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CarBAMazepine may decrease the serum concentration of MethylPREDNISolone.  Management: Consider an alternative corticosteroid. If this combination cannot be avoided, monitor for diminished methylprednisolone effects during carbamazepine treatment, and increased methylprednisolone effects following carbamazepine discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: CarBAMazepine may decrease the serum concentration of Nefazodone. Concentrations of active Nefazodone metabolites may also be reduced. Nefazodone may increase the serum concentration of CarBAMazepine. Also, concentrations of the active CarBAMazepine epoxide metabolite may be reduced.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: CarBAMazepine may decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced.  Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paliperidone: CarBAMazepine may decrease the serum concentration of Paliperidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CarBAMazepine may decrease the serum concentration of Perampanel.  Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used with carbamazepine.  Patients receiving this combination should be followed closely for response, especially with any changes to carbamazepine therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: CarBAMazepine may decrease the serum concentration of Phenytoin. CarBAMazepine may increase the serum concentration of Phenytoin. Possibly by competitive inhibition at sites of metabolism. Phenytoin may decrease the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inducers (Strong) may decrease the serum concentration of Pirfenidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP1A2 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: CarBAMazepine may increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: CarBAMazepine may decrease the serum concentration of QuiNINE. QuiNINE may increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reverse Transcriptase Inhibitors (Non-Nucleoside): CarBAMazepine may decrease the serum concentration of Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of CarBAMazepine. This mechanism applies specifically to efavirenz.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: CarBAMazepine may decrease the serum concentration of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: CarBAMazepine may decrease the serum concentration of Rufinamide. Rufinamide may decrease the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CarBAMazepine may increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: CarBAMazepine may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: CarBAMazepine may decrease the serum concentration of Temsirolimus. Concentrations of the active metabolite, sirolimus, are also likely to be decreased (and maybe to an even greater degree).  Management: Temsirolimus prescribing information recommends against coadministration with strong CYP3A4 inducers such as carbamazepine; however, if concurrent therapy is necessary, an increase in temsirolimus adult dose to 50 mg/week should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May decrease the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: CarBAMazepine may decrease the serum concentration of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: CarBAMazepine may decrease the serum concentration of Topiramate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: May enhance the CNS depressant effect of CarBAMazepine. TraMADol may diminish the therapeutic effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of TraMADol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: CYP2C8 Inducers (Strong) may decrease the serum concentration of Treprostinil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: CarBAMazepine may increase the metabolism of Tricyclic Antidepressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     ClomiPRAMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: CarBAMazepine may increase the metabolism of Valproic Acid. Valproic Acid may decrease the serum concentration of CarBAMazepine. Carbamazepine-Epoxide concentrations might increase, offsetting the decreases in the parent compound.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vecuronium: CarBAMazepine may decrease the serum concentration of Vecuronium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): CarBAMazepine may decrease the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: CarBAMazepine may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ziprasidone: CarBAMazepine may decrease the serum concentration of Ziprasidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: May enhance the CNS depressant effect of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Zolpidem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F145583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Avoid concurrent use of ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Carbamazepine serum levels may be increased if taken with food and/or grapefruit juice. Management Avoid concurrent ingestion of grapefruit juice. Maintain adequate hydration, unless instructed to restrict fluid intake.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Evening primrose may decrease seizure threshold. Valerian, St John's wort, kava kava, and gotu kola may increase CNS depression. Management: Avoid evening primrose. Avoid valerian, St John's wort, kava kava, and gotu kola.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F145555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F145571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Studies in pregnant women have demonstrated a risk to the fetus. Carbamazepine and its metabolites can be found in the fetus and may be associated with teratogenic effects, including spina bifida, craniofacial defects, cardiovascular malformations, and hypospadias. The risk of teratogenic effects is higher with anticonvulsant polytherapy than monotherapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Developmental delays have also been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to carbamazepine (per manufacturer); however, socioeconomic factors, maternal and paternal IQ, and polytherapy may contribute to these findings. Pregnancy may cause small decreases of carbamazepine plasma concentrations in the second and third trimesters; monitoring should be considered. When used for the treatment of bipolar disorder, use of carbamazepine should be avoided during the first trimester of pregnancy if possible. The use of a single medication for the treatment of bipolar disorder or epilepsy in pregnancy is preferred. Carbamazepine may decrease plasma concentrations of hormonal contraceptives; breakthrough bleeding or unintended pregnancy may occur and alternate or back-up methods of contraception should be considered.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to carbamazepine during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F145598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F145572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Carbamazepine and its active epoxide metabolite are found in breast milk. Carbamazepine can also be detected in the serum of nursing infants. Transient hepatic dysfunction has been observed in some case reports. Nursing should be discontinued if adverse events are observed. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Respiratory depression, seizures, nausea, vomiting, diarrhea, and/or decreased feeding have been observed in neonates exposed to carbamazepine",
"     <i>",
"      in utero",
"     </i>",
"     and may represent a neonatal withdrawal syndrome.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F145573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drug may cause GI upset, take with large amount of water or food to decrease GI upset. May need to split doses to avoid GI upset.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F145570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 12-hour",
"     </b>",
"     (CarBAMazepine ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (120): $214.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (120): $214.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (120): $214.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 12-hour",
"     </b>",
"     (Carbatrol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (120): $255.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (120): $255.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (120): $255.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 12-hour",
"     </b>",
"     (Equetro Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (120): $244.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (120): $288.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (120): $331.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (CarBAMazepine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $23.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (CarBAMazepine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (450 mL): $74.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (TEGretol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (450 mL): $101.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (CarBAMazepine ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $93.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $187.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (TEGretol XR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $80.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $159.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $319.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (CarBAMazepine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $40.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Epitol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $30.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (TEGretol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $157.19",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F145557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with platelet count and differential, reticulocytes, serum iron, lipid panel, liver function tests, urinalysis, BUN, serum carbamazepine levels, thyroid function tests, serum sodium; pregnancy test;  ophthalmic exams (intraocular pressure, pupillary reflexes); observe patient for excessive sedation, especially when instituting or increasing therapy; signs of rash;",
"     <i>",
"      HLA-B*1502",
"     </i>",
"     genotype screening prior to therapy initiation in patients of Asian descent; suicidality (eg, suicidal thoughts, depression, behavioral changes)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F145560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Timing of serum samples: Absorption is slow, peak levels occur 8-65 hours after ingestion of the first dose; the half-life ranges from 8-60 hours, therefore, steady-state is achieved in 2-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Epilepsy: Therapeutic levels: 4-12 mcg/mL (SI: 17-51 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic concentration: &gt;15 mcg/mL; patients who require higher levels of 8-12 mcg/mL (SI: 34-51 micromole/L) should be watched closely. Side effects including CNS effects occur commonly at higher dosage levels. If other anticonvulsants are given therapeutic range is 4-8 mcg/mL.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F145574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actinerval (AR, PY);",
"     </li>",
"     <li>",
"      Apo-Carbamazepine (MY);",
"     </li>",
"     <li>",
"      Azepal (HU);",
"     </li>",
"     <li>",
"      Bamgetol (ID);",
"     </li>",
"     <li>",
"      Brucarcer (MX);",
"     </li>",
"     <li>",
"      Camapine (TW);",
"     </li>",
"     <li>",
"      Carazepin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Carbadac (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Carbagen (GB);",
"     </li>",
"     <li>",
"      Carbalex (EE);",
"     </li>",
"     <li>",
"      Carbam (EC);",
"     </li>",
"     <li>",
"      Carbamazepin-B (HU);",
"     </li>",
"     <li>",
"      Carbapin (PE);",
"     </li>",
"     <li>",
"      Carbatol (IN, TW);",
"     </li>",
"     <li>",
"      Carbatol CR (SG);",
"     </li>",
"     <li>",
"      Carbazene (TH);",
"     </li>",
"     <li>",
"      Carbazep (MX);",
"     </li>",
"     <li>",
"      Carbazina (MX);",
"     </li>",
"     <li>",
"      Carmapine (TH);",
"     </li>",
"     <li>",
"      Carmaz (IN);",
"     </li>",
"     <li>",
"      Carmian (CN);",
"     </li>",
"     <li>",
"      Carmine (KP);",
"     </li>",
"     <li>",
"      Carpin (MX);",
"     </li>",
"     <li>",
"      Carzepin (MY);",
"     </li>",
"     <li>",
"      Clostedal (MX);",
"     </li>",
"     <li>",
"      Degranol (ZA);",
"     </li>",
"     <li>",
"      Elpenor (DE);",
"     </li>",
"     <li>",
"      Epazin (PH);",
"     </li>",
"     <li>",
"      Epileptol (KP);",
"     </li>",
"     <li>",
"      Eposal Retard (CO);",
"     </li>",
"     <li>",
"      Espa-lepsin (DE);",
"     </li>",
"     <li>",
"      Finlepsin (BG, HU);",
"     </li>",
"     <li>",
"      Gericarb SR (IE);",
"     </li>",
"     <li>",
"      Hermolepsin (SE);",
"     </li>",
"     <li>",
"      Karbamazepin (DK, NO);",
"     </li>",
"     <li>",
"      Lepsitol (ID);",
"     </li>",
"     <li>",
"      Mezacar (PH);",
"     </li>",
"     <li>",
"      Mezacar SR (PH);",
"     </li>",
"     <li>",
"      Neugeron (MX);",
"     </li>",
"     <li>",
"      Neurolep (MX);",
"     </li>",
"     <li>",
"      Neurotol (FI);",
"     </li>",
"     <li>",
"      Neurotop (AT, BG, HU);",
"     </li>",
"     <li>",
"      Sepibest (MX);",
"     </li>",
"     <li>",
"      Sirtal (DE);",
"     </li>",
"     <li>",
"      Stazepine (HU);",
"     </li>",
"     <li>",
"      Taver (MY);",
"     </li>",
"     <li>",
"      Tegol (TW);",
"     </li>",
"     <li>",
"      Tegral (PK);",
"     </li>",
"     <li>",
"      Tegrepin (PH);",
"     </li>",
"     <li>",
"      Tegretal (CN, DE);",
"     </li>",
"     <li>",
"      Tegretol (AE, AR, AU, BB, BD, BE, BF, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CO, CR, CY, CZ, DK, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IT, JM, JO, JP, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PT, PY, QA, RU, SA, SC, SD, SE, SG, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, UY, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Tegretol CR (CZ, EE, IL, KP, NZ, PE, SG);",
"     </li>",
"     <li>",
"      Tegretol Retard (FI);",
"     </li>",
"     <li>",
"      Temporol (HU, ZA);",
"     </li>",
"     <li>",
"      Teril (AU, HK, IL, NZ);",
"     </li>",
"     <li>",
"      Teril-CR (IL);",
"     </li>",
"     <li>",
"      Timonil (DE, HU);",
"     </li>",
"     <li>",
"      Timonil Retard (CH, DE, IL);",
"     </li>",
"     <li>",
"      Trepina (MX);",
"     </li>",
"     <li>",
"      Vulsivan (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F145547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In addition to anticonvulsant effects, carbamazepine has anticholinergic, antineuralgic, antidiuretic, muscle relaxant, antimanic, antidepressive, and antiarrhythmic properties; may depress activity in the nucleus ventralis of the thalamus or decrease synaptic transmission or decrease summation of temporal stimulation leading to neural discharge by limiting influx of sodium ions across cell membrane or other unknown mechanisms; stimulates the release of ADH and potentiates its action in promoting reabsorption of water; chemically related to tricyclic antidepressants",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F145566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Neonates: 1.5 L/kg; Children: 1.9 L/kg; Adults: 0.59-2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Carbamazepine: 75% to 90%, may be decreased in newborns; Epoxide metabolite: 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 to active epoxide metabolite; induces hepatic enzymes to increase metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 85%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"     <b>",
"      Note:",
"     </b>",
"     Half-life is variable because of autoinduction which is usually complete 3-5 weeks after initiation of a fixed carbamazepine regimen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carbamazepine: Initial: 25-65 hours; Extended release: 35-40 hours; Multiple doses: Children: 8-14 hours; Adults: 12-17 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epoxide metabolite: Initial: 25-43 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Unpredictable:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: Suspension: 1.5 hour; tablet: 4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: Carbatrol&reg;, Equetro&reg;: 12-26 hours (single dose), 4-8 hours (multiple doses); Tegretol&reg;-XR: 3-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine 72% (1% to 3% as unchanged drug); feces (28%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 87.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barr J, Fraser G, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(1):263-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/23269131/pubmed\" id=\"23269131\" target=\"_blank\">",
"        23269131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooney GF, Mochon M, Kaiser B, et al, &ldquo;Effects of Carbamazepine on Cyclosporine Metabolism in Pediatric Renal Transplant Recipients,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1995, 15(3):353-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/7667170/pubmed\" id=\"7667170\" target=\"_blank\">",
"        7667170",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furst SM and Uetrecht JP, &ldquo;The Effect of Carbamazepine and Its Reactive Metabolite 9-Acridine Carboxaldehyde, on Immune Cell Function",
"      <i>",
"       in vitro",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Int J Immunopharmacol",
"      </i>",
"      , 1995, 17(5):445-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/7591369/pubmed\" id=\"7591369\" target=\"_blank\">",
"        7591369",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gilman JT, &ldquo;Carbamazepine Dosing for Pediatric Seizure Disorders: The Highs and Lows,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1991, 25(10):1109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/1803802/pubmed\" id=\"1803802\" target=\"_blank\">",
"        1803802",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hans P, Brichant JF, Pieron F, et al, &ldquo;Elevated Plasma Alpha 1-Acid Glycoprotein Levels: Lack of Connection to Resistance to Vecuronium Blockade Induced by Anticonvulsant Therapy,&rdquo;",
"      <i>",
"       J Neurosurg Anesthesiol",
"      </i>",
"      , 1997, 9(1):3-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/9016432/pubmed\" id=\"9016432\" target=\"_blank\">",
"        9016432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iwahashi IS, Miyatake R, Suwaki H, et al, &ldquo;The Drug-Drug Interaction Effects of Haloperidol on Plasma Carbamazepine Levels,&rdquo;",
"      <i>",
"       Clin Neuropharmacol",
"      </i>",
"      , 1995, 18:233-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/8635181/pubmed\" id=\"8635181\" target=\"_blank\">",
"        8635181",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keating A and Blahunka P, &ldquo;Carbamazepine-Induced Stevens-Johnson Syndrome in a Child,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(5):538-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/7655141/pubmed\" id=\"7655141\" target=\"_blank\">",
"        7655141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ketter TA, Kalali AH, and Weisler RH, &ldquo;A 6-Month, Multicenter, Open-Label Evaluation of Beaded, Extended-Release Carbamazepine Capsule Monotherapy in Bipolar Disorder Patients With Manic or Mixed Episodes: SPD417 Study Group,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2004, 65(5):668-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/15163253/pubmed\" id=\"15163253\" target=\"_blank\">",
"        15163253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Korinthenberg R, Haug C, and Hannak D, &ldquo;The Metabolization of Carbamazepine to CBZ-10,11 Epoxide in Children From the Newborn Age to Adolescence,&rdquo;",
"      <i>",
"       Neuropediatrics",
"      </i>",
"      , 1994, 25(4):214-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/7824094/pubmed\" id=\"7824094\" target=\"_blank\">",
"        7824094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lerer B, Moore N, Meyendorff E, et al, &ldquo;Carbamazepine Versus Lithium in Mania: A Double-Blind Study,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1987, 48(3):89-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/3546274/pubmed\" id=\"3546274\" target=\"_blank\">",
"        3546274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu H and Delgado MR, &ldquo;Influence of Sex, Age, Weight, and Carbamazepine Dose on Serum Concentrations, Concentration Ratios, and Level/Dose Ratios of Carbamazepine and Its Metabolites,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1994, 16(5):469-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/7846744/pubmed\" id=\"7846744\" target=\"_blank\">",
"        7846744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Matos ME, Burns MM, and Shannon MW, &ldquo;False-Positive Tricyclic Antidepressant  Drug Screen Results Leading to the Diagnosis of Carbamazepine Intoxication,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 105(5):e66",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/10799630/pubmed\" id=\"10799630\" target=\"_blank\">",
"        10799630",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCormack M, Alfirevic A, Bourgeois S, et al, \"HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 364(12):1134-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/21428769/pubmed\" id=\"21428769\" target=\"_blank\">",
"        21428769",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miles MV, Lawless ST, Tennison MB, et al, &ldquo;Rapid Loading of Critically Ill Patients With Carbamazepine Suspension,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(2):263-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/2371100/pubmed\" id=\"2371100\" target=\"_blank\">",
"        2371100",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Okuma T, Inanaga K, Otsuki S, et al, &ldquo;Comparison of the Antimanic Efficacy of Carbamazepine and Chlorpromazine: A Double-Blind Controlled Study,&rdquo;",
"      <i>",
"       Psychopharmacology",
"      </i>",
"      , 1979, 66(3):211-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/119267/pubmed\" id=\"119267\" target=\"_blank\">",
"        119267",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ory JP, Bourscheld D, Lebrun C, et al, &ldquo;Drug-Induced Pseudolymphoma in a Lupus Patient: One Case Due to Carbamazepine,&rdquo;",
"      <i>",
"       Clin Exp Rheumatol",
"      </i>",
"      , 1995, 12(Suppl 11):93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/8162652/pubmed\" id=\"8162652\" target=\"_blank\">",
"        8162652",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patterson BD, &ldquo;Possible Interaction Between Metronidazole and Carbamazepine,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1994, 28(11):1303-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/7849350/pubmed\" id=\"7849350\" target=\"_blank\">",
"        7849350",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Placidi GF, Lenzi A, Lazzerini F, et al, &ldquo;The Comparative Efficacy and Safety of Carbamazepine Versus Lithium: A Randomized, Double-blind 3-year Trial in 83 Patients,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1986, 47(10):490-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/3093468/pubmed\" id=\"3093468\" target=\"_blank\">",
"        3093468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rabins PV, Blacker D, Rovner BW, et al, &ldquo;American Psychiatric Association Practice Guideline for the Treatment of Patients With Alzheimer's Disease and Other Dementias. Second Edition,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2007, 164(12 Suppl):5-56.  Available at file://psychiatryonline.org/guidelines.aspx",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/18340692/pubmed\" id=\"18340692\" target=\"_blank\">",
"        18340692",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richard A, Girard F, Girard DC, et al, &ldquo;Cisatracurium-Induced Neuromuscular Blockade is Affected by Chronic Phenytoin or Carbamazepine Treatment in Neurosurgical Patients,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2005, 100(2):538-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/15673889/pubmed\" id=\"15673889\" target=\"_blank\">",
"        15673889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rispal P, Lasseur C, Labouyrie E, et al, &ldquo;Pseudolymphoma-Induced by Carbamazepine. Report of Two Cases,&rdquo;",
"      <i>",
"       Rev Med Interne",
"      </i>",
"      , 1995, 16(3):214-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/7740234/pubmed\" id=\"7740234\" target=\"_blank\">",
"        7740234",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soriano SG, Sullivan LJ, Venkatakrishnan K, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Vecuronium in Children Receiving Phenytoin or Carbamazepine for Chronic Anticonvulsant Therapy,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 2001, 86(2):223-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/11573664 /pubmed\" id=\"11573664 \" target=\"_blank\">",
"        11573664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stafstrom CE, Nohria V, Loganbill H, et al, &ldquo;Erythromycin-Induced Carbamazepine Toxicity: A Continuing Problem,&rdquo;",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 1995, 149(1):99-101.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/7827672/pubmed\" id=\"7827672\" target=\"_blank\">",
"        7827672",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Suppes T, Dennehy EB, Hirschfeld RMA, et al, &ldquo;The Texas Implementation of Medication Algorithms: Update to the Algorithms for the Treatment of Bipolar I Disorder,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2005, 66(7):870-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/16013903/pubmed\" id=\"16013903\" target=\"_blank\">",
"        16013903",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tohen M, Castillo J, Baldessarini RJ, et al, &ldquo;Blood Dyscrasias With Carbamazepine and Valproate: A Pharmacoepidemiological Study of 2,228 Patients at Risk,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1995, 152(3):413-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/7864268/pubmed\" id=\"7864268\" target=\"_blank\">",
"        7864268",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weisler RH, Kalali AH, and Ketter TA, &ldquo;A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Extended-Release Carbamazepine Capsules as Monotherapy for Bipolar Disorder Patients With Manic or Mixed Episodes: SPD417 Study Group,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 2004, 65(4):478-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/15119909/pubmed\" id=\"15119909\" target=\"_blank\">",
"        15119909",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Woolston JL, &ldquo;Case Study: Carbamazepine Treatment of Juvenile-Onset Bipolar Disorder,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1999, 38(3):335-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/10/25770/abstract-text/10087696/pubmed\" id=\"10087696\" target=\"_blank\">",
"        10087696",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9198 Version 59.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_10_25770=[""].join("\n");
var outline_f25_10_25770=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708660\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145588\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145589\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145636\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145593\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145612\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145594\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11510104\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11510105\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145559\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145544\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10968527\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145564\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145563\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145633\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145644\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145634\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145567\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145548\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145630\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145553\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145583\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145555\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145571\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145598\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145572\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145573\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145570\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145557\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145560\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145574\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145547\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145566\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9198\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9198|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/8/13446?source=related_link\">",
"      Carbamazepine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=related_link\">",
"      Carbamazepine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_10_25771="Identified structures EUS";
var content_f25_10_25771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal pancreatico-biliary anatomy: Structures identified with radial scanning EUS according to approximate transducer positions within the GI tract",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Transducer location",
"       </td>",
"       <td class=\"subtitle1\">",
"        Major structures identified with EUS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric body",
"       </td>",
"       <td>",
"        Confluence of splenic and portal vein, body/tail of pancreas, PD, left kidney, left RV, left RA, celiac axis, aorta, SMA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric antrum",
"       </td>",
"       <td>",
"        Confluence of splenic and portal vein, pancreas, liver, gallbladder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Duodenal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Bulb",
"       </td>",
"       <td class=\"sublist_other\">",
"        Pancreas, PD, liver, gallbladder, CBD, PV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Ampullary region",
"       </td>",
"       <td class=\"sublist_other\">",
"        Head of pancreas, PD, CBD, PV, ampulla",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Post-ampullary region",
"       </td>",
"       <td class=\"sublist_other\">",
"        Head/uncinate process of the pancreas, IVC, aorta, SMA, SMV, PD, right kidney",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PD: pancreatic duct; RV: renal vein; RA: renal artery; SMA: superior mesenteric artery; SMV: superior mesenteric vein; CBD: common bile duct; PV: portal vein; IVC: inferior vena cava.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_10_25771=[""].join("\n");
var outline_f25_10_25771=null;
var title_f25_10_25772="LV pressure volume loop";
var content_f25_10_25772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left ventricular pressure versus volume relationship",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 202px; height: 160px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normally contracting left ventricle ejects blood under pressure and the relationship between left ventricular pressure generation and ejection can be expressed in a plot of developed pressure versus volume. In the idealized pressure-volume loop, the left ventricular end-diastolic pressure is represented by point A. Isovolumic contraction at the beginning of systole is represented by line AB. As the developed left ventricular pressure exceeds that of the aorta, the aortic valve opens at point B. This leads to left ventricular ejection of blood (line BC). The volume of blood ejected (point B minus point C) represents the forward effective stroke volume of this contraction. At end-ejection, the aortic valve closes at point C followed by isovolumic relaxation (line CD). The mitral valve then opens at point D with left ventricular diastolic filling represented by line DA. The shaded area enclosed by the PV loop (ABCD) represents the external left ventricular stroke work, which can be represented mathematically as &int;PdV.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_10_25772=[""].join("\n");
var outline_f25_10_25772=null;
var title_f25_10_25773="Epiglottitis in children  Rapid overview";
var content_f25_10_25773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rapid overview: Epiglottitis (supraglottitis) in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Signs and symptoms that may indicate epiglottitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Respiratory distress: stridor, tachypnea, anxiety, refusal to lie down, \"sniffing\" or \"tripod\" posture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sore throat, dysphagia, drooling, anterior neck pain (at the level of the hyoid)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Muffled \"hot potato\" voice",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Marked retractions and labored breathing indicate impending respiratory failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Consider epiglottitis in",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Febrile, toxic-appearing children with rapid onset and progression of dysphagia, drooling, and respiratory distress, especially if unimmunized",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Evaluation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Secure airway before diagnostic evaluation if respiratory distress is severe",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Communicate early with otolaryngologist, anesthesiologist, and intensivist",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Keep the patient in a setting where the airway can be rapidly managed if necessary (eg, the emergency department, operating room, or intensive care unit)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Examination:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Defer examination of the pharynx in children with signs of moderate/severe respiratory distress",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Examine the patient in the upright position",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Attempt to visualize the epiglottis (with aid of tongue depressor, direct or indirect laryngoscopy) only in patients with mild distress and not in those with more severe distress",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Maintain the child in a position of comfort with parent present",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Avoid invasive procedures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Findings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Stridor, drooling, suprasternal and subcostal retractions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Swollen, erythematous epiglottis, inflammation of the supraglottic structures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Look for signs of extra-epiglottic infection (eg, pneumonia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Imaging:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Soft-tissue radiograph of the lateral neck (portable if possible) when the clinical diagnosis is in doubt",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Defer imaging in patients with severe respiratory distress or in whom it will delay definitive visualization of the epiglottis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Findings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       Enlarged epiglottis (\"thumb\" sign), loss of vallecular air space, thickened aryepiglottic folds, distended hypopharynx, loss of cervical lordosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Management",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Airway",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Secure the airway, if time allows, in the operating room by anesthesia or otolaryngologist (artificially or surgically if necessary)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       If abrupt obstruction:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Attempt bag-valve mask ventilation first",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       During laryngoscopy, pressure on the chest by an assistant may produce bubbling and help indicate the location of the glottis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Perform needle cricothyrotomy or surgical cricothyrotomy if unable to ventilate or intubate*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Laboratory studies:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Epiglottal cultures after establishment of artificial airway",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Blood cultures after the airway is secured",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Antimicrobial therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_single\">",
"       Administer empiric antimicrobial therapy:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent2\">",
"       <p>",
"        Cefotaxime OR ceftriaxone",
"       </p>",
"       <p>",
"        <span class=\"red\">",
"         PLUS",
"        </span>",
"       </p>",
"       <p>",
"        Clindamycin OR vancomycin",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Monitor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Monitor patient in the intensive care unit",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    * Needle cricothyroidotomy may be performed on children of any age. The age at which one can safely perform a surgical cricothyroidotomy on a child is not well established, and recommendations vary from 5 to 12 years old. Surgical cricothyroidotomy is best performed in children in whom external landmarks of the neck (eg, the cricothyroid membrane) are easily palapable. (See \"Needle cricothyroidotomy with percutaneous transtracheal ventilation-I\" and see \"Emergent surgical cricothyroidotomy (cricothyrotomy)\").",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_10_25773=[""].join("\n");
var outline_f25_10_25773=null;
var title_f25_10_25774="Clinical breakpoints for common Candida spp";
var content_f25_10_25774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical breakpoints for common Candida species",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Clinical breakpoints (in mcg/mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Susceptible",
"       </td>",
"       <td class=\"subtitle2\">",
"        Susceptible dose-dependent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Intermediate",
"       </td>",
"       <td class=\"subtitle2\">",
"        Resistant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        C. albicans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Caspofungin",
"       </td>",
"       <td>",
"        &le;0.25",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        &ge;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anidulafungin",
"       </td>",
"       <td>",
"        &le;0.25",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        &ge;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Micafungin",
"       </td>",
"       <td>",
"        &le;0.25",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        &ge;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluconazole&nbsp;",
"       </td>",
"       <td>",
"        &le;2.0&nbsp;",
"       </td>",
"       <td>",
"        4.0&nbsp;",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        &ge;8&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Itraconazole&nbsp;",
"       </td>",
"       <td>",
"        &le;0.12&nbsp;",
"       </td>",
"       <td>",
"        0.25-0.5&nbsp;",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        &ge;1&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Voriconazole",
"       </td>",
"       <td>",
"        &le;0.12",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        0.25-0.5",
"       </td>",
"       <td>",
"        &ge;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        C. parapsilosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Caspofungin",
"       </td>",
"       <td>",
"        &le;2",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        &ge;8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anidulafungin",
"       </td>",
"       <td>",
"        &le;2",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        &ge;8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Micafungin",
"       </td>",
"       <td>",
"        &le;2",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        &ge;8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluconazole&nbsp;&nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td>",
"        &le;2&nbsp;",
"       </td>",
"       <td>",
"        4.0&nbsp;",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        &ge;8&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Voriconazole",
"       </td>",
"       <td>",
"        &le;0.12",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        0.25-0.5",
"       </td>",
"       <td>",
"        &ge;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        C. tropicalis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Caspofungin",
"       </td>",
"       <td>",
"        &le;0.25",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        &ge;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anidulafungin",
"       </td>",
"       <td>",
"        &le;0.25",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        &ge;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Micafungin",
"       </td>",
"       <td>",
"        &le;0.25",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        &ge;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluconazole&nbsp;",
"       </td>",
"       <td>",
"        &le;2.0&nbsp;",
"       </td>",
"       <td>",
"        4.0&nbsp;",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        &ge;8&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Voriconazole",
"       </td>",
"       <td>",
"        &le;0.12",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        0.25-0.5",
"       </td>",
"       <td>",
"        &ge;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        C. glabrata",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Caspofungin",
"       </td>",
"       <td>",
"        &le;0.12",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        &ge;0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anidulafungin",
"       </td>",
"       <td>",
"        &le;0.12",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        &ge;0.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Micafungin",
"       </td>",
"       <td>",
"        &le;0.06",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        0.12",
"       </td>",
"       <td>",
"        &ge;0.25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluconazole&nbsp;",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        &le;32&nbsp;",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        &ge;64&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        C. krusei",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Caspofungin",
"       </td>",
"       <td>",
"        &le;0.25",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        &ge;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anidulafungin",
"       </td>",
"       <td>",
"        &le;0.25",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        &ge;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Micafungin",
"       </td>",
"       <td>",
"        &le;0.25",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        &ge;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluconazole*&nbsp;",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"       <td>",
"        -&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Voriconazole",
"       </td>",
"       <td>",
"        &le;0.5",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &ge;2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        C. guilliermondii",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Caspofungin",
"       </td>",
"       <td>",
"        &le;2",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        &ge;8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anidulafungin",
"       </td>",
"       <td>",
"        &le;2",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        &ge;8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Micafungin",
"       </td>",
"       <td>",
"        &le;2",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        &ge;8",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    24-h 100 percent, MIC endpoints read as 100 percent inhibition at 24-h incubation; 24-h 50 percent, MIC endpoints read as 50 percent inhibition at 24-h incubation.",
"    <div class=\"footnotes\">",
"     WT: wild-type.",
"     <br/>",
"     * Fluconazole breakpoints are not available for C. krusei since this species is considered intrinsically resistant to this compound. All strains should be reported as resistant.",
"    </div>",
"    <div class=\"reference\">",
"     Data compiled from:",
"     <br>",
"      <ol>",
"       <li>",
"        Pfaller MA, Andes D, Diekema DJ, et al. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13:180.",
"       </li>",
"       <li>",
"        Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011; 14:164.",
"       </li>",
"       <li>",
"        Pfaller MA, Andes D, Arendrup MC, et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011; 70:330.",
"       </li>",
"       <li>",
"        Pfaller MA, Boykem L, Hollis RJ, et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol 2010; 48:52.",
"       </li>",
"       <li>",
"        Pfaller MA, Boyken L, Hollis RJ, et al. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. J Clin Microbiol 2011; 49:630.",
"       </li>",
"       <li>",
"        Pfaller MA, Castanheira M, Diekema DJ, et al. Triazole and echinocandin wild-type MIC distributions with epidemiological cutoff values for six uncommon species of Candida. J Clin Microbiol 2011; 49:3800.",
"       </li>",
"       <li>",
"        Pfaller MA, Espinel-Ingroff A, Canton E, et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol 2012; 50:2040.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_10_25774=[""].join("\n");
var outline_f25_10_25774=null;
var title_f25_10_25775="TEE LA thrombus and spontaneous echo contrast 1";
var content_f25_10_25775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/73470/teelatt1_conv.mp4?title=TEE+LA+thrombus+and+spontaneous+echo+contrast+1\" style=\"width:312px;height:224px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left atrial thrombus and spontaneous echo contrast seen on TEE",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 260px; height: 206px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transesophageal echocardiogram shows a large thrombus adherent to the left atrial wall. Spontaneous echo contrast can be seen within the left atrium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_10_25775=[""].join("\n");
var outline_f25_10_25775=null;
